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 Galectins are an evolutionary conserved family of galactoside-binding proteins. 
It has been shown that these proteins play important roles as regulators of homeostasis, 
because they control inflammatory response, cell adhesion, cell growth, apoptosis and 
immune response. They are differentially expressed by various immune cells and their 
expression levels depend on cell activation and differentiation, as well as on 
pathological conditions. Galectins not only bind host ligands, but they can bind to 
several glycans on pathogen surface, as it has been shown for viruses, bacteria, 
nematodes or parasites. The interaction of galectins with pathogens leads to activation 
of the immune system and can mediate cell-pathogen interactions. 
 Regarding T cruzi infection, it has been reported that galectin-3 binds to the 
parasite surface promoting adhesion to host cells in vitro, and it is known as well that 
galectin-1 and -3 modulate B cell response and macrophage activity during the course 
of infection.  
 In this work, we first investigated whether recombinant human galectins are able 
to bind T. cruzi in vitro. Our results confirm the reported observation regarding the 
ability of galectin-3 to bind T. cruzi as well. In addition, we observed that other 
members of the galectin family can bind T. cruzi surface, like galectin-1, 4, 7 and 8 in a 
specific and differential way regarding binding intensity and specificity. Moreover, 
galectins presented a higher avidity for infective forms of T. cruzi present in the host, 
amastigotes and trypomastigotes, than the non-infective forms, reflecting the changes 
that occur in the parasite during the metacyclogenesis process in order to become 
infective and face up the new challenge that the host means for the survival of the 
parasite. T. cruzi has developed during the evolution mechanisms to module and escape 
from the host immune response. Here we show that T. cruzi is able to proteolitically 
process galectin-3, -4 and -8, resulting in truncated galectins that preserve the 
Carbohydrate Recognition Domain, but lack the multivalency associated to many of the 
galectin biological functions. The processing of galectins by T. cruzi is shown to be 
dependent of Zn-metalloproteases and collagenases. When these proteases were 
inhibited, recombinant galectins induced parasite death, suggesting that galectins could 
act as direct microbicide agents, meanwhile this ability is counteracted by specific 
proteases in T. cruzi implicated in galectin cleavage.   
 The results obtained in vitro suggest an important role of galectins during T. 
cruzi infection, and this was confirmed in vivo after experimental murine infection. In 
general, galectins were highly regulated during the course of infection, in different 
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spleen cell subsets and in the heart, both in cardiac cells and infiltrating immune cells. 
The role of galectin-3 during the outcome of the infection was studied using genetically 
deficient mice. The lack of galectin-3 led to a higher parasitemis during T. cruzi 
infection. Galectin-3 deficient mice mounted an altered humoral response, in the sense 
that they generated antibodies against the glycan epitope Galb1-3GlcNAcb1-3Galb1-X, 
structure not immunogenic in wild type mice. In addition, they presented a diminished 
inflammatory and immune response, in concordance with the reported pro-inflammatory 
functions reported for galectin-3. Galectin-3 knock-out mice showed a misbalanced 
cytokine serum levels during infection, down-regulation of inflammatory genes 
associated to resistance to T. cruzi infection, IFN-γ, iNOS, IL-12 and COX-2, and up-
regulated expression of the Toll Like Receptors, an important family of pathogen 
recognition receptors implicated in T. cruzi recognition. Parasite burden in the heart of 
infected galectin-3 deficient mice was not significantly different from wild type mice, 
but in contrast, showed a dramatically reduction in the number of infiltrating immune 
cells, suggesting a pivotal role of galectin-3 in cell recruitment to the site of infection.  
 In an attempt to elucidate the immunological mechanisms that led to these 
abnormalities, we differentiated galectin-3 deficient dendritic cells in vitro, which 
showed a reduced TNF-α and IL-1 production after T. cruzi infection. This deficiency 
was correlated to a deficient TLR2-TLR1 heterodimer surface formation, due to the lack 
of TLR-1 surface expression. The defects in dendritic cells responses due to the lack of 
galectin-3, could explain the systemic alterations observed in the experimental infection 
of deficient mice.       
 Taken all the data together, galectins might play key roles in innate and adaptive 
responses during T. cruzi infection by modulating parasite recognition, interactions with 
host cells, parasite clearance and initiation and progression of the outcome of the 
immune response mounted against T. cruzi. 
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 Las galectinas son una familia de proteínas de unión a carbohidrato altamente 
conservadas a lo largo de la evolución. Se ha demostrado que estas proteínas juegan un 
papel importante como reguladores de la homeostasis, debido a su capacidad de 
modular la respuesta inflamatoria, adhesión celular, crecimiento celular, apotosis y 
respuesta immune. Son expresadas diferencialmente por diferentes células del sistema 
inmune, y sus niveles de expresión dependen del estado de activación y diferenciación 
celular, asi como de procesos patológicos. Las galectinas no solo unen ligandos propios 
del hospedador, si no que pueden unirse también a ligandos presentes en la superficie de 
organismos patógenos como virus, bacterias, nematodos o parásitos. La interacción de 
las galectinas con organismos patogénicos conduce a la activación del sistema inmune y 
puede mediar interaciones célula-patógeno.  
 Con respecto a la infección por T. cruzi, ha sido descrito que galectina-3 se une a 
la superficie del parásito potenciando la adhesión a células del hospedador, y se sabe 
que galectina-1 y -3 modulan la respuesta de células B y macrófagos durante el 
desarrollo de la infección.  
 En el presente trabajo, investigamos primero si galectinas humanas 
recombinantes eran capaces de unirse in vitro a T. cruzi. Nuestros datos confirmaron 
que galectina-3 es capaz de unirse a T. cruzi. Además, observamos que otros miembros 
de la familia de galectinas pueden unirse también a T. cruzi, como galectina-1, -4, -7 y -
8de una manera específica y diferencial en lo relativo a la intensidad de la unión y a su 
especificad. Además, galectinas recombinantes mostraron una afinidad mayor por las 
formas infectivas de T. cruzi que estan presentes en el hospedador, amastigotes y 
trypomastigotes, que las formas no infectivas, reflejando los profundos cambios que 
ocurren en el parasito durante el proceso de mataciclogénesis con el objetivo de ganar 
infectividad y afrontar el nuevo reto que el hospedador supone para el parásito y su 
supervivencia. T. cruzi ha desarrollado durante la evolución mecanismos para modular y 
escapar de la respuesta inmune del hospedador. En este trabajo mostramos que T. cruzi 
es capaz de procesar proteolíticamente la galectina-3, -4 y -8, conduciendo a la 
aparición de galectinas truncadas que preservan intacto el dominio de reconocimiento a 
carbohidrato, pero pierden la multivalencia asociada a muchas de sus funciones 
biológicas. El procesamiento de las galectinas por T. cruzi resulta ser dependiente de 
Zn-metaloproteasas y colagenasas. Cuando estas proteasas son inhibidas, las galectinas 
recombinantes inducen muerte en el parásito, sugiriendo que las galectinas podrían 
actuar como agentes microbicidas per se, mientras que esta capacidad es contrarrestada 
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por T. cruzi mediante proteasas específicas para producir cortes en la secuencia de las 
galectinas.  
 Los resultados obtenidos in vitro inducen a pensar que las galectinas juegan un 
papel prioritario durante la infección por T. cruzi, como fue confirmado in vivo después 
de la infección experimental murina. En general, las galectinas fueron altamente 
reguladas durante el curso de la infección, en distintos tipos celulares procedentes de 
bazo de animales infectados, y en el corazón, tanto en células cardiacas y en células 
inmunes infiltradas. El papel de la galectina-3 durante el desarrollo de la respuesta 
inmune fue analizado usando ratones genéticamente deficientes. Estos ratones 
mostraron una mayor parasitemia, y generaron anticuerpos contra el epitope glicano 
Galb1-3GlcNAcb1-3Galb1-X, estructura no inmunogénica para ratones salvajes. 
Además, mostraron una respuesta inflamatoria disminuida, en concordancia con 
trabajos previos señalando el papel pro-inflamatorio de la galectina-3. Ratones 
defiecientes en galectina-3 mostraron un desajuste en los niveles de citoquinas en suero 
durante la infección, regulación a la baja de genes asociados a la resistencia a la 
infección como IFN-γ, iNOS, IL-12 and COX-2, y regulación a la alza de la familia de 
receptores Toll Like, importantes en el reconocimiento de T. cruzi. La carga parasitaria 
en el corazón de ratones deficientes en galectina-3 no fue significamente diferente de 
los ratones salvajes control, pero mostraron una reducción drástica en el numero de 
células inmune infiltradas, indicando un papel central de la galectina-3 en el proceso de 
reclutamiento de células inmunes a los sitios de infección.  
 Intentando profundizar en los mecanismos inmunológicos que condujeron a 
estas anormalidades, se diferenciaron in vitro céluas dendríticas deficiencientes en 
galectina-3, las cuales mostraron una producción muy reducida de TNF-α y IL-1 
después de infectarlas con T. cruzi. Esta deficiencia se correlaciona con una deficiente 
presentación en la superficie celular del complejo TLR1-TLR2, debido a una ausencia 
de TLR-1 en la membrana celular. Este defecto, producto de la falta de galectina-3, en 
la respuesta inmune de células dendríticas podría explicar las alteraciones sistémicas 
observadas en los ratones deficientes durante la infección experimental.  
 Considerando todos los datos, podemos concluir que las galectinas deben jugar 
un papel clave durante el establecimiento de la respuesta immune innata y adaptativa, 
debido a sus implicaciones en  el reconocimiento de T. cruzi, interacciones del parásito 
con células hospedadoras, eliminación del parásito e iniciación y progreso de la 
respuesta inmune montada contra T. cruzi. 
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1. Chagas disease, history, etiological agent, distribution and clinical 
manifestations. 
  
 Chagas disease is a chronic illness caused by the protozoan Trypanosoma cruzi. 
It was first described by Carlos Chagas in 1909 (Chagas 1909; WHO 2006), but the 
disease was not seen as a major public health problem until the 1960s. He discovered 
that the intestines of Triatomidae harboured an unknown specie of the genus 
Trypanosoma, a flagellate protozoan. He named the parasite that causes the disease 
Trypanosoma cruzi, recalling the Brazilian physician and epidemiologist Oswaldo Cruz. 
Carlos Chagas identified the causative agent, vector, host, clinical manifestations and 
epidemiology of the disease.  
 Chagas disease currently affects 16–18 million people, with some 100 million 
(25% of the whole Latin American population) at risk of acquiring the disease, killing 
around 50,000 people annually. It is estimated that the disease is responsible of 649,000 
DALYs every year (Disability Adjusted Life Years, the number of healthy years of 
work lost due to premature death and disability) (WHO 2006). The disease is distributed 
in the Americas, from Southern Argentine to the Southern United States, covering 18 
countries distributed in 2 different ecological zones, the Southern Cone and the 
Northern South America, Central America and Mexico. Nowadays, there is an 
increasing risk of infection in the developed countries, like the European Union and 
Spain, due to migration movements.  
 
 
 
 
 
 
 
 
 
 
 
 
Illustration 1: geographical 
distribution of Chagas disease. 
Endemic areas of infection in 
humans are highlighted in red.  
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 T. cruzi is transmitted by hemiptera from the family Reduviidae, such as 
Triatoma, Rhodnius or Panstrongylus, via the vector faeces after a bug bite. T. cruzi life 
cycle is really complex. An infected triatomine insect vector feeds on blood and releases 
trypomastigotes in its feces near the site of the bite wound. Those affected, by 
scratching the site of the bite, causes trypomastigotes to enter the host through the 
wound, or through intact mucosal membranes, such as the conjunctiva. Then, inside the 
host, the trypomastigotes invade cells, where they differentiate into intracellular 
amastigotes. The amastigotes multiply by binary fission and differentiate into 
trypomastigotes, then are released into the circulation as bloodstream trypomastigotes. 
These trypomastigotes infect cells from a variety of biological tissues and transform 
into intracellular amastigotes in new infection sites. The bloodstream trypomastigotes 
do not replicate. Replication resumes only when the parasites enter another cell or are 
ingested by another vector. The reduviid bug, also known as `kissing´ bug, becomes 
infected by feeding on human or animal blood that contains circulating parasites. The 
ingested trypomastigotes transform into epimastigotes in the vector’s midgut. The 
parasites multiply and differentiate in the midgut and differentiate into infective 
metacyclic trypomastigotes in the hindgut, completing the life cycle. 
 
 
 
 
 
 
 
 
 
 
 
 
Illustration 2: Schematic representation of the life cycle of T.cruzi. T. cruzi is naturally transmitted by 
hemiptera from the family Reduviidae. During blood sucking, the insect defecates on the skin (1), 
carrying the infective metacyclic trypomastigotes that enter the mammalian host and infect local cells (2). 
Parasites inside the cells turn into amastigotes which multiply intracellularly (3). Some amastigotes 
transform again into trypomastigotes that disrupt the cell (4) infecting new cells and enter the 
bloodstream. Bugs are infected when they feed on blood containing parasites (5). Once inside the insect, 
T. cruzi transform into epimastigote form 6), multiplies by binary fision (7) and differentiate into infective 
metacyclic trypomastigotes (8), thus completing the life cycle. 
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 Two different transmission cycles exist for T. cruzi: one related to wild, non-
human vertebrate hosts (over 100 mammalian species like opossums and armadillos), 
called the `sylvatic cycle´; and another one, dependent on home-dwelling hemiptera and 
involving humans and household animals. This is called `domestic cycle´. Humans are 
considered to be a very new host for T. cruzi. In fact, it is estimated that the first contact 
with humans occurred in the late Pleistocene, 30000-15000 years ago, meanwhile the 
parasite emerged as a specie over 150 million years (Briones, Souto et al. 1999). 
 However, Trypanosoma cruzi can also be transmitted through blood 
transfusions, organ transplantation, transplacentally, breast milk, oral ingestion 
(Yoshida 2008) and in laboratory accidents. Children can also acquire Chagas' disease 
while still in the womb.  According to the World Health Organization, the infection rate 
in Latin American blood banks varies between 3% and 53%, a figure higher than of 
HIV infection and hepatitis B and C (WHO 2006). 
 This high blood prevalence has made that the original distribution of the disease 
is being modified nowadays due to population movements and immigration, and new 
cases have been reported in other regions like Unite States and Europe, turning into a 
new public health problem in countries where the disease was unknown, mainly due to 
blood transfusions.   
 T. cruzi infection progress has been divided into successive acute and chronic 
stages, according to our current pathogenic knowledge of Chagas disease. Following the 
parasite infection, there is a short acute phase showing an abundant parasitemia, but 
frequently with very mild and unspecific symptoms and the infection can be unnoticed. 
A small sore can develop where the parasite enters the body. When the inoculation site 
is the conjunctival mucous membranes, the patient may develop unilateral periorbital 
edema, conjunctivitis, and preauricular lymphadenitis. This constellation of symptoms 
is referred as Romaña's sign. Most patients results to be asymptomatic in the acute 
phase, making difficult the diagnosis. In addition to those asymptomatic patients, others 
develop symptoms that include fever, enlarged and painful lymph nodes and fatigue. 
This can last up to four weeks, and then these symptoms disappear. Death in acute 
Chagas disease can be related to heart failure and/or meningitis in immune-
compromised patients but more commonly, patients enter a symptomless phase known 
as indeterminate phase that can last for 10-20 years. During this phase the parasitemia is 
virtually undetectable, and the parasites are invading most organs of the body. Only one 
third of the individuals with indeterminate infections will develop clinical 
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manifestations. The disease has a very variable clinical presentation, affecting nervous 
system, digestive system or heart. Thus, chronic infections result in various neurological 
disorders, including dementia, damage to the heart muscle, and sometimes dilation of 
the digestive tract (megacolon and megaesophagus) (Lopes, Rocha et al. 1989; Adad, 
Andrade et al. 1991), as well as weight loss. Swallowing difficulties may be the first 
symptom of digestive disturbances and may lead to malnutrition. However, considering 
the epidemiology data, the most devastating manifestation of the disease is the Chagas 
cardiomyopathy. After several years of an asymptomatic period, 27% of those infected 
develop cardiac damage, 6% develop digestive damage, and 3% present peripheral 
nervous involvement. Several cardiac symptoms are associated to the disease, including 
premature contractions, ECG abnormalities, enlarged heart, altered heart rate or rhythm, 
heart failure and cardiac arrest (Tanowitz, Kirchhoff et al. 1992). Only the 
chemotherapeutic agent Benznidazole is used for the treatment of chagasic patients, 
despite is highly toxic and has limited efficacy, especially in the chronic phase of the 
disease. 
 Two primary hypotheses are proposed to account for pathogenesis in chronic 
Trypanosoma cruzi infections. One claims that the pathology is directly linked to the 
parasite persistence in infected tissues (Zhang and Tarleton 1999; Tarleton 2001), 
resulting in chronic inflammatory reactivity. The other one postulates an autoimmune 
basis for the pathology (Kierszenbaum 1986; Levin, Kaplan et al. 1993; Soares, Pontes-
De-Carvalho et al. 2001; Girones, Cuervo et al. 2005; Girones, Carrasco-Marin et al. 
2007). According to this one, the parasite presence is not crucial for the Chagas 
pathology, since there are not a big number of parasites in some affected organs during 
the chronic phase, but it claims that T. cruzi infection induces immune responses which 
are targeted at self tissues. However, both events are not mutually exclusive, and they 
could occur simultaneously during Chagas disease (Girones and Fresno 2003; 
Kierszenbaum 2005).   
 It has been proposed that the diversity in the clinical manifestations of Chagas 
disease may depend on the genetic host background (Andrade, Machado et al. 2002), 
and also on the genetic diversity of the parasite. Different studies have demonstrated 
that T. cruzi is a very heterogeneous taxon (Macedo and Pena 1998; Devera, Fernandes 
et al. 2003; Macedo, Machado et al. 2004). DNA markers like rDNA or miniexon gene 
have generated a consensus about the existence of two major phylogenetic lineages 
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within the taxon (Zingales, Souto et al. 1998), that has been designated as T cruzi I and 
T cruzi II. 
 The relevance of this genetic variability can be a determinant of differential 
tissue tropism or distribution, and consequently of the clinical forms of the disease 
(Montamat, De Luca D'Oro et al. 1996; Andrade, Machado et al. 1999) Thus, it is 
natural to think that not all T. cruzi strains are able to infect humans, and that different 
strains can show different clinical manifestations (Vago, Andrade et al. 2000). The 
genetic structure of T. cruzi populations is even more complex, because there are 
different subgroups described in every single lineage T. cruzi I or T. cruzi II (Montamat, 
De Luca D'Oro et al. 1996; Brisse, Dujardin et al. 2000). Recently, it has been identified 
five lower phylogenetic subdivisions in the TcII group, proposing the existence of six 
discrete lineages in total (Brisse, Dujardin et al. 2000; Brisse, Verhoef et al. 2001; 
Sturm, Vargas et al. 2003). Tc I and Tc II are associated to the `sylvatic cycle´ and 
`domestic cycle´ respectively. Cases of human infection by T cruzi I strains are rare and 
usually asymptomatic. However, a correlation between genetic variability and clinical 
symptoms of the disease has not yet been establish, because the available diversified 
methods used to type or group T. cruzi strains may face drawbacks that interfere with 
the results. They are, for instance, the isolation of T. cruzi populations from hosts that 
harbor more than a single strain or the selection of populations during the maintenance 
of strains in laboratory conditions or during their amplification in experimental animals 
or in cultures (Devera, Fernandes et al. 2003).  
 
2. Immune response  
  
 2.1 Innate and immune response against T. cruzi 
  
 T. cruzi triggers a complex immune response. Soon after the parasite overcomes 
the skin barrier, it is recognized by the immune system in order to activate a proper 
immune response. Complement and acute phase proteins bind to T. cruzi, and mediates 
the first interaction between parasite and phagocytic cells. Subsequently, other host 
receptors interact with the parasite. Tool Like Receptors, TLRs, are the best 
characterized receptors that identify parasite components, but others can collaborate, 
like the mannose receptor or the dectin family. TLRs are pathogen recognition receptors 
(PRRs) associated to the innate immune system. The family consists of several 
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members. TLR-2, TLR-4 and TLR-9 are known to recognize T. cruzi (Bafica, Santiago 
et al. 2006; Tarleton 2007). Moreover, mice deficient in the adaptor molecule MyD88 
were unresponsive to T. cruzi (Campos, Closel et al. 2004), in a very similar fashion 
shown by TLR-2 and TLR-9 deficient mice. TLR-4 works as a homodimer on the cell 
surface, meanwhile TLR-2 needs to form heterodimers either with TLR-1 or TLR-6 in 
order to trigger intracellular signals (Sandor, Latz et al. 2003). PRRs recognize 
pathogen associated molecular patterns (PAMPs), molecular structures found only in 
pathogens but not in the host. Thus PRRs in general and TLRs particularly, can 
distinguish self from nonself components. Glycoconjugates presents on T. cruzi are 
recognized by TLRs in DCs, leading to cytokine and chemokine production: IL-8, IL-
12, macrophage inflammatory protein-1-α and monocyte chemoattractant protein-1 
(MCP-1/CCL2) (Ouaissi, Guilvard et al. 2002). This recruits macrophages to the 
infection site, cells that are infected by the parasite. Macrophages and DCs secrete high 
amounts of pro-inflammatory cytokines, like IL-12 and IL-1, which activates natural 
killer cells to produce interferon-γ (IFN-γ) (Aliberti, Cardoso et al. 1996). This IFN-γ 
acts over macrophages and DCs to induce TNF-α production, that synergistically with 
IL-12 and TNF-α produce nitric reactive species (NO) through up-regulation of the 
enzyme iNOS, which in turn, leads to parasite killing (Munoz-Fernandez, Fernandez et 
al. 1992; Abrahamsohn and Coffman 1996). The parasite avoids the early immune 
response and spreads through the body invading tissues. During the acute phase, T. 
cruzi can infect almost every nucleated cell. Immune response against T. cruzi also 
involves activation of the humoral and cellular components of the adaptive response. 
Immune response induces a polyclonal expansion of T (CD4P+P and CD8 P+P) and B cells. 
Despite this polyclonal activation, there is a high humoral and cellular 
immunosuppression. The mechanisms of such immunosupression range from 
downregulation of IL-2 receptor in activated T cells (Majumder and Kierszenbaum 
1996),  to immature myeloid suppressor cells (Goni, Alcaide et al. 2002)  or  to the 
enhanced cell death of lymphocytes (Lopes and DosReis 1996; Zuniga, Motran et al. 
2000). This functional deficiency has been implicated in the ability of the parasite to 
evade the immune response and persist in the host.  Although the balance Th1/Th2 
(which appears to result from mutual functional antagonism exerted by IFN and IL-10) 
is important for the outcome of the immune response in other parasite diseases like 
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Leishmaniosis, there is a co-existence of both types of response during Chagas 
disease(DosReis 1997). Th1 T cells produce IFN-γ, increasing TNF-α and NO by  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
macrophages, in a classical LPS-dependent macrophage activation. The polyclonal 
expansion affects also to the B cell repertoire, accompanied by a huge increase in 
immunoglobulin production. However, most of these antibodies are not effective, 
because they are non-specific for T. cruzi, and this could favor the appearance of 
autoimmune processes. When parasites disappear from the blood stream, the strong Th1 
response is controlled by Th2-like cytokines (IL-4, IL-10) (Hunter, Ellis-Neyes et al. 
1997; Abrahamsohn, da Silva et al. 2000) and regulatory T cells. Once the acute phase 
Ilustración 3: Scheme of 
immune response 
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is over, parasites are virtually undetectable in the blood of patients, and they restrict 
their presence to target tissues, commonly the heart. Parasite burden in the heart is 
elevated during the acute phase, and heart invasion by T. cruzi leads to chemokine 
production by cardiomyocites (Ccl5/RANTES, CXCL3/MIP-2β), cytokines (IL-6, IL-
1β, TNF-α) and NO (Zhang and Tarleton 1996; Chandrasekar, Melby et al. 1998; 
Machado, Martins et al. 2000). The only presence of this cytokines induce parasite 
killing by NO-dependent mechanism in macrophages (Villalta, Zhang et al. 1998), and 
besides this creates an inflammatory scenario and recruits infiltrating CD4P+P T cells, 
CD8 P+P T cells and macrophages. IFN-γ produced by T cells induces NO production by 
macrophages increasing parasite killing.  After the acute phase, the parasite burden in 
heart is gradually reduced, but a significant number of infiltrating cells still remain in 
the heart, supporting the hypothesis of autoimmunity processes as a cause of Chagas 
cardiomiopathy.        
  
 
 2.2 The Danger model, a new link between innate and adaptive response 
  
 For over 50 years immunologists have based their work on the idea that the 
immune systems functions by distinguish between self and nonself. Nowadays, a new 
theory is emerging in the field, attempting to complete the inherent problems of the self 
versus nonself classical theory, and it has been named `the Danger Model´. In this 
Model, innate immunity is more concerned with damage inducing by invading 
pathogens than with the `foreignness´ of invading pathogen. Then, immunity is called 
into action by alarm signal coming from the injured cells. For instance, the presence of 
certain intracellular molecules out of the usual location serves to activate the subsequent 
innate immune events that will lead to the acquired immunity. Thus, danger signals 
initiate the immune response, although the original pathogen is the responsible of the 
activation of such danger signals. In homeostatic condition, although there is antigen 
presentation, the lack of these danger signals keeps the immune system in a non-
reacting status. (Brown and Lillicrap 2002; Matzinger 2002), The model is an effort to 
understand the initiation of immune response, and how self and non-self is distinguish 
by the immune system, or in other words, how pathogens generate an immune response, 
meanwhile self components do not. 
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3. Glycoconjugates present in Trypanosoma cruzi. 
 
 Some protozoa present a simple life cycle, like Trichomonas, but others like 
Leishmania sp. or T. cruzi present a really complex life cycle as exposed previously. T. 
cruzi colonizes different habitats during its life cycle, from the intestinal tract of an 
insect to the cytoplasm of a mammalian cell, with a brief passage by the blood of the 
vertebrate host. An adaptation of the parasite to theses different environments should 
occur and, consequently, differences on the composition of the plasma membrane 
should happen, because the surface of parasitic protozoa plays a primary role in the 
interaction with the environment. A thick coat of glycoconjugates covers the surface of 
Trypanosoma cruzi, and the nature and composition of these glycoconjugates change on 
the different parasite biological stages. It is known that glycans are of great importance 
in parasite protection, attachment to insect guts, interaction with host cells and host 
immunomodulation, since most of the PRRs described so far in T. cruzi are 
glycosilated.    
 Glycosylphosphatidylinositol (GPI)-anchored molecules are the most abundant 
molecules present on the parasite surface, and are indeed essential to control activation 
of the innate immune system as well as initiation of the acquired host immune response 
in the vertebrate host. (GPI)-anchored molecules are basically GIPLs, mucins and trans-
sialidases.  
 
 T3.1 Structure and function of GIPLs T.  
  
 GIPLs are small molecules composed by a conserved GPI glycan core, 
containing the conserved motif Manα1-4GlcNacα1-6phosphatidylinositol(PI) and a 
ceramide moiety. Additional differences may be found in the lipid tails and 
carbohydrate branches linked to the conserved glycan core. Based on this, GIPLs can be 
grouped in three different types. Type I GIPLs (Manα1-6Manα1-4GlcNacα1-6PI) are 
the main plasma components of epimastigotes and metacyclic trypomastigotes 
(Previato, Gorin et al. 1990; Carreira, Jones et al. 1996). GIPLs are the dominant 
glycolipids present on all the developmental stages of T. cruzi, but are much less 
abundant in trypomastigotes than in epimastigotes (Golgher, Colli et al. 1993). The 
most common glycoproteins of trypanosomatids are anchored by 
 glycoinositolphospholipids (GIPLs) to their plasma membrane. In addition, free GIPLs 
have been described, for instance the lipopeptidophosphoglycan (LPPG) which is a 
major component of the surface of T. cruzi epimastigotes. It has been demonstrated the 
presence of an immunogenic epitope in LPPG containing β-galactofuranose (Galf) 
(Schnaidman, Yoshida et al. 1986). The ability of GIPLs to modulate the immune 
response has been clearly demonstrated. They have a wide range of non-specific 
activities in macrophages (Freire-de-Lima, Nunes et al. 1998), NK cells (De Arruda 
Hinds, Previato et al. 1999),T (Gomes, Previato et al. 1996; Bellio, Liveira et al. 1999; 
Oliveira, Peixoto et al. 2004) and B lymphocytes (Bento, Melo et al. 1996; Bilate, 
Previato et al. 2000). 
 
  
 
 
 
Ilustración 4: Schematic 
representations of GIPLs 
(LPPG is shown), mucins 
and trans-sialidases found 
in T. cruzi.  23
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 3.2 Structure and function of the mucin-like glycoprotein family. 
  
 The major protein components of the T. cruzi surface are mucin-like proteins. 
Mucins are GPI-anchored peptides enriched in hydrophilic aminoacids (threonine, 
serine, lysine and glycine) that serve as scaffold for the extensive addition of O-glycans 
(Schenkman, Ferguson et al. 1993; Previato, Jones et al. 1994; Previato, Jones et al. 
1995; Serrano, Schenkman et al. 1995). The oligosaccharides of T. cruzi mucins 
represent approximately 60% of the total mass of the glycoprotein, are highly branched 
and contain Galp, Galf and sialic acids units besides O-linked GlcNAc. The mucins 
expressed by different stages of T. cruzi are highly polymorphic. Those from 
epimastigotes and metacyclic trypomastigotes migrate in SDS-polyacrilamide gels as 
double or triple bands of 35-43 and 35-50 KDa (Di Noia, Sanchez et al. 1995). In 
contrast, in tissue cultured trypomastigotes mucins are much bigger, in the range of 60-
220 KDa (Freitas-Junior, Briones et al. 1998; Previato, Sola-Penna et al. 1998). Mucins 
are responsible of many of the immunomodulatory properties of T. cruzi. α-galactosyl 
epitopes are targets of the abundant lytic anti-Galactose antibodies from acute and 
chronic chagasic patiens (Freitas-Junior, Briones et al. 1998; Previato, Sola-Penna et al. 
1998), and the trypomastigote mucin GPI-anchor can alone induce the synthesis of 
proinflammatory cytokines and nitric oxide by macrophages (Camargo, Almeida et al. 
1997), but the same fraction obtained from epimastigotes did not show such properties. 
In contrast, a purified complete mucin, AgC10, inhibits pro-inflammatory cytokine 
production in macrophages, (de Diego, Punzon et al. 1997; Alcaide and Fresno 2004), 
showing the complexity of the immunomodulation that these molecules are able to.  
  
3.3 Structure and function of members of the trans-sialidase family.  
 
 Several surface antigens of T. cruzi have been grouped in a superfamily defined 
by the presence of a consensus amino acids sequences homologous to bacterial 
sialidases (de Diego, Punzon et al. 1997; Alcaide and Fresno 2004).They are a highly 
polymorphic family of glycoproteins, but the glycan moiety is not so important for this 
family as it is for the mucins. Active trans-sialidases catalyze the transfer of terminal 
sialic acid from the host glycoconjugates to parasites mucins. 
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 Although the name of family is trans-sialidase, not all the subgroups present 
trans-sialidase (TS) activity. The family can be subdivided based on their sequences into 
four different subgroups: Type I includes proteins with catalytic activity like TCNA 
(“trypomastigote cultured neuraminadase”), SAPA (“shed acute-phase antigen”) and TS 
clone 154(Pereira, Mejia et al. 1991; Pollevick, Affranchino et al. 1991; Uemura, 
Schenkman et al. 1992; Pollevick, Sanchez et al. 1993). The rest of the subgroups do 
not present activity. Family II comprises a number of trypomastigote surface antigens 
designated generically as Tc-85 KDa (Peterson, Wrightsman et al. 1986; Kahn, Colbert 
et al. 1991). Family III is represented by the 160 KDa antigens located on the flagellar 
region of trypomastigotes (Norris, Schrimpf et al. 1997). The unique members 
described for the family IV are the antigens Tc-13.1 and Tc-13.5. They contain amino 
acids repetitions not related to the other groups.  
 The importance of trans-sialidases for T. cruzi survival remains unclear, but 
might be relevance due to the existence of multiple copies of genes encoding each of 
these proteins. Many of the Tc-85 KDa proteins have been implicated in a number of 
processes important for parasite like adhesion to host cells and extracelullar matrix 
proteins (Giordano, Chammas et al. 1994; Giordano, Chammas et al. 1994; Alves 1996; 
Giordano, Fouts et al. 1999), although this subgroup lacks trans-sialidase activity. Type 
I trans-sialidases catalyze the transference of sialic acid to β-galactosyl acceptor 
molecules. As T. cruzi is not able to synthesize sialic acid, such transglycosidase 
activity allows the parasite to acquire sialic acid from the host. The host sialic acid is 
added to the galactosyl terminal residues present on the abundant mucin-like proteins on 
the parasite surface. The importance of this acquisition of sialic acid is not yet well 
understood, but it seems that the sialic acid can help the parasite to adhere and penetrate 
non-phagocytic cells (Ming, Chuenkova et al. 1993; Schenkman, Vandekerckhove et al. 
1993).  
 However, the abundance of sialic acid on the parasite surface might indicate that 
sialylation have a primary protective role, protecting the parasite from the environment 
like a physical barrier and a strong negative charge, and changing terminal glycans in 
host cells and parasite. Galactosyl residues are exposed now in the host cells, 
meanwhile the parasite hides its own galactosyl terminal residues, abundantly expressed 
in the surface mucins. Interestingly, mucin sialylation increases the resistant of T. cruzi 
to lysis mediated by chagasic anti-galactosyl antibodies (Pereira-Chioccola, Acosta-
Serrano et al. 2000). 
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4. Glycoconjugates in the mammalian host.  
  
 The glycoconjugates are important for the biology of T. cruzi, but they play also 
an outstanding role in the vertebrate host. Indeed, the glycobiology is emerging as a 
new relevant field for a lot of biological processes. Glycans cover the surface of all 
mammalian cells. They are added to protein and lipid backbones, thanks to a process 
called glycosilation. This take place during glycoprotein biosynthesis from the 
endoplasmic reticulum to the golgi and membrane. During this journey to the cell,  
membrane glycans are important for a proper protein folding being a quality control in 
the endoplasmatic reticulum, for intracellular transport and targeting, sorting in the 
endoplasmatic reticulum, golgi and secretion (Helenius and Aebi 2001; Helenius and 
Aebi 2004; Molinari 2007). Glycosilation is mediated by a complex set of enzymes, 
termed glycosiltransferases and glycosidases. Glycosiltransferases catalyze the transfer 
of a sugar to a substrate, and glycosidases are enzymes that catalize the hydrolysis of 
glycosidic bonds in glycan structures. Glycosilation is a very dynamic process. 
Ilustration 5: T. cruzi Trans-sialidase (TSTC) transfers sialic acids from host glycoconjugates to 
parasite mucins. TSTC modifies terminal glycans, both parasite mucins (a) and host glycoconjugates (b). 
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Expression or glycosiltransferases and glycosidases glycan profile change between cell 
types, and these enzymes are highly regulated according to cell metabolism, activation 
or pathological conditions. However, some types of glycosylation occur outside the 
secretory pathway. In mammals, N-acetylglucosamine has been found linked to serine 
or threonine residues in many cytoplasmic and nuclear proteins (Hart, Kreppel et al. 
1996). For instance, it has been reported the importance of this O-glycosidation in the 
oncogenic protein p53 affecting phosphorilation sites, and regulating by the balance of 
both events activity and stability of the protein (Yang, Kim et al. 2006). 
 
 The importance of glycosylation is shown by the fact that >1% of the total 
genome encodes genes for the glycosylation machinery, 50% of the proteins are 
glycosylated in mammals (Apweiler, Hermjakob et al. 1999), 80% of membrane 
proteins, and is by far the most common post-translational modification, highly 
evolutionary conserved. The classes of glycoconjugates found in eukaryotic cells are 
divided according to the nature of the linkage of the sugar moiety to the aglycome (the 
non sugar part of the molecule, a protein or a lipid).  Within the mammalian 
glycosilation repertoire, N-glycosilation and O-glycosilation have been identified, and 
this leads to three different types of glycoconjugates, N-glycans, O-glycans and 
glycosaminoglycans. An N-glycan is a sugar chain covalently linked to an asparagine 
residue within the consensus peptide sequence Asn-X-Ser/Thr. O-glycans are typically 
linked to the peptide chain via N-Acetyl-galactosamine to a serine or threonine residue, 
although other types of O-glycans do exist (Schachter 2000; Yan and Lennarz 2005). 
Glycosaminoglycans (often termed proteoglycans) are also linked to serine or threonine, 
but they are linear, produced by different biosynthetic pathways and are often higly 
sulphated (Esko and Selleck 2002). 
 
 Historically, the importance of glycans has been attributed to metabolism and 
structural properties, but glycans influence the structure and function of the mature 
glycoproteins that are attached at, thus controlling molecular recognition, cell 
interactions and signal triggering for cellular functions.  
 The way that glycans can modify protein functions is associated to the high 
variability that can be found in these molecules. Meanwhile nucleotides and amino 
acids form linear polimers, monosaccharides form branched structures, which means a 
huge number of three-dimensional different structures. For example, using 20 amino 
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acids, around 64 millions of different combinations can be achieved. However, using 
only 6 hexopyranoses as much as 10 P12 Pdifferent combinations could be possible. From a 
cellular point of view, structure is synonymous of information. Besides, the same 
peptide sequence can hold different glycans, leading to the possibility to have different 
glycoforms with identical protein backbone, expanding even more the diversity linked 
to glycans; this fact joins glycoconjugates to a primordial role in the context of 
molecular recognition. Nevertheless, there is no communication without the proper 
tools to interpret the code, and the biological information that glycans encode should be 
decoded by specific receptors, able to recognize it. In order to recognize these glycans, 
there are various classes of glycan binding proteins (CBPs), or lectins. CBPs are 
proteins of non-immune origin able of recognize specific glycan structures without 
metabolic sugar modification, turning the structural information into biological 
information. The term “lectin” tends to refer nowadays to CBPs present in plants, 
meanwhile CBPs is used for animal lectins. 
 CBPs are implicated in molecular recognition phenomena, and this is so in part 
due to the surprisingly fine specificity that CBPs show to ligands presented by distinct 
glycoconjugates. There are several families of CBPs, some recoginize not only 
mammalial glycans, but they can also recognize glycans present on the surface of 
several pathogens. This reflects their dual function in host-pathogen recognition and 
biological cell responses. On the other hand, some pathogens may also express specific 
glycan epitopes not present in vertebrate host, recognized also by other mammalian 
CBPs.  Four CBPs families are predominantly intracellular and four generally function 
outside the cell.  The intracellular CBPs are the calnexin family, M-type, L-type and P-
type, and are located in luminal compartments of the secretory pathway and function in 
the trafficking, sorting and targeting of maturing glycoproteins.  The extracellular CBPs 
enclose the C-type (collectins, selectins, mannose receptor, and others), R-type, I-type 
(siglecs) and galectins. They are either secreted into the extracellular matrix or body 
fluids, or localized to the plasma membrane, and mediate a range of functions including 
cell adhesion, cell signalling, glycoprotein clearance and pathogen recognition.  These 
eight families are the best known, but recent findings point to the existence of additional 
new groups of animal lectins - F-box lectins, ficolins, chitinase-like lectins, F-type 
lectins and intelectins - some of which have roles complementary to those of the well-
established lectin families. More information about animal CBPs can be found at 
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Uhttp://www.imperial.ac.uk/research/animallectinsU or 
HTUhttp://www.functionalglycomics.orgUTH.    
 Glycan recognition through CBPs participate in multiple mechanism of cellular 
regulation, from protein folding to processes involved in cell-cell communication, 
adhesion, cellular homeostasis receptor activation and signal transduction (Ohtsubo and 
Marth 2006). Several CBPs play an outstanding role within the immune system, like C-
type lectins (van Kooyk and Geijtenbeek 2003), siglecs (Crocker, Paulson et al. 2007; 
Varki 2007) and galectins.   C-type lectins and Siglecs are antigen-uptake receptors that 
facilitate antigen presentation to T cells by APCs. Galectins are more versatile 
molecules able to modulate the physiology of different immune cells by acting as 
adhesion proteins, cytokine regulators or cell activators. The features of the galectin 
family will be exposed in detail.    
 
5. Galectins. 
  
 5.1 General Concepts  
  
 Galectins are a quite new family of animal glycan binding proteins highly 
conserved throughout animal evolution. Although the first galectin was discovered in in 
1979, it was only in the lates 1990s that a growing body of experimental evidences 
made the scientific community look at these proteins with interest.  Galectins are 
defined by a conserved carbohydrate recognition domain (CRD) of about 130 amino 
acids with affinity for β-galactosides, as it was defined in 1994(Barondes, Castronovo et 
al. 1994). Galactose is a necessary but insufficient requirement for high-affinity 
binding. Most mammalian galectins bind preferentially to glycoconjugates containing 
the ubiquitous disaccharide N-Acetyllactosamine (Galβ1-3GlcNAc or Galβ1-4GlcNAc). 
Binding to individual lactosamine units is low, Kd around 1µM, but avidity increases 
when they bind to lactosamine disaccharide in repeating units (polylactosamines). 
However, monosaccharides flanking the basic lactosamine unit modify the affinity of 
each galectin for the different glycoconjugates, due to the subtle differences in the CRD 
structure of individual members.  
 To date, 15 mammalian galectins have been identified in a wide variety of 
tissues from several species are more are likely to be discovered. Galectins are 
subdivided into three different groups according to their structure: monomeric, tandem-
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repeat and quimeric galectins (Hirabayashi and Kasai 1993). Monomeric galectins have 
only one CRD. Galectin-1, -2, -5, -7, -10, -11, -13, -14 and -15 are the member of this 
group. Although they are monomers, monomeric galectins can dimerize depending on 
the concentration. Tandem repeat galectins are composed by two CRDs, which can have 
different sugar specify in same galectins. The two CRDs present in the protein are 
joined covalently by a peptide linker of variable length, and sometimes the length is the 
different between isotypes of the same galectin member, like galectin-8 (Hirabayashi 
and Kasai 1993). Members of this group are galectin-4, -6, -8, and -9. The last group is 
formed only for one protein, galectin-3. Gal-3 is composed by a CRD fused to an N-
terminal domain. The N-terminal domain shows a high degree of homology with 
collagen, composed by tandem repeats aminoacids sequences. This collagen-like 
domain is responsible for the protein oligomerization that can be observed in soluble 
galectin-3. Galectin-11, also known as GRIFIN (galectin-related inter-fiber protein) is 
special within the family, in the sense that this protein lacks galactoside binding activity  
 
 
 
 
 
 
 
 
 
 
(Ogden, Nunes et al. 1998). It is expressed only in the lens, and it was included in the 
galectin family due to sequence homology, but its CRD lacks seven essential amino 
acids required for sugar binding, at least in mammals. For this reason its inclusion in the 
gatin family has been debated for many authors. However, a homologous GRIFIN has 
been found in zebrafish in lens, showing in this case carbohydrate binding activity 
(Ahmed and Vasta 2008). Many galectins are either mono-, bi- or multivalent with 
regards to their carbohydrate binding activities. Monomeric galectins can form non 
covalent dimmers, tandem-repeat galectins have two CRDs in their sequence and 
galectin-3 forms olligomers and lattices when it binds to complex glycoconjugates on 
Galectins 1,2,5,7,
10,11,13,14,15 Galectins 4,6,8,9,12
Galectin 3
MONOMER
TANDEM 
REPEAT QUIMERA
Ilustración 6: The galectin family 
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the cell surfaces. This multivalency is a critical feature for their biological function, 
because this allows galectins to cross-link different receptors on the cell surface, 
triggering so intracellular signals that will address cell biology (Fred Brewer 2002). 
Biological functions of galectins are not exclusively depending on receptors cross 
linking. It has been described for Gal-3 the formation of lattices on the cell surface. This 
lattice is formed because Gal-3 is able to form oligomers, and the effect is a 
modification of surface receptors motility and clustering, altering the receptor threshold 
to trigger signals inside the cells. It is well described this effect on the TCR motility on 
T cells. Remarkably, the responsiveness of cells to individual members of galectin can 
fluctuate depending on the glycoconjugates expressed on the cell surface, and glycan 
composition is the result of selective glycosiltransferases activity, enzymes that are 
regulated according to the differentiation and activation of the cells.       
 It has been shown that galectins are present in all the cellular locations, nucleus, 
cytoplasm and cell surface. Galectins are synthesized in the cytoplasm, but they can be 
either traslocated to the nucleus or can be secreted, despite they do not contain signal 
peptides to direct them through the classical endoplasmic reticulum-Golgi apparatus 
secretion system (Mehul and Hughes 1997; Hughes 1999). This unorthodox mechanism 
has been described for Gal-1 and -3 secretion. They are secreted to non-classical 
secretory pathways, and once outside the cell, they can bind to, and cross link multiple 
glycoconjugates present on the cell surface, in the extracellular matrix or even on the 
surface of pathogens present during an infectious process. Besides, this unusual route 
might prevent galectins to bind to nascent glycoproteins.  
 Some galectins are distributed in a wide variety of tissue and cell types, 
meanwhile others are restricted to more specific locations. For example, galectin-1 is 
expressed ubiquitously, and galectin-4 is expressed only in the digestive tract under 
normal physiological conditions (Huflejt and Leffler 2004). Galectins are commonly 
expressed in immune cells (Rubinstein, Ilarregui et al. 2004). They are found in 
activated macrophages (Sato and Hughes 1994; Rabinovich, Iglesias et al. 1998; 
Rabinovich, Riera et al. 1999; Correa, Sotomayor et al. 2003; Sano, Hsu et al. 2003), 
activated B cells (Zuniga, Rabinovich et al. 2001; Acosta-Rodriguez, Montes et al. 
2004),activated T cells (Blaser, Kaufmann et al. 1998; Joo, Goedegebuure et al. 2001), 
dendritic cells (Vray, Camby et al. 2004) and NK cells (Hanna, Bechtel et al. 2004). 
Recently it has been also shown elevated expression of galectins in CD4P+PCD25 P+ P 
regulatory T cells (Ocklenburg, Moharregh-Khiabani et al. 2006; Garin, Chu et al. 
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2007; Kubach, Lutter et al. 2007).  Expression of galectins during activation, 
differentiation and infectious processes is highly regulated in immune cells, pointing out 
the important role that galectins play during the immune response. Galectins have been 
implicated in cell-cell adhesion, cell-ECM interaction, inmunomodulation, 
inflammation, cell growth or chemotaxis (Rabinovich, Baum et al. 2002; Liu 2005; 
Rabinovich, Toscano et al. 2007), functions that will be exposed below. All of  these 
functions are of great importance during the development of the immune response and 
inflammatory processes, and together with the fact that galectins are markedly up-
regulated and secreted by several cell types in response to pathogen invasion, have 
prompted to several research groups to postulate that galectins are “danger signals” 
(Sato 2002; Sato and Nieminen 2004).  
 The wide diversity that has been reported in galectins functions is in 
concordance with the broad distribution of individual galectins in different tissue, as 
well as in the subcellular locations. Most of the functions attributed to galectins have 
been shown to be extracellularly, interacting with glycosilated surface molecules to 
regulate intracellular signalling. However, some intracellular functions has also been 
postulated, like regulation of pre-mRNA splicing (Dagher, Wang et al. 1995; 
Vyakarnam, Dagher et al. 1997), protection (Yu, Finley et al. 2002) and induction of 
apoptosis (Kuwabara, Kuwabara et al. 2002) controlling the release of cytochrome c 
from the mitochondria. 
 
 So, galectins operate at different levels of innate and adaptive response, but in 
addition, and to make the scenario even more complex, β-galactosides-related 
carbohydrates are commonly present in pathogen-associated glycoconjugates, that are 
potential ligands for galectins. This can affect almost every immune event triggered by 
galectins: i) pathogen recognition that in turn will mount the proper response against 
specific pathogens, ii) adhesion promotion of pathogen to host cells and extracellular 
components, iii) galectins-mediated response in the host, including for example 
regulation of apoptosis, cytokine balance and cell adhesion and migration. There is in 
the literature a growing number of pathogens that can bind galectins. The consequences 
of galectin-pathogen interaction are being revealed by the use of galectin deficient mice 
models, mainly Gal-3P-/-P mice, as it will be showed below in detail.   As several examples 
of pathogens recognized by galectins, it can be mentioned the following. Gal-1 acts as a 
soluble factor that enhances adhesion of HIV to host cells (Ouellet, Mercier et al. 2005; 
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Mercier, St-Pierre et al. 2008). Gal-3 and Gal-9 bind Leishmania sp.(Pelletier and Sato 
2002; Pelletier, Hashidate et al. 2003), Gal-3 binds mycolic acids of Mycobacterium 
tuberculis (Barboni, Coade et al. 2005), and also Klebsiella pneumoniae (Mey, Leffler 
et al. 1996), the helminth Schistossoma mansoni (van den Berg, Honing et al. 2004) and 
Candida sp., (Kohatsu, Hsu et al. 2006) showing antifungical activity.  
 Nevertheless, most of the galectin functions reported to date have been 
demonstrated using recombinant proteins added exogenously to different cell types. 
Whether endogenous galectins exert all these proposed activities remains to be clarified. 
It is worthy to mention this point, because when in vitro experiments are done, several 
important features about galectin way of action are not been considering. i) 
Concentration of galectins in solution affects their glycan affinity and multivalency, 
thus their ability to cross link several receptors. ii) subcellular location is essential to 
address galectin function. For example, Gal-3 is an anti-apoptotic factor in T cells when 
it is intracellular overexpressed, but induces apoptosis of the same cells when is added 
in vitro extracellularly. iii) glycans that are the natural ligands of galectins can change 
their sugar composition depending on the physiopatological status. In the last years, 
new approaches have been made, by knocking out with siRNA specific galectin genes 
and using knock out animal models. This will be extremely useful to address the real 
functions of galectins. Despite that, it is available now a lot of information about 
galectin functionality that will be exposed now, focusing on their immunomodulatory 
and inflammatory abilities.  
Anderson et al., 2007
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6. Galectin-1 
   
 6.1 General Aspects 
 
 Galectin-1 was the first protein discovered in the family. It has been named 
previously L-14, galaptin and BHL between other names. It is encoded by the 
LSGALS1 gene, located on chromosome 22q12. Galectin-1 occurs as a monomer of 
around 14KDa as well as a non-covalent homodimer consisting of subunits of one CRD. 
The integrity of the dimer is maintained through interaction in the hydrophobic core, 
region separated from the CRD (Lopez-Lucendo, Solis et al. 2004). This gives to the 
dimer a high stability in molecular terms. Nevertheless, one of the main properties of 
the protein is that it spontaneously dissociates at low concentration (Kd 7µM) into 
monomeric form (Cho and Cummings 1995), that it is still able to bind to glycans but 
with lower affinity and different specifity (Leppanen, Stowell et al. 2005). Interestingly, 
each form is associated with different biological activities. The arrangement of 
lactosamine disaccharides in multiantennary repeating chains (up to 3 branches) 
increases the binding avidity for dimeric gal-1 (dGal-1), but in contrast there is no 
increase when the recognition lactosamine unit is repeated in a string glycan (Schwarz, 
Ahmed et al. 1998; Ahmad, Gabius et al. 2004).   Although terminal galactose reidues 
are important for dGal-1 binding, dGal-1 binds well to α3-sialylated and α2-fucosylated 
terminal N-acetyllactosamine, but not to α6-sialylated or α3-fucosylated terminal N-
acetyllactosamine (Amano, Galvan et al. 2003; Leppanen, Stowell et al. 2005). The 
importance of this structural differences has been proved in the case of thymocyte 
selection, because activity of the ST6Gal I sialyltransferase leads to express α6-
sialylated N-glycans containing. This avoids gal-1 binding and the subsequent induction 
of galectin mediated apoptosis, and therefore promotes cell survival (Amano, Galvan et 
al. 2003). This example shows the very close relation between glycan structure 
consequence of selectively glycosyltransferases expression and cell response mediated 
by galectins.    
 Gal-1 is present both inside and outside the cells. It has been described in the 
cytosol and cell nuclei. It is secreted to the extracellular medium, in a way 
independently of the classical endoplasmic reticulum-Golgi pathway, and outside the 
cells can bind glycoconjugates on the cell surface or on the extracelullar matrix. The 
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secreted pathway of Gal-1 is still unclear. It seems that Gal-1 is secreted in a manner 
similar to the pro-angiogenic factor FGF-2 or interleukin-1β, requiring some 
unidentified integral membrane proteins. It has been proposed that the gal-1 export 
pathway might imply sugar recognition and the Na+/K+ -ATPase pump, because a 
selective inhibitor of the sodium pump, ouabain, inhibits these export processes (Nickel 
2005).  Extracelullar functions of gal-1 are associated to the sugar binding actity, 
meanwhile intracellular functions are commonly CRD independent.   
 Gal-1 is expressed broadly in the organism. It has been located in skeletal, 
smooth and cardiac muscle, neurons, thymus, kidney, spleen, placenta, etc (Chiariotti, 
Salvatore et al. 2004).  Regarding immune cells, gal-1 is expressed by a variety of cells 
in central and peripheral immune compartments, including thymic epithelial cells 
(Baum, Pang et al. 1995), activated T cells (Blaser, Kaufmann et al. 1998; Gonzalez, 
Rubinstein et al. 2005), macrophages (Rabinovich, Iglesias et al. 1998) and activated B 
cells after T. cruzi infection (Zuniga, Rabinovich et al. 2001).   
  
 6.2 Galectin-1 in inflammation and immune response 
   
 TModulation of cell adhesion and migrationT.  
 Several reports describe the role of Gal-1 during cell migration. Cell migration is 
the net result of adhesion and invasion. It has been published several reports pointing 
out the role of Gal-1 in the two processes, but most of the work has been done in 
relation to tumour cells. Gal-1 increases the adhesion of various normal and cancer cells 
to ECM via the cross linking of glycosilated integrins. Gal-1 transiently increases 
availability of β1 integrins, modulating adhesion of smooth muscle cells (Moiseeva, 
Williams et al. 2003). Gal-1 can also mediate aggregation of human melanoma cells, 
and induce adhesion between cancer and endothelial cells, process that favours the 
dispersion of the tumour cells (Glinsky, Huflejt et al. 2000). Gal-1 has been described as 
a marker of high cell invasiveness in mammary carcinoma cell lines, and binds to a 
number of ECM components like laminin, fibronectinand vitronectin. Regarding T 
cells, it has been shown a negative regulation of T-cell recruitment to the endothelium 
mediated by Gal-1, under both physiological and pathophysiological conditions, and 
Gal-1 inhibited interleukin-1ß-induced polymorphonuclear leukocytes recruitment intoP 
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Pthe mouse peritoneal cavity under experimental inflammation(La, Cao et al. 2003; 
Norling, Sampaio et al. 2008). 
 
 TRegulation of cell growthT.  
 Effects of gal-1 in the regulation of cell growth are positive or negative 
depending on the cell types involved, cell activation status and might be influenced by 
factors related to the Gal-1 itself, like the balance of monomeric versus dimeric forms, 
and intracellular versus extracellular location (Scott and Weinberg 2004). Gal-1 is 
mitogenic for various types of murine and human cells,   including spleen cells, 
lymphocytes (Symons, Cooper et al. 2000)  and various vascular cells (Sanford and 
Harris-Hooker 1990; Moiseeva, Javed et al. 2000). On the other hand Gal-1 inhibits 
proliferation of other cell types like neuroblastoma (Kopitz, von Reitzenstein et al. 
2001) and stromal bone marrow cells (Andersen, Jensen et al. 2003). In addition, Gal-1 
inhibits antigen-induced proliferation of CD8P+P T cells (Blaser, Kaufmann et al. 1998).  
 
 T  cell homeostasis and survivalT.  
 Gal-1 has emerged as a new regulator of T cell homeostasis. Indeed, this is the 
most studied and best understood function of Gal-1. It has already been said, that Gal-1 
inhibits proliferation of activated CD8 T cells, but regulation of T cell response is much 
more regulated by Gal-1. Gal-1 controls T cell central and peripheral tolerance 
(Sotomayor and Rabinovich 2000). During T cell development in Thymus, negative 
selection of potentially auto reactive T cell clones may occur, in order to avoid 
autoimmune disease. The mechanisms underlaying thymocite selection are not well 
understood, but it has been shown that Gal-1 expressed on thymic epithelial cells 
induces selective apoptosis of immature thymocytes (Perillo, Uittenbogaart et al. 1997), 
suggesting a potential role for this protein in the processes of negative/positive selection 
within the thymic microenvironment. Moreover, once T cells are activated in the 
periphery, to maintain cellular homeostasis and to protect activated mature T cells from 
the continued secretion of potentially harmful amounts of cytokines, these activated 
cells must be removed by apoptotic mechanisms. This apoptosis used to be mediated by 
Fas-Fas interaction, but other molecules seem to be involved in the induced apoptosis. 
Gal-1 induced apoptosis of activated T cells in the periphery but not of resting T cells 
(Perillo, Pace et al. 1995), and the cell death seems to be dependent on the expression of 
the core 2 β-1,6 N-Acetylglucosaminyltransferase (C2-GnT I) (Galvan, Tsuboi et al. 
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2000; Nguyen, Evans et al. 2001). This enzyme is responsible of the core branched 
glycan structure present on O-glycans of the surface proteins that lead to Gal-1 
dependent apoptosis. Thus, cell lines lacking this glycosyltransferase are resistant to cell 
death induced by Gal-1. Interestingly, differential glycan expression has been shown in 
different T cell subsets, and this leads to a different susceptibility to Gal-1 induced 
death. Meanwhile Th1 and Th17 T cells has been shown to undergo Gal-1 mediated 
apoptosis, Th2 were resistant, due to a differential sialylation of cell surface 
glycoproteins (Toscano, Bianco et al. 2007). CD45 was the first glycoprotein 
demonstrated to be a galectin-1 receptor in activated T cells (Perillo, Pace et al. 1995; 
Walzel, Schulz et al. 1999). Subsequently, other counter-receptors were demonstrated to 
bind Gal-1, like CD43, CD2, CD3 and CD7. Gal-1 binding to activated T cells results in 
a dramatic redistribution of these glycoproteins into segregated membrane 
microdomains. However, although deletion of CD45 confirmed its importance in gal-1 
mediated cell death, gal-1 is still able to induce apoptosis in CD45-deficient T cells 
(Fajka-Boja, Szemes et al. 2002). The signal transduction events that gal-1 triggers into 
the cell to promote apoptosis involve several intracellular mediators like the activation 
of Lck/ZAP-70/MAPK signalling pathway (Ion, Fajka-Boja et al. 2006) , Bcl-2 function 
modulation, cytochrome c release from the mitochondria, caspase-8 (Matarrese, Tinari 
et al. 2005) and induction of specific transcription factors like NFAT, AP-1 
(Rabinovich, Alonso et al. 2000) and NF-kappaB (Koh, Lee et al. 2008). Gal-1 also 
suppresses the production of the pro-inflammatory cytokine IL-2 (Vespa, Lewis et al. 
1999), and favors the anti-inflammatory IL-10 (van der Leij, van den Berg et al. 2004), 
effect that was enhanced when a recombinant covalently dimeric galectin-1 was used 
(van der Leij, van den Berg et al. 2007). Moreover, Gal-1 decreased TNF-α and IFN-γ 
production by IL-2 activated T cells (Rabinovich, Ariel et al. 1999). Taken all the data 
together, Gal-1 seems to be a key regulator of T cell homeostasis, first acting during the 
central tolerance, and later controlling the activated T cells. Several facts support this 
hypothesis: Gal-1 is ubiquitously expressed, and is overexpressed in organs of immune 
privilege, such as retina, testis or placenta. Here, gal-1 might ensure the rapid 
elimination of inflammatory T-cells, protecting so the integrity and function of the 
tissue. And finally, under inflammatory conditions, high amounts of Gal-1 are secreted 
by macrophages, antigen-induced T cells and B cells. This lead to the killing of effector 
T cells after the completion of the immune response.  
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 In addition to this pro-apoptotic activity, Gal-1 has been shown to modulate the 
cytokine balance under pathological conditions. Gal-1 has efficiently skews the 
cytokine profile from Th1 to Th2. This is showing promising new therapeutic 
approaches for the treatment of inflammation-related diseases including graft versus 
host disease (Baum, Blackall et al. 2003), arthritis (Rabinovich, Daly et al. 1999), 
autoimmune retinal disease (Toscano, Commodaro et al. 2006) colitis and nephritis 
(Tsuchiyama, Wada et al. 2000), and could be useful in some neurodegenerative 
diseases and in cancer (Rabinovich 2005).    
  
 TGalectin-1 functions in other immune cell typesT.  
 Compelling evidence has been accumulated regarding the effects of galectin on 
T cell fate, but limited information is available on how galectin-1 may impact other 
immune cell types. In concordance with the anti-inflammatory properties of this protein, 
Gal-1 has been shown to inhibit IL-12 and nitric oxide production by macrophages in 
vitro, and Gal-1 inhibited the classical pathwayP Pof NO production and iNOS expression 
after LPS macrophage activation, increased arginase activity,P Pand favored the alternative 
route of L-arginine metabolism (Correa, Sotomayor et al. 2003). It has been reported, 
that Gal-1 reduces IFN-γ-induced MHC II expression and antigen presentation 
(Barrionuevo, Beigier-Bompadre et al. 2007). The effects of Gal-1 over dendritic cells 
(DCs) have also been studying. Gal-1 maturated DCs showed an activation status 
similar to the one after LPS treatment, in the means of up-regulation of activation 
markers (CD80, CD86, CD83, HLA-DR), IL-6 and TNF-α production. In contrast, Gal-
1 did not induce IL-12 production by DCs, as LPS does (Fulcher, Hashimi et al. 2006). 
This suggests a possible role of Gal-1 during initiation of innate immune response. It 
has been attempted to take advantage of this Gal-1 ability over DCs to treat type I 
diabetes in mice. Engineered DCs overexpressing Gal-1 have been shown useful to 
increase the apoptosis of T cells and to reduce the number of IFN-gamma-secreting 
CD4+ T cells in pancreatic lymph nodes (Perone, Bertera et al. 2006)  
 
 Galectin-1 in infectious diseases and during Chagas disease. 
 Some of the Gal-1 functions have been deeply described, like regulation of T 
cell homeostasis, and many others need still to be clarified. Nevertheless, as immune 
and inflammatory modulator, it is clear to think that Gal-1 might play an outstanding 
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role during the mounting and resolution of the immune response. However, there are not 
many works about the role of galectin-1 during infectious diseases. It has been shown 
the implications of gal-1 during HIV infection, because gal-1 acts as an adhesion 
molecule that promotes virus attachment to host cells (Ouellet, Mercier et al. 2005; 
Mercier, St-Pierre et al. 2008), and because HIV infection changes the glycan 
composition of infected T cells, enhancing their susceptibility to Gal-1 mediated cell 
death (Perone, Bertera et al. 2006).  
 In regard to our experimental model, the Trypanosoma cruzi infection, it has 
been published an up regulation of gal-1 in macrophages and B cells after parasite 
infection in the murine model by the same group in 2001 (Zuniga, Gruppi et al. 2001; 
Zuniga, Rabinovich et al. 2001).  They showed that Gal-1 expression is up-regulated in 
macrophages, both in vivo and in vitro, after T. cruzi infection, and that Gal-1 is 
secreted to the extracellular medium in response to the parasite infection. Interestingly, 
they showed that Gal-1 is able to control macrophage activity and survival. Low 
concentration of Gal-1 was able to increase T. cruzi intracellular replication in vitro and 
reduced the inflammatory macrophage activity, because IL-12 secretion was 
diminished, as well as nitric oxide levels. This led to increase parasite replication. 
However, a higher concentration of Gal-1 showed a very different activity in the 
modulation of macrophage activity, because higher Gal-1 concentrations were found to 
trigger macrophage apoptosis inhibiting parasite replication. Gal-1 was also up-
regulated in B cells during T. cruzi infection, mainly in the cytosol, although it was also 
found that activated B cells secreted Gal-1. This secreted Gal-1 did not induce apoptosis 
in B cell, but it did in activated T cells. Moreover, secreted Gal-1 by B cells inhibits 
INF-γ by T cells during infection. It is likely that activated B cells regulate T cell 
activity through the expressionP Pof Gal-1, but this results needs still to be confirmed. 
Another point is that Gal-1 could be implicated in autoimmunity processes during 
Chagas disease, because it has been shown the occurrence of anti-Gal-1 auto antibodies 
in the sera from infected patiens, both in acute and in chronic stages. Because Gal-1 
expression was highly up-regulated in the hearts of these patients, the authors speculate 
with a possible link between Gal-1 expression and Chagas cardiomyopathy, by means 
of autoimmunity processes (Giordanengo, Gea et al. 2001), but whether these antibodies 
have some clinical relevance or not, is still under controversy.  P P  
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7. Galectin-3 
 
 7.1 General aspects 
  
 Galectin-3 is the sole member of the chimera-type galectins. It is encoded by the 
LSGALS3 gene, located on chromosome 14q21-22. Other names attributed to this 
protein were Mac-2 antigen, CBP35 or IgEBP. The monomer in solution is a protein of 
35 KDa. Gal-3 is composed by two different domains. One is the C-terminal domain, 
composed by 130-135 amino acid residues. This is the carbohydrate recognition 
domain, and this is what defines the molecule as a galectin. Like other galectins, this 
domain is arranged in 12 β strands and it has affinity for lactose (Lac) and N-
acetylactosamine (LacNAc). The affinity of Gal-3 is increased for complex branched 
ligands (Hirabayashi, Hashidate et al. 2002). Gal-3 acts as a receptor for ligands 
containing poly-N-Acetyllactosamine sequences which consist of many disaccharide 
units: Gal β1,4 GlcNAc bond to each other by β1,3 linkage. Extension at the non-
reducing end of the disaccharide units with NeuNAcα2,3 or with GalNAcα1,3 and Fuc 
α1,2 substituents greatly enhances affinity for galectin-3 (Hughes 2001). The molecular 
interaction of human galectin-3 with the LacNAc moiety is well characterized thanks to 
structural and mutagenic studies. The arginine in position 144 is known to interact with 
the GlcNAc residues linked to the O-3 of the terminal galactose (Seetharaman, 
Kanigsberg et al. 1998).  
 
 Galectin-3 is so far unique in the family in having an extra, long and flexible N-
terminal domain. This domain is composed by around 100 amino acid residues, and it is 
made up of repetitive sequences rich in proline, glycine, tyrosine and glutamine, and 
lacking hydrophobic residues (Krzeslak and Lipinska 2004; Rubinstein, Ilarregui et al. 
2004). It has been reported than the N-terminal domain has 33.5% of homology with 
collagen α1 (II) chain of bovine cartilage (Raz, Pazerini et al. 1989), so it is also 
designated as collagen-like domain. The N-terminal domain contains sites for 
phosphorilation, (Ser 6, Ser 12), that seems to be implicated in the regulation of its 
intracellular location and in the regulation of its activities, like control of apoptosis 
(Mazurek, Conklin et al. 2000; Yoshii, Fukumori et al. 2002). Although this domain 
lacks sugar binding activity, it has been recently shown by molecular modelling and 
mutagenic analysis that it contributes together with the CRD in oligosaccharide binding 
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through TyrP102P and adjacent residues for some fucosylated sugar structures (Barboni, 
Bawumia et al. 2000). However, the N-terminal domain is essential to regulate Gal-3 
function because it is also responsible for the oligomerization of the protein (Massa, 
Cooper et al. 1993), and oligomers are critical for cross-linking of surface receptors and 
signal transduction. Gal-3 can form oligomers composed up to 5 units, and is able to 
form lattices on the cell surface. These lattices are important because they control 
protein motility. In this way, Gal-3 modulates receptor clustering, segregation and 
activation threshold on the cell surface (Rabinovich, Toscano et al. 2007). One example 
is the interaction of galectin-3 with the T-cell receptor (TCR). The interaction is 
promoted by modifications on glycan composition of the TCR, mainly by the activity of 
the N-Acetylglucosaminyltransferase, MGat5, and results in a lattice formation that 
restricts TCR motility and down-regulation of the T cell response (Demetriou, 
Granovsky et al. 2001).  
 Gal-3 has been found in the cytosol, nucleus and attached to the cell surface.  As 
it has been mentioned before, Gal-3 can be actively secreted to the extracellular milieu 
via a reticulum-golgi independent pathway, in response to inflammatory stimulus like 
LPS or infections. In the case of Gal-3, it is likely that the N-terminal domain contains 
signals that address the protein to this non-conventional secretion pathway. It has been 
shown that a hamster CRD Gal-3 fragment lacking the N-terminus, when expressed in 
transfected Cos cells, is not secreted (Menon and Hughes 1999). Moreover, the addition 
of the Gal-3 N-terminus to a non-related cytosolic protein makes the protein to be 
secreted outside the cell (Mehul and Hughes 1997). Immunohistochemical studies have 
indicated that the first step for Gal-3 secretion is the accumulation of Gal-3 at the 
cytoplasmic side of the plasma membrane, and then vesicles containing Gal-3 are 
pinched off. The transfer of the protein to the plasma membrane domains seems to be 
dependent on heat shock proteins and other molecular chaperones. The capture of Gal-3 
to the membrane domains is mediated by the Src protein family of tyrosine kinases 
(Zlatkine, Mehul et al. 1997).  
  The wide distribution of Gal-3 in the different cell compartments reflects its 
multivalent functionality, as it will be exposed below. There have been described 
several glycosilated surface ligands for Gal-3, like extracellular matrix components and 
membrane integrins. The extracellular recognition of these ligans is usually glycan-
dependent via CRD, and is related to cell-cell interaction, adhesion and signal 
transduction. There have been described some intracellular proteins as Gal-3 ligands, 
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and interactions have been described to be CRD-dependent or independent, depending 
on the protein. Intracellular ligands are cytokeratins (Goletz, Hanisch et al. 1997), 
Gemin4 (Park, Voss et al. 2001) and Bcl-2 (Yang, Hsu et al. 1996). The presence of 
Gal-3 in the cellular nucleus appears to be associated with alternative pre-RNA splicing 
(Patterson, Wang et al. 2004), and regulation of gene transcription (Lin, Pestell et al. 
2002). Gal-3 stabilized transcription binding factor in the cyclin DB1 B promoter region and 
induced trans-activation of CREB and SP1 transcription factors to activate promoter 
activity. Since CREB and SP1 elements are present in many promoter regions of many 
genes, it is reasonable to speculate that Gal-3 could be regulating other gene expression.  
It has been shown two possible mechanisms to explain nuclear import of Gal-3 to the 
nucleus, one a passive diffusion and another one an active transport (Nakahara, Oka et 
al. 2006). An increasing effort is being done regarding this event, because the import of 
Gal-3 to the nucleus is, in part, the malignant phenotype of various cancers. 
 Although it was found in many normal tissues, Gal-3 expression in adults, 
similarly to its expression during embryogenesis, is mainly related to the epithelial cells 
and myeloid cells.  However, Gal-3 is expressed in other tissues under pathological 
conditions, like infections or many tumours: human pancreas, colon and thyroid 
carcinomas. This is not surprising, taking into account the many biological functions 
that Gal-3 is modulating: cell-cell adhesion, cell-extracellular matrix interactions, 
immunoregulation, inflammation, chemotaxis and pathogen recognition.   
 
 7.4 Galectin-3 in inflammation and immune response 
   
 A large body of work has demonstrated the role of galectin-3 in the regulation of 
the function of immune cells. Gal-3 expression has been detected in activated 
macrophages, eosinophils, neutrophils, activated B cells, mast cells, epithelium of the 
gastrointestinal and respiratory tracts (Frigeri and Liu 1992; Truong, Gruart et al. 1993; 
Truong, Gruart et al. 1993; Liu, Hsu et al. 1995; Acosta-Rodriguez, Montes et al. 2004). 
Many studies have been performed using exogenously added recombinant galectins, but 
in the last years the use of Gal-3 deficient mice has provided additional evidence to 
consider this protein an important mediator during inflammatory and immune processes. 
Thus, Gal-3 is able to recognize many pathogens, being a new candidate for a new type 
of pathogen recognition receptor (PRR). In general, Gal-3 is a powerful pro-
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inflammatory signal and specific Gal-3 functions related to inflammation and 
immunology will be shown. 
  
 Regulation of apoptosis and cell growth 
 Galectin-3 has been shown to be both a pro- and anti-apoptotic molecule. In 
general, intracellular Gal-3 acts as an inhibitor of apoptosis, meanwhile extracellular 
Gal-3 is a pro-apoptotic factor. Apoptosis in lymphocytes exemplifies this fact. Gal-3 
transfected Jurkat T cells (Yang, Hsu et al. 1996) and Gal-3 transfected Burkitt 
lymphoma cells (Hoyer, Pang et al. 2004) were more resistant to anti-Fas mediated 
death. In contrast, when Gal-3 was added exogenously to lymphocytes or T cell lines, it 
induced apoptosis by clustering of the surface glycoprotein CD71 (Stillman, Hsu et al. 
2006). Studies in cancer lines that have been transfected with Gal-3 cDNA showed 
contradictory results too. Meanwhile overexpression of Gal-3 in human brest carcinoma 
cell line BT594 induced apoptosis (Lee, Song et al. 2003), it protected from apoptosis in 
human bladder carcinoma cell line J8 (Lee, Song et al. 2003). As neither of these cell 
lines express endogenous Gal-3, differences can be attributed to the expression of 
different Gal-3-associatted proteins in each cell line. Gal-3 was found to be up-regulated 
in keratinocytes during UV-B-induced apoptosis, acting as an anti-apoptotic mediator 
(Lee, Song et al. 2003), and induced mast cell apoptosis by oxidative stress and 
mitochondrial permeability (Suzuki, Inoue et al. 2008).    
 
 The molecular mechanism that Gal-3 triggers when acts intracellularly to 
prevent apoptosis are not yet completely understood. It seems that Gal-3 prevents 
mitochondrial damage and therefore inhibits cytochrome c release, down-regulating 
caspase activation. In addition, it has been established that Gal-3 binds Bcl-2 (Yang, 
Hsu et al. 1996). There is 48% of similarity between Gal-3 and Bcl-2, and it can be 
found within the CRD of Gal-3 the NWGR motif (residues 180-183 of the human Gal-
3). This motif is essential for the anti-apoptotic activity of Gal-3, since the acivity 
disappears when the glycine present in this motif is substituted for an alanine (Akahani, 
Nangia-Makker et al. 1997). Gal-3 it is the only galectin found to have this motif. 
Interaction with the death receptor family CD95 (APO-1/Fas) could be another way 
used by Gal-3 for its anti-apoptotic function (Fukumori, Takenaka et al. 2004).  
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 Gal-3 was also shown to modulate cell growth. Proliferation and differentiation 
of certain cell types is accompanied by increased or suppressed expression of Gal-3, 
depending on the cell type. Moreover, exogenous Gal-3 can induce or inhibit cell 
growth. Gal-3 was able to induce outgrowth of neuritis from dorsal root ganglia 
explants (Pesheva, Kuklinski et al. 1998), rat mesangial cells (Sasaki, Bao et al. 1999) 
and human lung fibroblast (Inohara, Akahani et al. 1998). On the other hand, Gal-3 
inhibits cell proliferation of granulocyte-macrophage colony-stimulating factor (GM-
CSF)-induced rat bone marrow cells (Krugluger, Frigeri et al. 1997) and MDCK cells 
(Bao and Hughes 1999). It seems that Gal-3 is able to modulate specific signal 
pathways related to cell growth and proliferation. Gal-3 has been shown to interact with 
the oncogenic K-Ras protein in its activated status (Elad-Sfadia, Haklai et al. 2004), 
enhancing the duration and strength of the K-Ras signal. In adittion, Gal-3 interacts with 
N-Ras and H-Ras proteins, loading them into active complexes (Shalom-Feuerstein, 
Levy et al. 2008).  
 
 Modulation of cell adhesion 
 Gal-3 is able to modulate cell-cell and cell-extra cellular matrix interactions in 
account of its multivalency, acting as a bridge between glycosilated components of the 
extracellular medium. In a sugar-dependent way, Gal-3 binds extracellular matrix 
components like laminin (Woo, Shaw et al. 1990; Sato and Hughes 1992; Ochieng and 
Warfield 1995), fibronectin (Sato and Hughes 1992), tenascin (Probstmeier, Montag et 
al. 1995), and membrane integrins present on the surface of the macrophages, the main 
membranes molecules implicated in cell adhesion: CD11b/18, α1/β1, N-CAM, LAMP-
1,2 (Dong and Hughes 1997; Ochieng, Leite-Browning et al. 1998). Gal-3 also binds the 
heavy chain of CD98, induces CD98 dimerization, showing that this is not only a 
passive event, but it promotes integrin activation (Hughes 2001). So, Gal-3 is able to 
mediate cell adhesion of different cell types on extra cellular matrix, in a positive or a 
negative way. It promotes adhesion of human neutrophils to laminin (Kuwabara and Liu 
1996) and to endothelial cells (Friedrichs, Torkko et al. 2007), supports eosinophil 
rolling and adhesion in a process mediated by the integrin VCAM-1 (Rao, Wang et al. 
2007) and mediates binding of L-selectin-triggered lymphocytes to dendritic cells 
(Swarte, Mebius et al. 1998). In contrast, Gal-3 can inhibit adhesion, as observed in 
thymus, where Gal-3 disrupts thymocyte interactions with thymic epithelial cells.  
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Although not deeply discussed in this thesis, it is worth mentioning that Gal-3 is an 
important factor for many processes related to cancer and cell adhesion, like metastasis 
and cancer progression, and Gal-3 it is being considering nowadays as a possible 
therapeutic target for cancer treatment (Hasan, Ashraf et al. 2007). 
  
 Chemotaxis and Cell activation in vivo and in vitro models.  
 Extracellular Gal-3 was first found to be a potent chemoattractant for monocytes 
and macrophages (Sano, Hsu et al. 2000), as observed both in vitro and in vivo. The 
recruitment of these phagocytic cells to the sites of infection is in concordance with the 
pro-inflammatory role attributed to this protein. High concentrations of Gal-3 are 
needed for its chemotactic activity, and both protein domains are necessary for 
macrophages chemotaxis. Recently it has been found that Gal-3 can recruit other cell 
types, like neutrophils during Streptococcus pneumoniae infection (Sato, Ouellet et al. 
2002; Nieminen, St-Pierre et al. 2008). Moreover, Gal-3 is a potent immune cells 
activator. Gal-3 in monocytes and macrophages induces superoxide anion production, 
increases the pro-inflammatory cytokine IL-1 and potentiates the phagocytosis (Sano, 
Hsu et al. 2003), what defines the classical macrophage activation. However, 
endogenous Gal-3 has been implicated in the regulation of alternative macrophage 
activation (associated with exposure to IL-4/IL-13 and distinct fromP Pthose induced by 
IFN- ), through a Gal-3 feedback loop stimulated by IL-4, via activation of CD98 and 
PI3K activation (MacKinnon, Farnworth et al. 2008). These inflammatory activities 
have been also observed in other cell types. Therefore, in neutrohils, Gal-3 also 
activates NADPH-oxidase, and enhances the respiratory burst in exudated and LPS-
activated neutrophils. Gal-3 mediates the degranulation of eosinophils and mast cells, 
possibly through the cross-linking of FcεRI and/or FcεRI-IgE complex. The exposure of 
Jurkat human T cells activates the cells, as evidenced by IL-2 production. Besides these 
positive effects, suppressive actions of Gal-3 on myelid cells have also been observed. 
Exposure of human eosinophils, peripheral blood mononuclear cells (PBMC) and an 
antigen-specific T cell line to Gal-3 leads to inhibition of IL-5 production.  
 The effects of Gal-3 on cell activation shown till now have been done mainly by 
use of exogenous protein. The role of Gal-3 in the inflammatory response has been 
confirmed in the last years in Gal-3 deficient mice. These animals do not exhibit any 
developmental or morphological abnormalities, and young adult mice have not shown 
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so far apparent phenotypes under standard laboratory conditions. However, targeted 
disruption of gal-3 gene in mice results in a diminished inflammatory response during 
many infections and diseases. In an inflammatory scenario, it has been shown that Gal-3 
deficient mice showed reduced number of granulocytes compared to wild-type animals 
after thioglycolate-induced peritonitis (Colnot, Ripoche et al. 1998). In agreement with 
this result, two years later another research group showed that Gal-3P-/-P mice developed 
fewer inflammatory cell infiltrations in the peritoneal cavities than the wild-type mice in 
response to thioglycollate broth treatment, mainly by a reduced number of infiltrated 
macrophages (Hsu, Yang et al. 2000). Besides, Gal-3P-/-P macrophages were more 
susceptible to inducible apoptosis, pointing out that Gal-3 could favor not only the 
initiation of the immune response, but the prolongation over time of such response.  
  The lack of Gal-3 protected mice against induced asthma reactions, developing 
the mice significantly less airway hyper-reactivity (Zuberi, Hsu et al. 2004). This 
protection was attributed to the capacity of Gal-3 to skew the cytokine balance to a 
lower Th2 response. 
 These facts prompted several groups to study the role of Gal-3 in the 
development of infections defined by a strong Th2 response, like helminth infections. In 
this regard, the results obtained from Schistosome mansoni infection of Gal-3 -/- mice 
have given contradictory data. On one hand, Bickle et all (Bickle and Helmby 2007) 
showed that Gal-3 is not affecting neither the humoral nor the cellular response against 
S. mansoni, and therefore they showed that there were no changes in the Th2 response 
and no differences in hepatic granulome formation. On the other hand, Breuilh et all 
(Breuilh, Vanhoutte et al. 2007), and Oliveria et all (Oliveira, Frazao et al. 2007) 
independently showed that Gal-3 -/- developed reducer liver granulomas and mount a 
biased cellular and humoral Th1 response, implicating Gal-3 in the T cell priming by 
dendritic cells. Moreover, it was previously described the ability of Gal-3 to recognize 
specific glycan structures present on helminths. Gal-3 bound the epitope GalNAc1-
4GlcNAc (LDN), abundantly present on the surface of S. mansoni, and they co-
localized in the schistosome egg-induced granulomas in the liver, supporting the 
primary role of Gal-3 in the immune response against this parasite (van den Berg, 
Honing et al. 2004; Van de Vijver, Deelder et al. 2006).  A higher Th1 immune 
response was mounted in Gal-3P-/-P mice when they were infected with the intracellular 
parasite Toxoplasma gondii, probably due to a higher IL-12 production by dendritic 
cells (Bernardes, Silva et al. 2006). This was corroborated by the fact that spleen cells 
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from S. mansoni infected Gal-3P-/-P mice produced more IFN-γ compared to the control 
animals, something similar to the data showed previously by Breuilh and Oliveira. It is 
noteworthy to mention that Gal-3P-/-P mice infected with T. gondii showed a reducing 
number of macrophages and CD8+ cells in all the organs analyzed except for the lungs, 
showing that the Gal-3 functions depends on the specific tissue as well as the infectious 
agent. Gal-3 has been shown to play a role during Streptococcus pneumoniae infection. 
First, it was observed that Gal-3 was expressed in lungs of infected mice, promoting 
adhesion of neutrophils to endothelial cells, and Gal-3 resulted to enhance neutrophil 
phagocytosis, acting like a bacteriostatic agent in vitro. Results after infection of Gal-3 P-/- P 
mice showed that knock-out mice developed a more severe pneumonia, and presented a 
lower number of recruited leukocytes, mainly neutrophils, in infected lungs (Sato, 
Ouellet et al. 2002; Farnworth, Henderson et al. 2008; Nieminen, St-Pierre et al. 2008). 
In contrast to helminths infections, where Gal-3P-/-P dendritic cells showed no defect in 
TNF-α production after infection,  Gal-3P-/-P mice infected with the yeast Candida 
albicans showed a reduced expression of the Th-1 promoting cytokine TNF-α 
compared to control animals (Jawhara, Thuru et al. 2008). The absence of this model 
showed a reduced inflammation and abolished the response of TLR-2 to C. albicans, 
through diminished TNF-α production. Interesting enough, this reflects that Gal-3 can 
trigger different immune response depending on the infective agent.  
 Gal-3 seems to play an important role on the outcome of the immune response 
during T. cruzi infection, although there are still many points that remain unclear. Today 
it has been demonstrated in vitro that Gal-3 can promote adhesion of T. cruzi to host 
cells, as it was shown using human coronary artery smooth muscle cells (Kleshchenko, 
Moody et al. 2004), and to coated laminin surfaces (Moody, Ochieng et al. 2000). 
However, the possible implications of Gal-3 during T. cruzi adhesion have not been 
demonstrated in vivo. From in vivo experiments it was shown that Gal-3 addressed B 
cell fate during infection, dendritic cell migration and thymocytes apoptosis.  In regard 
to B cells, Gal-3 was up-regulated after infection. Up-regulated Gal-3 skewed plasma 
immunoglobulin producing B cell to a memory B cell phenotype, in a process that 
implies IL-4 signalling   through the transcription factor Blimp-4 (Acosta-Rodriguez, 
Montes et al. 2004). It has been shown an increase of Gal-3 expression in dendritic cells 
during T. cruzi infection, and a subsequent altered migration (Vray, Camby et al. 2004), 
and a role of Gal-3 during the thymus atrophy, regulating death of cortical immature 
 thymocytes, since gal-3P-/-P mice did not show the thymus atrophy observed during 
Chagas disease (Silva-Monteiro, Reis Lorenzato et al. 2007).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Ilustración 7: The effects of galectin-3 on immune cells. Red upwards arrows indicate positive effects 
and blue downward arrows negative effects. Pro-inflammatory effects of galectin-3 are indicated in red 
shaded boxes, anti-inflammatory effects in blue shaded boxes. fMLP:formyl-methionyl-leucyl-
phenylalanine (J. Dumic et al. 2006)  48
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8. Other galectins 
 
 The best studied galectins are Gal-1 and Gal-3. However, they are only two of 
the fifteen members described so far. In the recent years there have been described new 
functions for these “unknown” galectins of great relevance for the outcome of 
inflammatory and immune processes. 
 
 8.1 Galectin-9 
 Gal-9 was first cloned from mouse embryonic kidney (Wada and Kanwar 1997), 
and soon it was found in tumor tissues of Hodgkin’s disease that is frequently 
characterized by blood and tissue eosinophilia (Tureci, Schmitt et al. 1997). It is found 
in liver, small intestine, thymus, kidney, spleen and cardiac and skeletal muscle. In 
immune cells it is expressed by T cells and eosinophils. It is not well understood its role 
under pathogenic conditions, but it is known that Gal-9 expression is up-regulated by 
different cell types after incubation with pro-inflammatory cytokines. It is up-regulated 
and released in astrocytes (Yoshida, Imaizumi et al. 2001) and endothelial cells 
(Imaizumi, Kumagai et al. 2002) after IL-1β and IFN-γ treatment respectively, and 
Jurkat T cells increase Gal-9 expression and release after PMA treatment (Chabot, 
Kashio et al. 2002).  
 Gal-9 is a tandem-repeat galectin, thus composed by two CRDs. Several 
isoforms have been described (Spitzenberger, Graessler et al. 2001), according to their 
different length of the peptide that join the two hologous CRDs. It has been also named 
ecalectin, because one of the first findings about this protein was that it posseses one of 
the most powerful eosinophil-specific chemoattractant activity (ECA), in vitro and in 
vivo (Hirashima 1999; Hirashima 2000). Carbohydrate binding of Gal-9 is needed for its 
ECA activity, since mutations of the CRDs completely abolished this activity, and it 
seems that the protein needs the two CRDs to exert it, because the recombinant CRDs 
separately did not show any chemoattractant activity (Matsushita, Nishi et al. 2000).  
Gal-9 is not only a potent eosinophil chemoattractant, but it is also an eosinophil 
activator as revealed by the fact that Gal-9 is able to induce superoxide production in 
eosinophils (Matsumoto, Hirashima et al. 2002).  
 Gal-9, like Gal-1, plays a role in immunomodulation of the T cell response. Both 
galectins induce apoptosis of activated T cells and thymocites, although they seem to 
bind different glycoconjugates receptors and trigger different pathways (Bi, Earl et al. 
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2008). Indeed, the pathways involved in Gal-9-induced apoptosis might vary in 
different T cells and status. Gal-9 induces apoptosis of activated CD4+ and CD8+ T 
lymphocytes via the Calcium calpain caspase 1 pathway (Kashio, Nakamura et al. 
2003), but in Jurkat T cells has been shown that Gal-9 induces apoptosis through an 
independent caspase mechanism (Lu, Nakagawa et al. 2007). Recently, it has been 
reported several works pointing out that the role of Gal-9 in the modulation of T cell 
response is much more specific, controlling specially the Th1 response. Gal-9 interacts 
with Tim-3, a member of the TIM family of proteins (T-cell immunoglobulin mucin) 
specific for Th1 cells. Binding of Gal-9 to Tim-3 leads Th1 cells to death and inhibition 
of IFN-γ production (Zhu, Anderson et al. 2005; van de Weyer, Muehlfeit et al. 2006). 
Tim-3 has been found in alloreactive CD8+ cytotoxic T cells, and that makes these CD8 
T cells susceptible of Gal-9 mediated apoptosis (Wang, He et al. 2007).   
 The role of Gal-9 in the control of the immune response is confirmed by the fact 
that Gal-9 is able to suppress collagen-induced arthritis in the mouse model by 
suppressing the generation of Th17 cells and promoting the induction of regulatory T 
cells (Seki, Oomizu et al. 2008). In addition, LPS-induced production of TNF-α, IFN-γ 
and IL-12 does not occur in Gal-9 transgenic mice, meanwhile Gal-9 deficient mice 
became susceptible to the LPS-induced anaphylactic shock (Tsuboi, Abe et al. 2007).  
 Regarding other immune cell types, it has been shown that Gal-9 induces 
maturation of dendritic cells, inducing IL-12 and Th1 cytokine production, in a 
carbohydrate independent way (Dai, Nakagawa et al. 2005).  
 
 8.2 Galectin-4 
 Gal-4 has a restricted expression to the digestive tract (Gitt, Colnot et al. 1998), 
and it was first involved in crosslinking the lateral cell membranes of the surface-lining 
epithelial cells (Wasano and Hirakawa 1999). There are two works that link Gal-4 to T 
cell response in gastrointestinal tract. One claims the Gal-4 is able to induce T cell 
activity, increasing IL-6 expression, and exacerbating chronic colitis (Hokama, 
Mizoguchi et al. 2004). On the contrary, the other one proposes that Gal-4 is 
ameliorating the T cell response, inducing apoptosis of activated T cells, and reducing 
TNF-, IL-6, IL-8, IL-10 production (Paclik, Danese et al. 2008). 
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 8.3 Galectin-8 
 Galectin-8 was cloned in 1995 (Hadari, Paz et al. 1995), and it has been shown 
to be widely expressed in tumoral tissues (Bidon-Wagner and Le Pennec 2004). The 
protein was described as a tandem-repeat galectin since it was composed by two 
different CRDs linked by a peptide linker. However, it has been reported that the gene 
LGALS8 could encode for six isoforms of Gal-8 by alternative splicing, three of them a 
tandem-repeat like protein, and three related to the monomeric galectin structure 
(Bidon, Brichory et al. 2001). Like other galectins, is a secreted protein, and as a soluble 
protein interacts with extracellular matrix components, modulating cell adhesion 
phenomena. Gal-8 is related to Gal-4, but unlike this last one that it is confined to the 
intestine and stomach, Gal-8 is expressed in liver, kidney, cardiac muscle, lung and 
brain. In addition to its role in cancer progression, it has been demonstrated other 
functions for Gal-8. First, it was shown that Gal-8 could modulate cell adhesion by 
means of interaction with specific integrins, as it was shown for human cancer cells, 
neutrophils and Jurkat T cells (Hadari, Arbel-Goren et al. 2000; Nishi, Shoji et al. 2003; 
Yamamoto, Nishi et al. 2008). In the recent years new articles have been published, 
suggesting that Gal-8 functions are closer to other galectins regarding 
immunomodulatory properties than it was expected. For example, Gal-8 is able to 
modulate neutrophil functions, inducing their adhesion, but inducing super oxide 
production too (Nishi, Shoji et al. 2003), an essential event in bactericidal function of 
neutrophils. It was shown that only the N-terminal CRD is needed to induce super oxide 
production, although other capacities of Gal-8 need the implication of both CRDs. Gal-
8 was recently found in the thymus, showing a pro-apoptotic activity of the thymocites 
subset CD4(high) CD8(high) (Tribulatti, Mucci et al. 2007). It is likely that Gal-8, as 
well as Gal-1 and -3, participate in thymocite selection during T cell development. 
Related to apoptosis, it has been published that Gal-8 is able to expose 
phosphatidylserine in the promielocitic HL-60 cell line, but surprisingly, independently 
of apoptosis (Stowell, Arthur et al. 2008). Regulation of Gal-8 functions could be more 
complicated, since this work shows that Gal-8 could form dimers through the N-
terminal domain. Further work needs to be done to elucidate the role of Gal-8 in the 
immune system, but the current data suggest a strong implication of this galectin in 
regard to immunemodulation.     
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OBJECTIVES 
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1- Study the ability of recombinant galectins belonging to the three different 
subgroups within the protein family to bind to infective and non-infective forms 
of the parasite T. cruzi and define the functional consequences of such 
interaction. 
 
2- Define the expression profile of galectins during the course of murine 
experimental infection with T. cruzi in immune cells and in the heart tissue. 
 
3- Establish the role of galectins in the outcome of the immune response mounted 
against T. cruzi by means of experimental infection of genetically galectin 
deficient mice.    
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MATHERIAL AND METHODS 
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1. Purification and either fluorescein isothiocyanate or biotin labelling of 
recombinant proteins. 
  
 Expression plasmid pQE9 containing the human galectin-1 sequence was kindly 
provided by Dr. Elena Moisevaa (Leicester Warwick Medical School, UK). The protein 
was purified as described previously (Andersen, Jensen et al. 2003). Expression 
plasmids for human galectin-3 and galectin-4 were provided by Dr. Hakon Leffler 
(Institute of Laboratory Medicine, Sweden))(Patnaik, Potvin et al. 2006) . Expression 
plasmid pGEX containing the human galectin-7 sequence were provided by Dr. Thierry 
Magnaldo (Institut Gustave Roussy, France) (Magnaldo, Bernerd et al. 1995). Four 
expression plasmids pGEX4T2 containing the human galectin-8 sequence and the 
mutant galectin-8 R69H, galectin-8 R233H, and galectin-8 R69H/R233H sequences 
were provided by Dr. Nozomu Nishi (Kagawa University, Japan) (Nishi, Shoji et al. 
2003).  All recombinant human galectins were overexpressed and purified using a clone 
of Escherichia coli BL21 containing each expression plasmid. Briefly, bacteria cultures 
were incubated with 1mM isopropyl-1-thiogalactopyranoside for 3h at 37ºC to induce 
recombinant protein production. Bacteria were pelleted, resuspended in phosphate-
buffered saline supplemented with 4mM EDTA, 2mM β-mercaptoethanol and 1mM 
lactose (PBS-MELac) together with a protease inhibitor cocktail. After sonication, 
bacteria were centrifuged to obtain the soluble fraction, where the recombinant proteins 
were present. They were purified by affinity chromatography, by Ni-NTA 
chromatography in the case of hrGalectin-1. hrGalectin-7, hrGalectin-8, hrGalectin-8 
mutants and GST were purified by glutation-Sepharose (Sigma) affinity 
chromatography. hrGalectin-3 and hrGalectin-4 were purified using α-lactose-agarose 
(Sigma). All recombinant galectins were proved to have affinity for α-lactose-agarose, 
except the galectin-8 R69/R233, which lacks lactose binding activity. Proteins were 
stored in PBS-MELac at 4 ºC. The purity of recombinant galectins was determined by 
coomasie-blue staining after SDS-PAGE, and their sugar binding capacity was 
periodically tested. 
Biotin-labelled galectins were prepared using the EZ-LinkP®P Sulfo-NHS-Biotin 
purchased from Pierce, according to manufacturer’s instructions, but 5 mM lactose was 
added into the coupling buffer, to avoid chemical modification of the active site in the 
carbohydrate recognition domain. Recombinant galectins were incubated in PBS 5mM 
lactose with fluorescein isothiocyanate isomer I (Sigma) to label fluorescently 
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recombinant galectins. Biotin or FITC-labelled proteins were dialysed against PBS-
MELac to remove the excess of unbound reagent. 
 
2. Galectins binding to T. cruzi and cleavage 
 
 Flow cytometry was used to evaluate galectin binding to the surface of different 
biological stages of T. cruzi. Isolated epimastigotes, amastigotes and trypomastigotes of 
T. cruzi Y and Dm28c strains were washed three times with cold PBS, and then they 
were incubated with FITC-labelled recombinant galectins (2- to 20 µM) at 4ºC for 20 
minutes in the presence or absence of lactose (50 mM). After incubation, parasites were 
washed three times with cold PBS to eliminate unbound galectins, and they were fixed 
in 1% paraformaldehyde in PBS for 30 minutes. After washing again with cold PBS, 
relative fluorescence intensity was measured on a FACScalibur flow cytometer (BD 
Biosciences). Data were analyzed using FlowJo analysis software. 
To study the binding and cleavage of purified galectins by T. cruzi, the parasites (1 × 
10P7 P) were incubated with recombinant galectins (2 µM) in 250 µl of serum-free RPMI 
containing 25 mM Hepes:PBS (1:1 ratio) at 37 °C with agitation (800 rpm/min) for the 
indicated time for the cleavage assay. After the incubation, parasite-free supernatants 
were obtained by spinning at 3000 rpm for 5 min. The supernatants were fractionated by 
SDS-PAGE, and proteins in the gels were stained by CBB staining. Alternatively, 
fractionated proteins on the SDS-PAGE gels were transferred to the nitrocellulose filters 
and the galectins-related fragments were detected by specific anti-galectin antibodies: 
mouse anti-human galectin-1 (Novo Castra, clone 25C1) µg/mL, mouse anti-human 
galectin-3 (Novo Castra, clone 9C4) µg/mL, mouse anti-human galectin-4 (R&D 
Systems, clone198616) 2 µg/mL, mouse anti-human galectin-7 (R&D Systems, 
clone198614) 2 µg/mL and mouse anti-human galectin-8 (R&D Systems, clone 210608) 
2 µg/mL. Membranes were incubated with horseradish peroxidase (HRP) goat anti–
mouse antibody (1:1000; Pierce) as secondary antibody. Proteins were detected using 
Supersignal reagent (Pierce). To inhibit cleavage, various protease inhibitors were 
added at the concentration ranging from that recommended by the manufacture to 10 
times higher. The protease inhibitors used were: pepstatin, (1-10 µM), leupeptin (1-10 
µM), aprotinin (0.3-3 µM), EDTA (1-10mM), phenylmethanesulphonylfluoride (0.1-
1mM), orto-phenantroline (0.5-5mM), bestatin (13-130 µM), antipain (50-500 µg/µL), 
HgCl B2 B (2-10µM), TLCK (2-50 µM), TPCK (2-50 µM), E-64 (2-50 µM).  
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3. N-terminal Peptide Sequencing  
 
 Galectins fragments that were generated by incubating recombinant galectins 
with T. cruzi were separated by SDS-PAGE and transferred onto a polyvinylidene 
difluoride membrane. Galectin fragments were located by staining with 0.5% Ponceau S 
solution. N-terminal protein sequencing of galectin-3 fragments was performed on a 
protein sequencer (Perkin Elmer, Procise 494) in Centro de Investigaciones Biológicas 
(Madrid) 
 
4. Adhesion assays of T. cruzi to host cells 
  
 To study the parasite adhesion to non-adherent cells like the monocyte cell line 
THP-1 or murine dendritic cells, T. cruzi trypomastigotes were labelled with the 
fluorescent dye CFSE (Molecular Probes). Parasites were incubated 10 minutes at 4ºC 
with 5 mM CFSE in cold PBS solution and then they were extensively washed to 
remove the excess of CFSE. Mammalian cells (10 P5P cells/assay) cells were resuspended 
in RPMI medium and CFSE-labelled parasites were added to the cells (cell:parasite 
ratio 1:3), they were incubated 15 min at 4 ºC with or without recombinant galectins at 
indicated concentrations. 50 mM lactose was added during the incubation time to inhibit 
galectin carbohydrate mediated effects.  Afterwards, the cells were fixed in 1% 
paraformaldehyde in PBS. Fluorescence attached to the cells was measured on a 
FACScalibur flow cytometer (BD Biosciences), gating the analysis in the cell 
population, more complex and bigger than the free parasites, allowing us to distinguish 
between free and cell attached parasites.  
To study adhesion of T. cruzi to LLcMK2 cell line, cells were cultured in microtiter 
plate wells and trypomastigotes were added to each cell in a 1:10 cell: parasite ratio, in 
the presence or absence of recombinant galectins (0.2-2µM) at 4ºC for 15 minutes. After 
PBS washing, the number of parasites attached to the cells was counted directly by 
optical microscopy. 
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5. Preparation of Galectin-3 Affinity Columns and identification of galectin ligands 
on T. cruzi 
 
 To prepare galectin immobilized columns, 5-10 mg of recombinant galectin-3 
were covalently coupled to HiTrap NHS-activated colums according to manufacturer’s 
instructions (Amersham Biosciences), including 5mM lactose in the coupling buffer. 
Parasites were lisated in buffer B, composed by 0,2 M NaCl, 20 mM tris-HCl, 0,1% 
CHAPS and protease inhibitors cocktail. Parasites were sonicated, and soluble fraction 
was separated by centrifugation at 14.000 rpm for 15 min. The soluble fraction was 
applied to the previously set up galectin column. The column was extensively washed, 
and eluted with buffer B 150 mM lactose. Eluate was someted to SDS-PAGE 
cromatography, and transferred to nitrocellulose filters. The T. cruzi AgC10 mucin was 
identified between the galectin-3 ligands by using a specific monoclonal antibody 
previously prepared in the laboratory (Alcaide and Fresno 2004). rhGalectin-7-GST and 
rhGalectin-8-GST were coupled in a non-covalent way to glutation-Sepharose columns, 
and soluble fraction of parasite lysate was loaded onto the columns. After washing, 
lactose was used to elute the column, and as describe before, AgC10 parasite mucin was 
found to be present in the eluate. 
 
 
6. Cell lines and parasites 
 
 Vero, LLcMK2 and THP-1 cells were grown in RPMI complete medium 
containing 5% FCS, 2mM L-glutamine, penicillin (100U/ml) and streptomycin (100 
ng/ml) (Gibco, Grand Island, NY) at 37ºC in an atmosphere containing 5% CO B2 B.  
Six different strains of T. cruzi were maintained: Y, CL-Brener and P2 strains, as Tc2 
lineage, and Dm28c, CT and CQ strains , as Tc1 lineage, according to the genetic 
dimorphism seen in T. cruzi(Souto, Fernandes et al. 1996). Epimastigotes forms of T. 
cruzi were grown in LIT (liver infusion triptose) medium (Castellani, Ribeiro et al. 
1967) containing 10% FCS at 28ºC. Intracellular amastigotes were obtained from 
infected Vero cells after lysis.  Pure culture trypomastigotes were collected from the 
extracellular medium of Vero cells 3 to 4 days after infection, centrifuged at 2000 x g 
for 10 min, and recovered from the supernatant 3 h later, when parasites left the bottom 
due to their motility.  
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7. Dendritic Cells culture 
 
 Femurs from healthy mice were removed, and dendritic cells (DCs) were 
derived by culture of bone marrow cells in complete RPMI medium (2 mM L-
glutamine, 100 U/ml penicillin, 100 ng/ml streptomycin, 10% FCS) supplemented with 
10% granulocyte–macrophage colony-stimulating factor (GM-CSF)-transfected X63 
myeloma cell line-conditioned medium and 50 µM 2-mercaptoethanol for 7 days under 
a humidified atmosphere of 5% CO2 at 37ºC. X63 myeloma cell line was kindly 
provided by Dr. Margaret Harnett (University of Glasgow, Scotland). Half of the 
medium was replaced with fresh medium every two days during one week, and then the 
cells became to exhibit morphology typical of immature DCs. They expressed CD11c, 
MHCII surface markers, and low expression of co-stimulatory molecules CD80 and 
CD86, as assessed by flow cytometry assay. These phenotype corresponds to immature 
DCs, and these DCs were either exposed overnight to 1 µg/mL LPS (Escherichia coli 
serotype O26:B6 [Sigma-Aldrich]), or infected overnight with 10 trypomastigotes (Y 
strain) per cell. Cells were then collected and washed to analyze surface marker 
expression by flow cytometry, and supernatants were collected for further cytokine 
measurement. 
 
8. Mice, experimental infection and analysis of the parasitological parameters  
 
 Six to 8-weeks-old male and female mice were used for experimental infection. 
BALB/c and C57BL/6 mice were purchased from Harlan Laboratories, and galectin-1P-/- P, 
galectin-3P-/-P, galectin-9P-/-P mice were supplied by The Consortium for Functional 
Glycomics (La Jolla, USA). Mice were maintained and bred under pathogen-free 
conditions in compliance with European norms (Convention 1986) in the animal 
facilities (Universidad Autónoma Madrid). Mice were infected with 2x10P3 P Y strain 
Trypomastigotes by means of intraperitoneal injection. All in vivo experiments were 
done in groups of 5 mice, and animals were sacrificed at days 14 and 28 after infection, 
keeping a group of non-infected animals as control. Parasitemia levels were determined 
every 2 days by directly visualizing and counting parasites in tail vein blood. 
To study the humoral response, mice were bled at 7, 14, 21, 28 and 42 days after 
infection, and non-infected mice were bled as controls. Soluble T. cruzi antigens were 
used to coat the microtiter plate wells, and an Enzyme-linked Immunosorbent Assay 
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(ELISA) was carried out to quantify the total amount of IgG1 and IgG2a present in 
mouse serum able to recognize T. cruzi antigens. Specific HRP-anti mouse IgG1 and 
IgG2a (Nordic Immunology) were used to detect the primary antibodies after addition 
of specific HRP substrate.  
 
9. Protein expression and Western blot 
 
 Heart protein extracts were prepared using a PT 1300 D homogenizer (Polytron). 
For Western blot analyses, 20 µg of tissue extract was fractionated on SDS–10% 
polyacrylamide gel and transferred to a nitrocellulose membrane. Primary antibodies 
were used as follows: anti-mouse galectin-1 (R&DSystems, clone 201066) 5 µg/mL, 
anti-mouse galectin-3 (R&DSystems) 1 µg/mL. Membranes were incubated with 
horseradish peroxidase (HRP) rabbit anti– goat antibody (1:10,000; Sigma-Aldrich) or 
goat anti–mouse antibody (1:1000; Pierce) as secondary antibody. Proteins were 
detected using Supersignal reagent (Pierce). 
 
 
10. Flow cytometry 
 
 For detection of surface markers, cells were washed with cold PBS and were 
incubated with 10% FCS in PBS solution to block unspecific immunoglobuline 
interactions. Cells were incubated for 20 minutes at 4ºC with specific antibodies, and 
they were extensively washed with cold PBS to eliminate unbound antibodies. Spleen 
cells where stained for anti-mouse CD3, anti-mouse CD11c, anti-mouse F4/80 and anti-
mouse CD45R/B220 in conjunction with anti galectins antibodies to detect galectin 
surface presence on the surface of different cell types within the spleen cells 
subpopulations. Dendritic Cells were first detached from the petri dish, as they are 
adherent cells, stained with antibodies specific for CD11c in conjunction with 
antibodies specific for major histocompatibility complex (MHC) class II, CD80 and 
CD86 along with the relevant isotype controls (BD Pharmingen). Flow cytometry was 
carried out using a FACScalibur Immunocytometry System (BD Pharmingen) and data 
were analyzed using Flow Jow software. Primary antibodies were used as follows: anti-
mouse galectin-1 (R&DSystems, clone 201066) 50 µg/mL, anti-mouse galectin-3 
(R&DSystems) 5 µg/mL, anti galectin-4 (Santa Cruz Biotechnologies) 2 µg/mL, anti 
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galectin-8 (Santa Cruz Biotechnologies) 2 µg/mL, anti galectin-9 (Santa Cruz 
Biotechnologies ) 2 µg/mL, phycoeritrin conjugate anti-mouse CD45R/B220 (BD 
Pharmingen, clone RA3-6B2) 10 µg/mL, phycoeritrin conjugate anti-mouse CD4 (BD 
Pharmingen, clone RM4-5 ) 4 µg/mL, phycoeritrin conjugate anti-mouse CD8 (BD 
Pharmingen, clone 53-6.7) 4 µg/mL, phycoeritrin-Cy5 conjugate anti-mouse CD3e (BD 
Pharmingen, clone 145-2C11) 10 µg/mL, phycoeritrin conjugate anti-mouse CD11c 
(BD Pharmingen, clone HL3) 10 µg/mL, fluorescein-5-isothiocyanate conjugate anti-
mouse CD11c (BD Pharmingen, clone HL3) 10 µg/mL,  phycoeritrin conjugate anti-
mouse F4/80 (eBioscience, clone BM8) 4 µg/mL, along with the isotype controls 
phycoeritrin conjugate rat IgG2a, phycoeritrin conjugate rat IgG2b, fluorescein-5-
isothiocyanate conjugate rat IgG2a, phycoeritrin conjugate armenian hamster IgG1. 
Alexa-FluorP®P 488 rabbit anti-goat IgG (Molecular Probes) 0.75 µg/mL and Alexa-
FluorP®P 488 rabbit anti-rat IgG (Molecular Probes) 3 µg/mL were used as secondary 
antibodies when it was necessary.  
 
11. Quantitative real-time polymerase chain reaction (PCR) and reverse-
transcription (RT) PCR. 
 
 The heart and spleen from non-infected and infected mice were removed. Heart 
DNA was isolated using the High Pure PCR Template Preparation Kit (Roche). 100 ng 
of genomic DNA were used for parasite detection, using quantitative PCR as reported 
before (Piron, Fisa et al. 2007). Total parasite DNA was quantified using pure parasite 
DNA as calibration curve.  
RNA was extracted from heart and spleen by use of TrizolP®P reagent (Invitrogen) 
according to manufacturer’s instructions, and the obtained RNA was subsequently 
cleaned up by use of RNeasy Mini Kit (Qiagen). Traces of genomic DNA 
contamination were removed using DNase I (Qiagen) on-column during RNA 
purification. Total isolated RNA concentration and purity was checked by UV 
spectrophotometry.  RNA was first reverse transcribed into cDNA using a reverse 
transcriptase (Super Array Bioscience Corporation) and the resulting cDNAs were used 
as template for subsequent PCR amplification using primers specific for selected genes. 
Gene expression of individual genes was performed using the Real Time P®P SYBR Green 
PCR Master Mix (Super Array Bioscience Corporation). Quantification of gene 
expression was calculated using the comparative threshold cycle (CBTB) method, 
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normalized to both the actin and GAPDH housekeeping genes and efficiency of the RT 
reaction (relative quantity, 2P-∆∆CTP). Results are shown as fold increase gene expression, 
comparing relative quantity expression of one sample versus another control one that 
was set as control, as indicated in each case. The genes analyzed are the followings: 
NM_021297 Toll-like receptor 4, NM_011604 Toll-like receptor 6, NM_030682 Toll-
like receptor 1, NM_011905 Toll-like receptor 2, NM_031178 Toll-like receptor 9, 
NM_008495.2 galectin 1, NM_025622.1 galectin 2, NM_010705.1 galectin 3, 
NM_010706.1 galectin 4, NM_010707.1 galectin 6, NM_008496.4 galectin 7, 
NM_018886.2 galectin 8, NM_010708.1 galectin 9, NM_008401 Integrin alfa M, 
NM_010578 Integrin beta 1, NM_010493 Icam1, NM_010104 Endothelin 1, 
NM_011345 E-Selectin, NM_011346 L-Selectin, NM_011347 P-selectin, NM_011333 
Ccl-2, NM_009915 Ccr-2, NM_009917 Ccr-5, NM_007482 Arginase I, NM_009705.1 
Arginase II,NM_010927 iNOs-2, NM_013693 TNF-α, NM_00837 IFN-γ, NM_011198 
COX-2, NM_009283 Stat1, NM_021704 CXCL12, NM_010177 FasL, NM_054039 
FOXp3, NM_009969 Csf2, NM_009424 Traf6, NM_007639 Cd1d1, NM_008689 
Nfkb1, NM_011487 Stat4, NM_146145 Jak1, NM_010851 MyD88, NM_008352 
IL12p40, NM_010558 IL5, NM_007393 Actin beta, NM_008084 GAPDH 
 
GeneBank Description GeneBank Description GeneBank Description 
NM_021297 Toll-like receptor 4 NM_010493 Icam1 NM_021704 CXCL12 
NM_011604 Toll-like receptor 6 NM_010104 Endothelin 1 NM_010177 FasL 
NM_030682 Toll-like receptor 1 NM_011345 E-Selectin NM_054039 FOXp3 
NM_011905 Toll-like receptor 2 NM_011346 L-Selectin NM_009969 Csf2 
NM_031178 Toll-like receptor 9 NM_011347 P-selectin NM_009424 Traf6 
NM_008495.2 galectin 1 NM_011333 Ccl-2 NM_007639 Cd1d1 
NM_025622.1 galectin 2 NM_009915 Ccr-2 NM_008689 Nfkb1 
NM_010705.1 galectin 3 NM_009917 Ccr-5 NM_011487 Stat4 
NM_010706.1 galectin 4 NM_007482 Arginase I NM_146145 Jak1 
NM_010707.1 galectin 6 NM_009705.1 Arginase II NM_010851 MyD88 
NM_008496.4 galectin 7 NM_010927 iNOs-2 NM_008352 IL12p40 
NM_018886.2 galectin 8 NM_013693 TNF-α NM_010558 IL5 
NM_010708.1 galectin 9 NM_00837 IFN-γ NM_007393 Actin, beta,  
NM_008401 Integrin alfa M NM_011198 COX-2 NM_008084 GAPDH 
NM_010578 Integrin beta 1 NM_009283 Stat1   
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12. Confocal immunofluorescence  
 
 Parasites were adhered to pre-treated BiobondP®P cover slips, and then they were 
fixed and permeabilized with acetone. Fixed parasites were incubated with recombinant 
FITC labelled galectins at 4 ºC at 0.2-2µM galectin concentration. Unbound galectins 
were removed by extensive washes with PBS.  
Hearts were fixed in 4% paraformaldehyde in PBS solution, incubated in 30% sucrose 
solution, embedded in Tissue-TekP®P O.C.T. compound (Sakura) and frozen. 10- to 15 
µm thick sections were fixed in paraformaldehyde in PBS solution. Sections were 
washed, 10% FCS and 10% mouse serum were used to block unspecific binding, and 
were incubated with the following antibodies: 50 µg/mL rat anti-mouse galectin-1 
(RDSystems), 10 µg/mL goat anti-mouse galectin-3 (RDSystems), 2 µg/mL rat anti- 
mouse CD68 (Serotec), µg/mL rat anti-mouse CD4 (eBioscience), µg/mL rat anti-
mouse CD8 (ebioscience). Secondary antibodies were used for detection as follows: 4 
µg/mL alexa fluorP®P 488 conjugated rabbit anti-goat (Molecular Probes), 4 µg/mL alexa 
fluor P®P 555 conjugated goat anti-rat (Invitrogen). To-Pro-3 (Invitrogen) was used for 
nucleic acid staining, and IgG (Jackson immunoResearch) and rat IgG (BD 
Transduction) were used for negative isotypes controls. Images were obtained using an 
LSM510 meta confocal laser coupled to an Axiovert 200 (Zeiss) microscope. ImageJ 
software was used for later image analysis, in order to quantify the number of CD68+, 
CD4+ and CD8+ cells stained in each field.  
 
 
13. Cytokine quantification 
 
 FASTQuant P®P Microspot Assays for Cytokine Quantification (Whatman) was 
used to detect cytokines in mice serum samples. Serums from 5 individual mice, either 
infected (14 days after infection) or non-infected mice were pooled and the presence of 
IL-1β, IL-5, IL-13, IL-2, IL-6, TNFα, IL-4, IL-10 and IFN-γ was measured. The 
protocol was done according to manufacturer’s instructions. Briefly, protein array slides 
were blocked and incubated with either serum samples or with cytokine standards 
overnight. After washing, slides were incubated first with biotinylated anti-cytokines 
antibodies, and second with secondary Cy5-labelled antibody. A Microarray Scanner 
(Agilent) was used for image acquisition, and data analysis was done by XXXXX  . 
  64
Analysis of cytokines from the supernatant of infected (trypomastigotes:cell ratio 10:1), 
LPS activated (1µg/mL) and RPMI control dendritic cells was conducted using a mouse 
Th1/Th2 cytometric bead array kit (Bender MedSystems). It was analyzed on a 
FACSCalibur flow cytometer. In this method, fluorescent polystyrol beads are coupled 
with antibodies specific to the analytes to be detected, a biotin conjugated antibody mix 
is added, which binds to the analytes bound to the capture antibodies. Streptavidin-
Phycoerythrin (PE) is added the last, which binds to the biotin conjugates. Beads are 
differentiated by their sizes and distinct spectral signature by flow cytometry. Standard 
curves were determined for each cytokine from a range of 27–20000 pg/ml. The lower 
limit of detection for the method, according to the manufacturer is 0.7–12.7 pg/ml, 
depending on the analyte. The following cytokines were measured: GM-CSF, IFN-
gamma, IL-1α, IL-2, IL-4, IL-5, IL-6, IL-10, IL-17, and TNF-α. IL-12p70 was 
measured too in dendritic cells supernatants, in this case performing a quantitative 
enzyme linked immunoabsorbent assay (ELISA), the Mouse IL-12 p70 ELISA Ready 
Set-Go!, purchased from eBioscience. 
 
14. Statistical analysis 
  
 Arithmetic means and standard deviation of the means were calculated. The 
Student´s t-test was used to determine the statistical significance of the differences 
observed. Differenced were considered statistically significant when p < 0.05.  
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1. INTERACTION GALECTINS-T. cruzi IN VITRO 
 
1.1 Galectins bind specifically T. cruzi, and the affinity of galectins is higher for 
infective stages of the parasite. 
 
 Among the properties described for galectins, it has been shown in the last years 
that galectins are able to bind to several human pathogens, from fungi (Fradin, Poulain 
et al. 2000; Jouault, El Abed-El Behi et al. 2006), bacteria (John, Jarvis et al. 2002; 
Fowler, Thomas et al. 2006), helminths (van den Berg, Honing et al. 2004) and 
protozoan like Leishmania major (Pelletier and Sato 2002; Pelletier, Hashidate et al. 
2003) and Trypanosoma cruzi (Moody, Ochieng et al. 2000; Kleshchenko, Moody et al. 
2004). Those findings suggest that galectins could act as pathogen recognition receptors 
for the immune system (Rabinovich and Gruppi 2005), not only recognizing pathogens, 
but also regulating the immune response after the first encounter (Rabinovich, Toscano 
et al. 2004). Much work has been done with the best studied galectins, galectin-1 and 
galectin-3, but very little is known about other family members. For this reason, it was 
studied whether different galectins were able to bind T. cruzi or not, by purifying 
recombinants human galectins and using them for in vitro experiments by means of a 
systematic study regarding several galectins of the three groups and all life cycle stages 
of the parasite. 
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Figure 1: Purified galectins are shown after SDS-PAGE running and Coomasie Blue Staining. 
Lines, 1: Gal-1, 2: Gal-3, 3: Gal-4, 4: Gal-7-GST, 5: Gal-8-GST, 6: Gal-9, 7: Gal-8R69A-GST, 8: 
Gal-8R233A-GST, 9: Gal-8R69A;R233A-GST, 10: Molecular weight markers, MW is indicated in 
KDa. 
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 First, recombinant human galectins were purified. Monomeric galectins 1 and 7, 
tandem repeat galectins 4, 8 and 9, and the quimera type galectin-3 were purified 
(Figure 1), and then conjugated to fluorophores, FITC or Alexa-488, in order to be used 
in flow cytometry and fluorescence microscope.  
 The first experimental approach to evaluate the ability of recombinant human 
galectins FITC labelled to bind the parasite was to incubate these proteins in solution 
with the parasite using the Y strain, that belongs to the TcII T. cruzi subgroup. It has 
already been reported that different parasite life cycle stages expose different glycan 
composition on their surface, and this could influence the galectin binding. Three 
parasite biological stages were analysed separately, and it was demonstrated a specific 
and differential binding profile regarding binding intensity and specificity. Galectins 
could bind much better to the infective parasite forms, the intracellular amastigotes and 
the bloodstream trypomastigotes, than the non-infective epimastigotes, present only in 
the insect vector. Epimastigotes showed to have more exposed ligands for Gal-3 and 
Gal-7, meanwhile Gal-7 and Gal-8 showed to have more exposed ligands in the case of 
trypomastigotes, and Gal-1 and Gal-4 in the case of amastigotes (Figure 2).  
 
 
 
Figure 2: Galectin binding to T. cruzi is 
specific for different biological stages.
FITC labeled recombinant human galectins 
were incubated with three parasite live cycle 
stages at 4ºC and galectin binding was 
quantified by flow citometry. A) FITC-
galectins were able to bind T. cruzi, and the 
affinity of galectins was higher for the 
infective forms of the parasites under the 
same experimental conditions. Parasites 
incubated with galectins are shown in solid 
black, unlabelled negative controls in white. 
B) Mean of fluorescence intensity from five 
independent experiments is shown. Standard 
deviation (SD) error bars are represented. 
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 In order to establish subcellular location of galectin ligands in T. cruzi, the 
binding of galectins by the parasites was examined under confocal microscopy, using 
FITC labelled galectins (Figure 3). Parasites were fixed and permeabilized. The binding 
of Gal-3 and -7 to epimastigotes was seen as granular, not restricted to a specific 
subcellular location. The binding pattern was observed both in citoplasmatic areas and 
in the cell surface. The same pattern was observed for the strong binding of Gal-7 to 
trypomastigotes, except for the lack of labelling in the parasite flagellar pocket. 
However, when Gal-8 was incubated with trypomastigotes, the binding was restricted to 
the parasite membrane. The binding of galectins by amastigotes was also restricted to 
ligands present on the cell surface.  FITC labelled Peanut Lectin Agglutinin was used 
for a positive staining of parasite surface galactosides. This is a lectin that specifically 
recognizes Gal-β(1-3)-GalNAc carbohydrates present on the parasite surface. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Subcellular location of galectin ligands in T. cruzi. Parasites were fixed and permeabilized 
with ice-cold methanol, and subsequently stained with the indicated FITC-galectins. Images were 
acquired by confocal microscopy. A- epimastigotes, gal-3FITC stained, B-epimastigotes, gal-7FITC 
stained, C-amastigotes, gal-1FITC stained, D- trypomastigotes, gal7FITC stained. Flagellar pocket is 
indicated by a red asterisk, E-trypomastigotes, gal-8FITC stained, F- epimastigotes, surface staining with 
PNA-FITC 
 
 
 
  
 Recombinant galectins were labelled with biotin in order to identify parasite 
ligands. Total protein extracts were resolved by SDS-PAGE and transferred to 
nitrocellulose membranes. After incubation with biotin labelled galectins and 
streptavidin horse peroxidase, galectin ligands were revealed. Proteins from 10 to 100 
KDa were detected. The main ligand was a band around 80KDa for every galectin 
tested, but the number of bands detected was different for each one (Figure 4A). 
Galectin immobilized columns were prepared in order to isolated those soluble galectin 
ligands. Soluble ligands were subjected to proteomic analysis, MALDI-TOF and mass 
spectrometry, but we failed to identify any parasite molecule, only T. cruzi tubulin. 
However, using specific antibodies again parasite mucins, it was demonstrated the 
presence of the mucin AgC10 between the galectin ligands in the case of Gal-7 and Gal-
8 (Figure 4B). 
 
 
1.2. Galectins- T. cruzi interaction is glycan-depen
 
 Once shown the specific binding, it was n
ability of galectins to bind β-galactosides is one o
family. Nevertheless, galectins can interact with oth
way. In order to define the nature of the galectin bin
were done in the presence of lactose as inhibito
dependent interactions. Galectin binding to T. cruzi wFigure 4: Identification of parasite 
galectin ligands D) Epimastigotes protein 
extracts were transferred to nitrocellulose 
membrane and western blotted with biotin 
labelled rgalectins. Subsequently, galectin 
ligands were revealed by streptavidin-
HRP. Lines are, 1: Gal-1, 2: Gal-3, 3: 
Gal4, 4: Gal-7, 5: Gal-8 E) Gal-7 and Gal-
8 were immobilized to Glutation-
sepharose, and parasite extracts were 
applied. GST was used as a negative 
control. After extensive washing, 
sepharose was eluted with 100mM lactose. 
Eluted   fractions were subjected to 
western-blot using specific antibodies for 
the parasite mucin AgC10. 1:Gal-7 lactose 
elution, 2:Gal-8 lactose elution, 3: GST 
lactose elution, 4: Sepharose elution in the 
absence of rGals, 5,6:washing elutions, 
7:purified AgC1069
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of 50 mM lactose, indicating that galectins are recognizing glycoconjugates in the 
parasite surface (Figure 5). In addition, due to the fact that monomeric galectins suffer 
concentration-dependent association affecting their valency, several galectin 
concentrations were tested, as it is known that the concentration is a critical factor to 
induce oligomerization of galectins in solution, and the affinity constant for many 
natural galectin ligands differs from the monomeric to the oligomeric status. Galectins 
were used at 0.2, 2 and 20 µM. An important difference was observed when Gal-7 
concentration was increased, but no difference was observed with other galectins tested 
(Figure 5). 
 
 The fact that the binding of galectins to the parasites was dependent on the 
carbohydrate recognition was confirmed by the use of recombinant galectin-8 proteins 
carrying punctual mutations in the carbohydrate recognition domains that abolish the 
carbohydrate binding. The mutants used were galectin-8R69, galectin-8R233 and the 
galectin-8R69R233, that have a non-functional N-terminal CRD, C-terminal CRD and 
both CRDs, respectively. The parasites used were metacyclic trypomastigotes, 
differentiated in vitro using a poor medium, named Grace medium (Castanys, Osuna et 
al. 1984). Grace medium imitates the acid environment of the final portion in the insect 
guts. This induces parasite differentiation, resulting into infective metacyclic 
trypomastigotes. Single Gal-8 mutants showed a reduced binding by metacyclic 
Figure 5: Galectin binding to trypomastigotes were totally inhibited when lactose (50 mM) 
was added. Negative controls are in solid grey, thin black line refers to parasites after incubation 
with FITC-galectins, 2 µM, for 15 minutes at 4ºC. Parasite-associated fluorescence was 
quantified by flow citometry. In the case of galectin-7, the thicker black line (-) corresponds to a 
galectin concentration of 20 µM, and the thin line  (-) to 2 µM.  
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trypomastigotes, and an absolute lack of binding for the double mutant galectin-8 
(Figure 6). This indicates that the binding of Gal-8 is mediated by the CRD, cooperating 
the two CRDs to increase binding affinity. 
 
Figure 6: The two carbohydrate recognition domains present in galectin-8 are needed to get an 
efficient binding to the parasite. Metaciclic trypomastigotes were incubated with FITC labelled 
galectin-8, and with the FITC labelled mutants R69, R233 and R69R233 for 15 minutes at 4ºC. The mean 
of fluoresce intensity was measured by flow citometry. All the mutants showed a reduced binding 
capacity to T. cruzi.  
 
 
1.3 Galectin binding to T. cruzi promotes parasite adhesion to host cells 
 
 It has been reported that galectin-3, and also galectin-1 and -9 play an important 
role during host-pathogen interactions, the initial steps leading to infection, suggesting 
that galectins can be one of the receptors that are involved in the adhesion of the 
parasite to the host cells (Rabinovich and Gruppi 2005). Once that it was seen that 
galectins were able to bind specifically to the infective forms of the parasite, we next 
tried to address whether this interaction could promote parasite adhesion to host cells. In 
vitro adhesion experiments were performed to test this hypothesis. Cell lines susceptible 
to be infected were used as a model, the murine monocyte cell line THP-1 and the 
epithelial cell line LLcMK2. Those cells express natural ligands for galectins. 
Fluorescence trypomastigotes were incubated with cells in the presence or in the 
absence of recombinant galectins, and parasites attached to the cells were counted as 
described in Material and methods. When the parasites were incubated with the host 
cells in the presence of recombinant galectins, the adhesion of parasites was 
significantly higher than the controls in the absence of exogenous galectins (Figure 7). 
The incubation time was limited to 10 minutes at 4 ºC to be sure that we are looking at 
parasite adhesion and not cell penetration, blocking parasites proteases that can 
influence over the recombinant galectin, as it will be discussed below. Not surprisingly, 
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not every galectin was able to promote adhesion with the same strength. The better that 
galectin bound to Trypomastigotes, the better the galectin was able to promote parasite 
adhesion. So, in concordance with galectin binding assays to T. cruzi, Gal-8, Gal-7 and 
Gal-3 promoted the adhesion to THP-1 cells. Besides, the adhesion was increased when 
galectin concentration used was higher. When lactose was included during the 
incubation the adhesion was abolished, and in the case of galectin-8, CRD mutations 
abolished this effect too (Figure 7). 
 
  
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Parasite adhesion to host cells was increased when recombinant galectins were present, A) 
parasites were labeled with CFSE, and incubated with non-labeled cells. Parasites and cells were resolved 
by flow cytometry due to their different size, and the fluorescence intensity associated to the cell gate (THP-
1) was quantified. Almost 100% of the parasites presented high fluorescence intensity, and only 6% of the 
cells showed fluorescence intensity when incubated with parasites in the absence of rGals. B) galectin-8
were added to the mixture of cells and parasites for 10 minutes at 4ºC, and the rate of positive cells 
increased to 43.9% of the total. This effect disappeared when 50 mM was included, or when galectin-8 R69,
R233 and R69R233 were used instead of the wild type galectin. C) mean fluorescence intensity is shown 
using the same approach with gal-1,-3,-4,-7 and -8, at 0.2 µM and 2 µM,  and in the presence of lactose. 
Result is significant from two independent experiments performed. D) Mean fluorescence intensity values 
for galectin-8 and mutants, significant from two independent experiments performed E) parasites were 
incubated with a LLcMK2 monolayer for 10 minutes at 4ºC, and attached parasites were counted after 
extensive washing in the presence or absence of 2 µM recombinant galectin-8. 
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1.4 The Incubation of Galectins with T. cruzi Results in the Formation of 
Truncated Galectins  
 
 In order to test if T. cruzi could modify the galectin structural integrity during 
the parasite-galectin interaction, soluble recombinant human galectins were incubated 
with live parasites for different times, from 5 to 120 minutes at 37ºC. It was seen that 
this led to the proteolitically processing of galectins by the parasite. Parasites were 
pelleted, and the cell-free supernatant was analyzed by SDS-PAGE. A time dependent 
effect was observed when Gal-3, -4 and -8 were incubated with live parasites. Gal-3 was 
processed by T. cruzi, and three different bands appeared in a sequential way.  The same 
effect was seen in the case of the tandem-repeat type Gal-4 and -8, a cleavage of these 
galectins was seen. No differences were seen after incubation with the parasite 
regarding Gal-1 and Gal-7, both monomeric galectins (Figure 8). 
 Parasite-free supernatants after the incubation were subjected to western blotting 
analysis with appropriated anti-galectin antibodies. As the antibodies used were 
monoclonal, they detected only the full-length galectin, and some of the new bands that 
appeared over time were detected depending on the presence of the specific epitope for 
the antibody in the resulting fragment. The recognition of the resulting smaller bands by 
specific anti-galectin antibodies confirmed that at least the recognized bands were 
truncated galectins as the result of parasite cleavage (Figure 8).  
 The kinetics of the cleavage was specific for each galectin tested, as it was 
defined by densitometry of the resulting bands at each time point. Half of the total 
recombinant galectin-3 and galectin-4 was processed after 10 minutes, and the time 
required for galectin-8 was around 40 minutes (Figure 8). 
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Figure 8: Time course of galectin-3,-4 and -8 cleavage by T.cruzi. Galectin-3 (A), -4 (B) and -8 (C) 
were incubated with parasites for given times and parasite-free supernatants were subjected to SDS-PAGE 
followed by CBB staining, showing the appearing bands. Integrated intensities of full length galectins and 
the new bands were obtained by densitometric scanning of CBB-stained SDS-PAGE gel. The cleavage of 
galectin-3, -4 and -8 was analyzed by Western blotting with monoclonal anti-galectins antibodies.  74
 
 
 In order to gain insight on the nature the processing, the resulting bands were 
subjected to N-terminal peptide sequencing. The aminoacid sequences where the 
cleavages take place on the galectin-3 are PP30 PAGUAGGUY, band 1, AP62 PYHUGAPUGAY, 
band 2 and GP105 P YUGAPUAG, band 3, all of them on the N-terminal collagen-like 
domain, out of the CRD (Figure 9). The first cleavages that appeared in time for Gal-4 
and -8 were in the sequences QP175 PLNUSLUPTMEP183P and QP160 PASUSLUELTEP168 Prespectively, 
both located in the peptide link between the two CRDs (Figure 10).  
 This allowed us to establish that neither of the galectins was being processed on 
the carbohydrate recognition domain, but at the linker peptide (Gal-4 and -8) and on the 
N-terminal domain (Gal-3). Interestingly, Gal-4 and -8 were cleaved by the parasite in a 
related sequence, sharing the aminoacids serin-leucin in the cleavage site. Thus, it can 
be establish a consensus sequence for this parasite protease, QXXSLXXXE. 
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Figure 9: Cleavage sites of galectin-3. T. cruzi-truncated galectin-3 was subjected to N-
terminal protein sequencing. Cleavage sites of bands 1, 2, and 3 are indicated in the 
peptide sequence of human galectin-3, and the sequences obtained by N-terminal protein 
sequencing are underlined. 
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1.4.1 Cleavage of Galectin-4 and -8 is Inhibited by the Specific Protease Inhibitor 
orto-Phenantroline.  
  
 The cleavage of Gal-4 and -8 by T. cruzi was shown to be sequence specific and 
related in both galectins. This implies that at least one parasite protease was implicated 
in such cleavage. In order to know the kind of protease that was processing the 
recombinant galectins, the assay was done in the presence of different protease 
inhibitors covering all known protease families as listed in material and methods. Of all 
inhibitors tested, only one was effective to prevent the cleavage of the recombinant 
galectins, the compound 1,10-ortho-phenantrolin (OPA), a Zn-metalloprotease inhibitor 
(Figure 11A).  
 
 
1.4.2. Cleavage of Galectin-3 is Inhibited by the Specific Proteases Inhibitors orto-
Phenantroline and Mercuric Chloride.  
 
 There were detected three different cleavage sites within the galectin-3 
sequence, with at least two of them unrelated. Two shared a common sequence, GAP, 
and the other one was quite different, AGGY. The same protease inhibitors used 
previously were employed to inhibit galectin-3 cleavage by T. cruzi. Only OPA resulted 
efficient to inhibit two of the three cleavages observed in the N-terminal domain of Gal-
3, the cleavage 2 and 3 placed at the common GAP sequence (Figure 11). Thus, it was 
likely that more than one protease were implicated. Since the cleavage within galectin-3 
took place exclusively in the N-terminal domain, domain that shares homology with 
collagen, a set of collagenases inhibitors were tested. Of all collagenases inhibitors 
assayed, mercuric chloride, TLCK and TPCK, just mercuric chloride was able to inhibit 
the cleavage left, in the sequence AGGY, the first one to occur.  The combination of 
magnesium chloride and OPA kept the full length galectin-3 (Figure 11). It is also 
known that both proteases work independently, because the presence of OPA does not 
affect the activity of the other protease susceptible to mercuric chloride, and vice versa.    
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3Figure 11. The cleavage of galectins by T. cruzi is inhibited by specific protease 
inhibitors. A). Galectin-3, -4 and -8 (2µM) were incubated with parasites in the 
presence or absence of the indicated protease inhibitors, or with heat-killed (100 °C 
for 10 min) T. cruzi. The zinc chelator, 1,10-ortho-phenanthroline (OPA) was able 
to inhibit galectins cleavage by the parasite. Concentrations are indicated at mM 
range.B) Galectin-3 (2µM) was incubated with parasites at given times and in the 
presence of OPA, mercuric chloride or the two compounds at the same time. The 
cleavage of galectin-3 was analyzed by CBB staining. Mercuric chloride inhibited 
the cleavage in the band B and C, and OPA in the band A. Only a combination of 
both inhibitors kept intact the full length galectin-3, even after 160 minutes in 
contact with T. cruzi. 77
e Protease Involved in the Cleavage of Galectins is Composed of a Complex 
rent proteins. 
n order to know if the proteases responsible of the cleavage of galectins were 
 to the extracellular medium, parasites were in vitro cultured and supernatants 
llected to test if these supernatants could process recombinant galectins. In 
, parasites were treated with phosphatidylinositol phospholipase C (PIPLC), 
 that releases GPI anchored proteins from the membrane. The PIPLC treated and 
d parasites and the resulting supernatants were incubated with recombinant 
s. This approach will indicate whether the protease that processes galectins is 
 by the parasites, and/or whether the protease is anchored to the membrane by 
ecombinant galectins were submitted to SDS-PAGE and coomasie blue staining 
ir incubation with parasites and supernatants (Figure 12). The protease that 
Gal-3 at the sequence AGGY is not secreted, and is not anchored through GPI. 
 specific for GAP was secreted, since the supernatants of cultured parasites 
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produced the cleaveages 2 and 3 in the Gal-3.  Gal-4 was cleaved by other protease, not 
secreted but GPI-anchored, because the conditioned supernatant after PIPLC treatment 
was able to process Gal-4. Gal-8 was processed by an actively secreted protease. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.4.4 Galectin Binding is needed for the Cleavage of Galectin-8 by T. cruzi.  
 
 The availability of the galectin-8 mutants allow us to answer different questions 
regarding the interaction and processing. It has already been shown, that this mutants 
are unable to bind to ligands present on the parasite surface. However, those proteins 
still have the sequence where the cleavage in the recombinant Gal-8 occurs, the 
QASSLELTE situated in the linker peptide. Mutants in only one CRD were slightly 
processed, but in a lesser extend than the wild type Gal-8 (Figure 13). It was observed 
that T. cruzi was unable to cleave Gal-8 R69R233 mutant, even after a long incubation 
of 120 minutes, when the wild type Gal-8 was totally processed. This is in concordance 
with the lack of binding for galectin-8R69R233, and the slightly binding of R69 and 
R233 mutants showed before (Figure 6). 
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Figure 12: Gal-3, -4 and -8 are processes by different parasite proteins. 
Parasites were treated with PIPLc in order to release GPI-anchored proteins to the 
medium. rGals were incubated 15 minutes at 37ºC  with parasites (Par) or 
supernatants (SN). After incubation, mixtures were centrifuged and parasite-free 
supernatants were resolved by SDS-PAGE following Coomasie Blue staining.   
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 Figure 13: Functional carbohydrate recognition domains are needed by 
T. cruzi to cleave the protein. Gal-8 and punctual mutants (2µM) were 
incubated at given times with parasites at 37ºC. Meanwhile mutants lacking 
glycan binding activity were not processed by T. cruzi, Gal-8 was cleaved as 
expected;  79
king the Proteolisis Leads to Galectin Induced Killing of Parasites.  
 cruzi as a parasite has developed during the evolution some molecules that 
 to the modulation of host responses to the infection. As described above, it 
shown a novel mechanism that the parasite develops to induce cleavage of 
 The question that arises now is what the functional meaning of this 
on can be. It is clear that the parasite proteases are able to disable the galectin 
ncy, and in that way, many of their functions. Now it is proposed the matter in 
he possible effects of the galectin over the parasite itself. In order to address 
ion, parasites were incubated with galectins in the presence of OPA, or in 
ds, when the parasite is not able to process the galectin.  
rasites were incubated with Gal-3, -4 and -8 in the presence of OPA, and then 
 stained with propidium ioide (Figure 14). The death was induced by the 
of galectins, because parasites in the presence of OPA alone kept live over the 
e experiment. 50% of the parasite population was killed in 5µM Gal-8 in the 
of OPA, meanwhile it was necessary 20-25 µM of Gal-3 or Gal-4 plus OPA to 
50% of dead parasites. Gal-1 was used as a control, showing no effect on the 
iability. 
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Figure 14: Parasites are killed when they are incubated with 
galectins in the presence of orto-phenantroline. A) Parasites were 
treated with propidium iodie (PI) to check cell viability. Live parasites 
where not stained by PI, neither parasite after OPA treatment, (10 
minutes, 37ºC) but parasites killed by heat shock (100ºC,10 min) did. 
B) Galectin incubation leads to parasite killing when OPA (5mM) was 
added (dotted line). No dead parasites were seen when parasite were 
treated only with OPA (grey tinted) or with galectins alone (thin black 
line) C) Concentration needed to induce parasite killing for each 
galectin was quantified. Parasites were incubated with galectins at 
given concentrations and OPA for 10 minutes at 37ºC.  Results 
represent the mean of three independent experiments showing SD. 
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2. GALECTIN EXPRESSION ASSOCIATED TO IMMUNE CELLS DURING 
MURINE EXPERIMENTAL INFECTION 
 
 The in vitro experiments with recombinant human galectins pointed out that 
galectins can bind to glycans exposed on the T. cruzi surface, and that this binding could 
play a role during parasite adhesion to host cells. The initial interaction could promote 
galectin induced parasite killing as a first defensive system of the innate immune 
response against T. cruzi, event that made T. cruzi to develop specific proteases through 
the evolution.  
 These findings give us little information about the global role of galectins though, 
and whether they have a real role in the immune response during Chagas disease. Our 
next goal was to define the pattern expression of different galectins during the murine 
experimental infection with T. cruzi in spleen and heart, as a first step to understand 
their roles.  Different galectins associated to different immune cell types were analyzed 
in spleen cell subpopulations. The spleen is an immune organ where the whole 
repertoire of immune cells meet, thus is a good example of the immune response 
outcome that it is occurring during the infection. In addition, it was addressed the role of 
galectins during the immune response that takes place in the heart in the acute phase of 
Chagas disease. Results are shown below. 
  
2.1 Profile of Galectin Expression and Galectin Ligands, and Changes during 
Infection in Spleen Cells 
  
 First, it was described the surface galectin profile in the major spleen cell 
populations by flow citometry, B cells (Anti-mouse CD45R B220), T cells (anti-mouse 
CD3), dendritic cells (DCs, anti-mouse CD11c) and macrophages (anti-mouse F4/80). 
Spleens from control mice and spleens from infected animals were compared. It was 
seen some of the immune events linked to T. cruzi infection, a marked splenomegaly as 
direct consequence of polyclonal leukocyte activation and an increased number of 
antigen presenting cells like dendritic cells and macrophages. 
 Resting B cells exhibited on their surface Gal-1 and -8, but galectin profile 
changed during infection. Gal-1 was constitutively expressed, and Gal-3 expression was 
highly up-regulated during infection. In contrast, Gal-8 was down-regulated on B cells 
from infected animals (Figure 15). 
    Regarding T cells, it was seen that spleen cells from control mice did not express 
none of the galectins evaluated, but during infection, T cells showed Gal-1, Gal-3 and 
Gal-9 expression (Figure 16). The same study was performed in antigen presenting 
cells, DCs and macrophages. Both cell types were increased in spleen during the 
infection in mice, and they expressed high levels of Gal-1, Gal-3 and Gal-9, both in 
control and infected mice, but they kept the same galectin expression profile during 
infection, varying the total cell number (Figure 17). 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: Surface associated gal-1, gal-3, gal-8 and gal-9 in B cells from control and infected 
mice. C57BL6 were infected with 2000 T. cruzi trypomastigotes from Y strain. Non-infected mice and 
mice at day 14 post infection were sacrificed, spleen cells were isolated and B220 in conjunction with
galectins presence were checked by the use of specific antibodies. In B cells, Gal-1 is constitutively 
expressed; Gal-3 and Gal-9 are up-regulated during infection, in contrast to Gal-8, that is down-
regulated during infection. 
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Figure 16: Surface associated gal-1, gal-3, and gal-9 in T cells from control and infected mice. 
C57BL6 were infected with 2000 T. cruzi trypomastigotes from Y strain. Control and infected mice at day
14 post infection were sacrificed, spleen cells were isolated and CD3 and galectins expression were tested
by FACs.   82
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Figure 17: Surface associated 
gal-1, gal-3, and gal-9 in 
dendritic cells and 
macrophages from healthy 
and infected mice. C57BL6 
were infected with 2000 T. 
cruzi trypomastigotes from Y 
strain. Non-infected mice and 
mice at day 14 post infection 
were sacrificed, spleen cells
from C57BL/6 mice were 
isolated and surface associated 
galectins were detected by flow 
cytometry. CD11c expression 
was used to label dendritic cells 
and F4/80 pan marker was used 
for macrophage labelling.  
 
 
 
 
 
 
 
 
 
 
 
 
 It was characterized the endogenous galectins that immune cells express in control 
mice and during infection. However, it is also important to understand the role of 
galectins if the exposure of endogenous ligands changes during infection. This could be 
a consequence of the parasite trans-sialidase activity, enzyme that uptakes terminal 
sialic acid from the host exposing the subjacent galactosyl residues, affecting so the 
galectin ligands structure and accessibility. To investigate whether galectin ligands 
change during infection, spleen cells were incubated with recombinant Gal-1 and Gal-3 
FITC labelled, and then fluorescence associated to the cells were quantified by flow 
citometric analysis. Cells showed a highly increase of galectin binding ability at 14 dpi, 
and at 28 dpi it returned to standard conditions (Figure 19). This indicates a higher 
presence of accessible galectin ligands on the spleen cell surface at the peak of 
parasitemia compared to cells from control animals.  
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2.2. Profile of Galectin Expression and Changes during Infection in Heart. 
  
 The heart is one of the major targets of T. cruzi, and the parasite settles down for 
long time in this tissue. During the acute phase, a great number of immune cells 
infiltrate the organ. Infiltrating immune cells persist in the cardiac tissue despite a 
reduction in the parasite burden. To gain insight into the galectin functions regarding 
immune response in heart during infection, we tried to attempt to identify the cells that 
are expressing galectins in the heart of infected mice.  
We first checked galectin genes expression by RT-PCR in heart of control, and infected 
mice.  
 
  
 
 
 
 
 
 
 
 
 
 
Figure 20. Galectin-1 expression is 
up-regulated in Hearts during T. 
cruzi infection. A) Infected 
C57BL/6 mice were sacrificed at 
indicated days after infection, hearts 
were removed and total protein 
extracts were resolved by SDS-
PAGE and transferred to a 
nitrocellulose membrane. Two 
independent mice are shown at 
every time point and non-infected 
mice were used as control. B) Heart 
frozen slides were stained with anti-
mouse galectin-1 and to-pro3 for 
nucleic acids detection. Slides were 
analyzed by confocal microscopy. 
Galectin-1 expression was found to 
be present in all cardiac cells.  
Figure 18: Galectin ligands on the spleen cell surface change during infection. Spleen cells from 
control and infected mice (14 and 28dpi) were incubated with recombinant Gal-1 and Gal-3 FITC 
labeled for 15 minutes at 4ºC. Galectin binding was quantified by FACs. Cells in the absence of rGals 
were used as negative control. 
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The gal-1 mRNA levels were not up-regulated over infection time, but a significant 
increase of the protein levels were observed by Western blotting, reaching the highest 
expression at day 21 post-infection (Figure 19A). Tissue sections from infected animals 
were stained with anti-mouse Gal-1 antibodies and nucleus were stained with TO-
PROP®P-3 iodide. This showed that Gal-1 was being expressed in cardiomiocytes cells 
(Figure 19B), with a broad distribution with no focalized expression. 
 Regarding gal-3 mRNA, there was a strong increase in hearts of infected animals 
compared with controls. Expression was up to 40 fold increase at 14 days post-
infection, and 20 fold increase at 28 days post-infection (Figure 20A). This gal-3 
mRNA increase was in concordance with the high protein expression observed by 
western blotting (Figure 20B). The western blot revealed the presence of monomeric 
and dimeric forms of Gal-3, and it can be observed the presence of a smaller band than 
the monomeric form, that might correspond to the truncated Gal-3 by parasite proteases, 
as it was observed in vitro. Heart sections were stained with anti-mouse CD68 and anti-
mouse Gal-3 to identify the cells responsible of the Gal-3 expression. CD68 is a 
intracellular macrophage marker, which co-localized with the Gal-3 expression in 
infected mice (Figure 20C). Thus, meanwhile cardiomiocytes were expressing Gal-1 in 
hearts of infected mice, Gal-3 is expressed by infiltrating macrophages. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 20: Galectin-3 expression is up-regulated in Hearts during T. cruzi infection. A)
Infected C57BL/6 mice were sacrificed at indicated days after infection, hearts were removed 
and total protein extracts were resolved by SDS-PAGE and transferred to a nitrocellulose 
membrane. Two independent mice are shown at every time point and non-infected mice were 
used as control. Gal-3 expression was detected using a specific anti-Gal-3 antibody. Gal-3 
expression was found markedly increased at 14 and 21 days post infection. B) Total heart RNA 
was isolated and mRNA gal-3 was found to be up-regulated at 14 and 28 dpi as seen by RT-PCR.
Results are expressed as the fold increase values (± standard deviation) of pooled RNA from 5 
different mice done in duplicate, comparing infected tissue at given times with the non-infected 
control C) Heart frozen slides were stained with anti-mouse Gal-3 and anti-mouse CD68 for 
macrophage detection. Slides were analyzed by confocal microscopy and Gal-3 expression was 
found to be associated mostly to infiltrating CD68+ cells. Isotype control antibodies were used 
for negative controls. 86
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3- ROLE OF GALECTIN-3 DURING INFECTION: 
 EXPERIMENTAL INFECTION IN THE GALECTIN-3 DEFICIENT MODEL 
 
 The ability of galectins to recognize T. cruzi in vitro, together with the regulation 
of galectin expression that was seen in vivo in immune cells, suggested that galectins 
might play a pivotal role for the initiation, maintenance and resolution of the immune 
response upon infection. The experimental approach was to use a deficient galectin-3 
mouse model. Knock-out mice were infected in the same way that wild type mice and 
parasitological and immunological parameters were measured over time of infection.   
 
T3-1. Galectin-3 -/- mice show increased parasitemiaT.  
  
 Both wild type mice and deficient galectin-3 mice were infected intraperitonially 
with 2000 blood trypomastigotes, Y strain. Blood parasitemia was measured every 2 
days by direct counting of parasites. Gal-3P-/-P mice showed a significant higher 
parasitemia compared with their wild type genetic background C57BL/6 mice, with no 
difference on the time course, presenting the peak at the same day after infection 
(Figure 21). 
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Figure 21: Galectin-3 deficient mice 
show a significantly higher parasitemia
than wild type mice. Parasite burden was 
quantified by direct counting under optical 
microscopy after tail vein bleeding. Data 
show the mean of 15 mice counted in 5 
independent experiments (±SD). Parasite 
burden in blood was quantified every 2 
days during 28 days. Galectin-3 deficient 
mice showed a significantly higher 
parasitemia at day 11 post infection. The 
kinetics of the infection were the same for 
wild type and deficient mice. **P<0.01 
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3.2. Humoral Response in gal-3 deficient mice. 
  
 3.2.1 The IgG1/IgG2a balance is not altered in gal-3P-/-P mice 
  
 The serum levels of anti-parasite IgG1 and IgG2a were measured throughout acute 
infection, since IgG1/IgG2 balance is shown to be related to a Th2 or Th1 immune 
response. As shown in Fig. 22, the amount and kinetic of specific IgG1 and IgG2a 
antibodies seemed to be similar in the two strains of mice, wild type and gal-3P-/-P. Both 
strains attained similar levels of specific antibodies over the time of infection, 
independently of the Gal-3 expression. 
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Figure 22: IgG1 and IgG2a antibody responses in infected C57BL/6 and gal-3P-/-
Pmice. ELISA plates were coated with 20 µg/ml of T. cruzi total protein extract, and 
pooled serum samples from five mice were analysed at a 1:100 dilution. IgG values are 
presented as mean ±SD of OD (450 nm). Results are significant from three independent 
experiments performed. 
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 3.2.2. Glycan Binding Specificity of Antibodies in Mice Serum. 
  
 The in vivo qualitative production of specific IgG antibodies was also investigated 
for a better evaluation of the host response. It was performed a screening of glycan-
binding specificity of the antibodies present in non infected and infected serum of 
control and gal-3P-/-P mice, since most of the glycoconjugates present in T. cruzi are 
highly antigenic.. A library of natural and synthetic glycans with amino linkers is 
printed onto slides to form printed glycan array. The array has 406 glycan targets, 
covering the most common glycans structures present in the nature. Array was 
incubated with serum from wild type and gal-3P-/-P mice,  non-infected and infected. 
Immunoglobulins present in mice serum recognized some glycan structures, and Alexa-
488 conjugated antibody raised against mouse immunoglobulins was used for detection. 
 Results are summarized in table 1. Non-infected wild type mice have antibodies 
that recognized small glycans structures and other more complex glycans that are 
associated to a natural innate immune response. There are not important differences in 
the anti-glycans antibodies in the case of Gal-3 deficient mice under non pathological 
conditions. However, after infection with T. cruzi, anti-glycan antibodies speificities are 
totally different when we compare wild type and Gal-3 deficient mice. As a 
consequence of infection, much more glycans are recognized by murine antibodies in 
wild type mice, meanwhile many of these glycans are not immunogenic in the absence 
of galectin-3. Between the glycans that are recognized by serum from infected wild type 
animals but not from Gal-3-/- mice can be found monossaccharide and dissacharides 
(glycan numbers 220,16,10,14), fucosylated glycans (glycan numbers 67,57) and 
sulfated glycans (glycan numbers 32,26,284,25,28). Antibodies from serum of infected 
Gal-3P-/- Pmice bound to the common structure Galb1-3GlcNAcb1-3Galb1-X, and this 
structure were not immunogenic for the wild type mice.  
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Wild Type Non Infected Controls
ID Glycan Structure RFU STDEV %CV
12 a-L-Rha-Sp8 24968 2076 8
16 b-D-Gal–Sp8 13711 2181 16
227 Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb–Sp0 10037 575 6
67 Fuca1-2Galb1-4(Fuca1-3)GlcNAcb–Sp8 8200 1208 15
65 Fuca1-2Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb-Sp0 7480 971 13
216 NeuAca2-3Galb1-3(Fuca1-4)GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb Sp0 6303 529 8
135 Galb1-4(Fuca1-3)GlcNAcb1-4Galb1-4(Fuca1-3)GlcNAcb-Sp0 5986 641 11
136 Galb1-4(Fuca1-3)GlcNAcb1-4Galb1-4(Fuca1-3)GlcNAcb1-4Galb1-4(Fuca1-3)GlcNAcb–Sp0 4027 1224 30
Gal3-/-  Non Infected Controls
ID Glycan Structure RFU STDEV %CV
12 a-L-Rha-Sp8 21175 860 4
227 Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb–Sp0 7723 436 6
16 b-D-Gal–Sp8 5966 1351 23
135 Galb1-4(Fuca1-3)GlcNAcb1-4Galb1-4(Fuca1-3)GlcNAcb-Sp0 4328 237 5
170 (GlcNAcb1-4)5b-Sp8 3415 356 10 **
297 Galb1-4GlcNAcb1-6Galb1-4GlcNAcb-Sp0 3354 201 6 **
306 GlcNAcb1-4GlcNAcb-Sp12 2973 99 3 **
67 Fuca1-2Galb1-4(Fuca1-3)GlcNAcb–Sp8 2772 263 9
Wild Type 28dpi Infected Controls
ID Glycan Structure RFU STDEV %CV
220 Neu5Aca2-3Galb-Sp8 36696 2647 7
67 Fuca1-2Galb1-4(Fuca1-3)GlcNAcb–Sp8 34639 5306 15
16 b-D-Gal–Sp8 27694 4342 16
184 GlcAb1-6Galb-Sp8 27202 1132 4
12 a-L-Rha-Sp8 17405 4787 28
57 Fuca1-2Galb1-3GalNAca-Sp8 16742 1776 11
218 Neu5Aca2-3Galb1-3[6OSO3]GalNAca-Sp8 16396 1146 7
227 Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb–Sp0 15429 1697 11
135 Galb1-4(Fuca1-3)GlcNAcb1-4Galb1-4(Fuca1-3)GlcNAcb-Sp0 12311 251 2
304 GlcNAcb1-3Man-Sp10 12277 859 7
136 Galb1-4(Fuca1-3)GlcNAcb1-4Galb1-4(Fuca1-3)GlcNAcb1-4Galb1-4(Fuca1-3)GlcNAcb–Sp0 12116 924 8
55 Fuca1-2Galb1-3GalNAcb1-3Gala1-4Galb1-4Glcb-Sp9 11517 745 6
167 GlcNAcb1-4(GlcNAcb1-6)GalNAca-Sp8 11060 609 6
32 [3OSO3]Galb1-3GlcNAcb–Sp8 10220 1156 11
26 [3OSO3][6OSO3]Galb1-4GlcNAcb-Sp0 9503 2364 25
10 a-L-Fuc–Sp8 9042 2157 24
284 [3OSO3]Galb1-4[6OSO3]GlcNAcb-Sp0 8344 971 12
24 GlcNAcb1-3(GlcNAcb1-4)(GlcNAcb1-6)GlcNAc-Sp8 7975 588 7
158 GlcNAcb1-3(GlcNAcb1-6)Galb1-4GlcNAcb–Sp8 7827 187 2
25 [3OSO3][6OSO3]Galb1-4[6OSO3]GlcNAcb-Sp0 7439 1946 26
274 Galb1-3(GlcNacb1-6)GalNAc-Sp14 7080 126 2
14 a-Neu5Ac–Sp11 7033 2164 31
28 [3OSO3]Galb1-4(6OSO3)Glcb–Sp0 6581 988 15
364 Fuca1-2Galb1-3GlcNAcb1-3[Galb1-4(Fuca1-3)GlcNAcb1-6]Galb1-4Glc-Sp21 6016 1401 23
Gal3-/-  28dpi Infected Controls
ID Glycan Structure RFU STDEV %CV
129 Galb1-3GlcNAcb1-3Galb1-4GlcNAcb-Sp0 37794 2011 5 **
277 Galb1-3GlcNAcb1-3Galb1-3GlcNAcb-Sp0 34816 1179 3 **
130 Galb1-3GlcNAcb1-3Galb1-4Glcb–Sp10 34459 589 2 **
114 Galb1-3(Fuca1-4)GlcNAcb1-3Galb1-4GlcNAcb-Sp0 34198 295 1 **
136 Galb1-4(Fuca1-3)GlcNAcb1-4Galb1-4(Fuca1-3)GlcNAcb1-4Galb1-4(Fuca1-3)GlcNAcb–Sp0 10956 588 5 **
227 Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb–Sp0 8450 794 9
12 a-L-Rha-Sp8 7848 223 3
132 Galb1-3GlcNAcb–Sp8 7098 2663 38 **
184 GlcAb1-6Galb-Sp8 6581 793 12
67 Fuca1-2Galb1-4(Fuca1-3)GlcNAcb–Sp8 5284 722 14
135 Galb1-4(Fuca1-3)GlcNAcb1-4Galb1-4(Fuca1-3)GlcNAcb-Sp0 4536 256 6
131 Galb1-3GlcNAcb–Sp0 3745 2134 57 **
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3.3 Serum Cytokines Profile is Drastically Altered in gal-3 Deficient Mice During 
Infection 
 
 It is well known that the cytokine balance is important to address the immune 
response against T. cruzi, and that galectin-3 is able to regulate cytokine production by 
different immune cell types. Considering the higher parasite burden that Gal-3 knock--
out mice showed, we next tested whether Gal-3P-/-P mice showed an altered cytokine 
serum levels. Cytokines were measured in serum of non-infected control and Gal-3P-/- P 
mice, at 14 days post infection, time point in the acute phase close to the peak of 
parasitemia, and 28 days post-infection, when no parasites can be observed in blood, 
and might be considered like the resolution of the acute phase.  
 
 Most of the cytokines measured were absent or at very low levels, both in wild 
type and gal-3P-/- Pmice in non-infected animals. However, non-infected wild type mice 
showed high IL-1β and IL-10 levels in sera, although control gal-3-/- mice showed 
reduced IL-10 level and absence of IL-1β. As expected, at 14 dpi wild type mice 
showed an elevation of IL-2, of Th-2 cytokines, IL-10 and IL-5, and pro-inflammatory 
cytokines like IFN-γ, TNF-α, IL-6 and IL-1β, going down at 28 dpi (Figure 23), when 
parasites disappear from the blood stream. In contrast, Gal-3P-/-P mice showed a lack of 
pro-inflammatory cytokine production like IL-2 and IL-1β at 14 dpi, although the IL-1β 
boost was observed at 28 dpi, suggesting a delay in the initiation of the immune 
response.  
 
 It was observed an induction of IFN-γ production both in wild type and Gal-3P-/- P 
mice in the infected animals, in coincidence with the highest parasite burden, but 
surprisingly, the total amount of this important cytokine during the infectious process 
was 5 times lower than in the Gal-3P-/-P mice than in the wild type animals.  
 TNF-α was also diminished in the Gal-3P-/-P mice at 14 dpi, but the major 
differences were found at 28 days post infection, when no TNF-α could be detected in 
gal-3P-/-P mice, in contrast to the wild type mice that still showed a significant amount of 
TNF-α in serum. IL-6 and IL-10 were also down-regulated in deficient mice during 
infection compared to wild type animals. 
 IL-5 was not detected in non-infected mice, neither in deficient nor in wild type, 
but it was observed a strong induction in the wild type mice at 14 dpi. Nevertheless, IL-
  92
5 was almost absent in gal-3P-/-P mice at this infection time point. However, at 28 dpi, IL-5 
is not detected in wild type mice, but in the case of Gal-3P-/-P mice, IL-5 are higher than 
those detected at 14 dpi (Figure 23), even when the levels were still very low. 
 
 
 
 
3.3. Spleen cell subpopulations and gene expression. 
 
 Once it was observed that infected Gal-3P-/-P mice presented higher parasitemia, and 
it was shown that the serum cytokine levels were down-regulated, our aim was to gain 
some insight on the mechanism underlying these alteration. In order to do this, spleen of 
infected animals were studied quantitatively and qualitatively. More precisely, we 
studied whether the cells type and quantity are the same in wild type mice and in Gal-3P-
/-
P mice, and then gene expression by RT-PCR of selected genes related to the evolution 
of the disease was examined.  
 
Figure 23: Cytokine seric levels 
during infection were altered in 
galectin-3 deficient mice during 
infection. Analyzed cytokines are 
indicated on the top for every 
graph. The levels of cytokines 
were measured in serum from 
non-infected and infected mice at 
14 and 28 days post-infection, in 
wild type and galectin-3 deficient 
mice. A protein array from 
FASTQuant® Microspot Assays
was used for cytokine detection. 
Results are the mean of two 
independent experiments done in 
triplicate. In each experiment, 
serum were collected and pooled 
together from a 5 mice group at 
every time point. Results are 
given in pg/mL and bars represent 
standard deviation. Solid black 
columns represent the non-
infected controls, white columns 
infected mice at 14 dpi, and 
striped columns infected mice at 
28 dpi.  
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3.3.1. Spleen cells and nature number of cell sub-populations. 
 
 To get an overview of what is happening in the Gal-3 deficient model we decided 
to study a major immune organ like the spleen. First at all, it was evaluated the total cell 
number present in the spleen of wild type and Gal-3P-/-P animals during the infection, at 14 
and 28 days post infection, and in control animals. The total cell number was counted 
and no significant differences were found (Figure 24). Next, the percentages of the 
major spleen cell subpopulations were quantified by flow cytometry. B cells, CD4 and 
CD8 positive cells, T cells, macrophages and dendritic cells were quantified by using 
specific antibodies, and no significant differences were found (Figure 24). In wild type 
animals, it was observed some of the known events expected during T. cruzi infection. 
B and T cells suffer a polyclonal expansion, total number of cells increase, and an 
important amount of macrophages and dendritic cells can be found in the spleen, 
normally almost absent in spleen of healthy animals. Despite our previous findings in 
cytokine production, no differences were observed in Gal-3P-/-P mice, neither in healthy 
mice nor in infected mice at any time point of infection measured, compared to the 
genetic C57BL/6 background, so Gal-3 is not relevant for spleen physiology. 
 
  
Figure 24: No significantly 
differences were found neither in 
the number nor in the nature of 
spleen cells of galectin-3 deficient 
mice during the infection course. 
Total cell number were equal in 
spleens of wild type and Gal-3P-/- P non 
infected mice (A), and infected at 14 
dpi (C) and 28 dpi (E). Percentages of 
different cell types present in spleen 
from infected animals were measured 
by the use of specific antibodies and 
flow cytometric analysis: non infected 
(B) at 14 dpi (D) and at 28 dpi (F). 
B220 positive cells were considered 
B cells; CD4 and CD8 were used to 
differentiate T cell subtypes, F4/80 
labelled macrophages and CD11c 
dendritic cells. Results are the mean 
of 10 individually analyzed mice 
from 3 independent experiments.  
Error bars show SD. Significat 
differences are shown by *P<0.05 
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3.3.2. Spleen Gene Expression during T. cruzi Infection 
  
 Once it was seen that the spleen cell composition of the Gal-3 deficient mice was 
similar to the wild type animals both in control and in infected mice, we studied the 
expression of several genes that had previously been related to processes that take place 
during the immune response. Chosen genes were implicated in cell migration, cell 
adhesion, inflammation and immune response. Galectin genes expression was also 
quantified, because there is the possibility that the lack of galectin-3 could be 
compensated by the over-expression of other members in the galectin family. The full 
gene list is shown in material and methods.  
 The table 2 shows the genes that were found to be regulated during infection. First 
at all, spleens from non-infected wild type and knock-out animals were compared, 
showing no differences in the selected gene expression profile. Infected animals at 14 
and 28 days post infection were compared to their non-infected controls. In accordance 
with our previous results, galectin genes were up-regulated during the infection in the 
wild type model. In addition to gal-1, and gal-3 mRNA, also gal-2 and gal-9 mRNA 
were strongly induced at 14 days post infection, and in a lesser extend at 28 days post 
infection, with no up-regulation of gal-9 at this time point. It is common that knock-out 
animal models develop some compensatory mechanism to supply the lack of a 
particular gene, this is what homeostasis is. Thus, in the galectin-3 deficient mice could 
happen that other galectins assume the role of the missing galectin-3. When galectin 
mRNA expression in Gal-3 -/- mice was compared with their genetic background 
during infection, we did not found major differences. gal-2, and gal-9 expression were 
not altered, and gal-1 was 3 times lower in the gal-3 -/-, but still up-regulated in regard 
to its non-infected control. The profile of galectin genes changes during infection is 
similar in wild type and gal-3P-/-P mice. That means that at least in spleen it is not likely a 
functional complementation by other galectins. 
  
  Surprisingly, TLRs were more up-regulated in the Gal-3P-/-P mice at the time points 
observed, specifically TLR1, TLR4, and TLR6, although differences were highly 
variable. 
  Regarding genes implicated in the immune response, IFN-γ was 8 and 15 times 
up-regulated at 14 and 28 days post infection respectively in the wild type model. This 
was expected, as IFN-γ is one of the most important mediators to mount an effective 
  95
response against T. cruzi, but it is something new that the gal-3P-/-P mice showed a fault of 
IFN-γ expression, up to 4 times lower than the wild type. This is in concordance with 
the lower amount of IFN-γ present in serum of infected Gal-3P-/-P mice. Other genes that 
showed lower up-regulation in the Gal-3 knock-out mouse were iNOS and COX-2, both 
implicated in inflammation, and Ccl2. Other genes showed the same kind of regulation 
in both animals, like Itgb1, Ccr5 or Gcnt.  (Table 2)    
 
 
Table2. Spleen. Regulated genes during T. cruzi infection in mice. 
Gene BL6 14dpi BL6 28dpi Gal-3-/- 14dpi Gal-3 -/- 28dpi 
gal-1 8.2 ± 4.2 2.9 ± 0.35 2.46 ± 0.1 2.86 ± 0.49 
gal-2 7.06 ± 5.5 2.59 ± 0.81 6.20 ± 2.05 1.99 ± 0.125 
gal-3 18 ± 6.02 8.93 ± 4.93 x x 
gal-4 -6.64 ± 2.4 - -1.9 ± 0.1 3.55 ± 1.79 
gal-7 - - - - 
gal-8 3 ± 0.6 1.84 ± 0.19 - 3.33 ± 0.9 
gal-9 7.82 ± 2.81 - 7.11 ± 2.11 - 
TLR1 - - 10.29 ± 6.1 10.98 ± 1.49 
TLR2 - - - - 
TLR4 2.3 ± 1.2 - 11.35 ± 7.65 5.8 ± 2.1 
TLR6 - - 22.8 ± 10.2 16.50 ± 3.2 
IFN-γ 8.2 ± 4.2 15.65 ± 0.6 2.68 ± 0.7 6.65 ± 2.25 
Cox-2 3.53 ± 2.03 -2.15 ± 0.14 - - 
iNOS 34.08 ± 7.92 - 20.25 ± 10.2 - 
Itgb1 - 4.23 ± 1.23 - 3.25 ± 0.95 
Ccr5 4.7 ± 3.0 3.87 ± 0.1 2.05 ± 0.55 3.2 ± 0.8 
FoxP3 -3.65 ± 0.38 - - - 
Jak1 -7.5 ± 3.05 - -5.49 ± 1.55 - 
Gcnt 2.52 ± 0.33 - 2.97 ± 0.57 - 
Ccl2 6.0 ± 3.9 - - -4.89 ± 2.18 
Table 2: Quantification of gene expression in the spleen of infected C57BL/6 mice and Gal-3 -/- 
mice. RNA was isolated from spleen on the indicated days after infection; RT-PCR was performed to 
quantify expression of the genes listed in Material and Methods. Results are expressed as the fold increase 
values (± SD) of pooled RNA from 5 different mice done in duplicate, comparing infected tissue at given 
times with the non-infected control. Values in red typing represent more than five times up-regulated 
genes, and in blue are shown genes more than five times down-regulated genes.  
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3.4. Galectin-3 Knock-out Mice Show a Deficient Immune Response in the Heart 
that Does not Affect to the Parasite Burden. 
 
 The data that have been exposed till now show the outcome of the systemic 
immune response in the deficient galectin-3 mouse model. Nevertheless, due to the 
great importance of the heart, like one of the main target of Chagas disease, we decided 
to study further the immunological processes that could be associated to galectins 
functions in the cardiac tissue. The goals of this section were to evaluate the parasite 
burden in heart, the nature and composition of the cellular infiltrate in the heart during 
the acute phase and the gene expression that is taking place in the organ.  
 
3.4.1 Galectin-3 deficient Mice Present the Same Parasite Burden in Heart, but Have 
a Deficient T cell and Macrophage Migration.  
  
 The parasite DNA in heart was measured by qPCR during the acute phase of 
infection using specific probes after total heart DNA purification. No parasite DNA was 
detected in the non-infected controls, and no significant differences were observed 
between the Gal-3P-/-P mice and the wild type, neither at 14 days post infection nor at 28 
days post infection (Figure 25).  
 
Figure 25: Quantification of 
Trypanosoma cruzi DNA in the heart 
tissue of infected C57BL/6 mice and 
galectin-3 deficient mice. DNA from 
ten independent mice was isolated from 
heart tissue on the indicated days after 
infection, and quantitative polymerase 
chain reaction (PCR) was performed as 
described in Materials and Methods to 
detect parasite DNA. T. cruzi DNA is 
expressed as the number of nanograms 
of parasite DNA per microgram of total 
DNA obtained from a heart tissue 
sample. Empty boxes denote values for 
C57BL/6 mice, and filled rhombi denote 
values for gal-3P-/- P mice. Results express 
values from 10 different mice. No 
differences between the parasite loads in 
C57BL/6 and gal-3P-/- Pmice were found to 
be statistically significant.  
 
  
 
  
 It is thought that the cardiac pathology during Chagas disease has to do with two 
factors; one is the parasite burden in the heart, and the other one is the composition and 
strength of the immune cell infiltrate in heart, leading to some autoimmune events. 
Parasite burden was no significantly different in Gal-3P-/-P mice, but that alone is not an 
image on what is happening in the tissue. Next, the nature and composition of 
infiltrating cells in infected hearts were evaluated. Anti-mouse CD4 and CD8 were used 
to count both T cells subtypes by confocal microscopy, and anti-mouse CD68 was used 
as a macrophage marker (Figure 26). No infiltrating cells were detected in hearts form 
not infected animals, neither in the wild type nor in the Gal-3P-/-P. Slides from ten 
individual mice were used to count infiltrating T cells and macrophages (Figure 27). It 
was observed a diminished presence of T cells at day 14 post infection, and a significant 
reduction of infiltrating CD68+ cells at 14 and 28 days post infection in Gal-3 P-/- P 
compared with wild type controls. In addition, the tendency of cell migration was quite 
different. T cells reached the highest number at 14 dpi, and at 28 dpi are disappearing 
from the infected heart in wild type animals. In contrast, macrophages are increasing the 
total cell number at 28 dpi. Gal-3P-/-P mice showed no reduction of T cells at 28 dpi, it is 
likely that T cells do not leave the tissue like the wild type model, and showed no 
increase of macrophage infiltration at 28 dpi. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 26: Immunohistochemical staining of infiltrating cells in infected hearts.
CD4, CD8 and CD68 specific antibodies were used to mark specifically T CD4 and
CD8 cells and macrophages in tissue sections. Thymus was used as positive control
for CD4 and CD8 staining, and isotype antibodies for negative controls. Sections
from non-infected and infected (28dpi) wild type and gal3-/- mice were used. 97
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Figure 27: Cell infiltrates in infected hearts of wild type and galectin-3 deficient mice. The numbers 
of infiltrating CD4+, CD8+, and CD68+ cells into the heart of T. cruzi-infected wild type and Gal-3P-/- P 
mice at 14 and 28 days after infection were counted by confocal microscopy. Cells were counted by 
immunohistochemistry, and data represent the mean of 10 individual mice from 2 independent 
experiments. Data from non-infected animals are not shown, as infiltrating cells are almost undetectable 
in healthy hearts. At least 20 different fields were counted for each individual heart. Bars represent SD, 
*P<0.05, ***P<0.001 
 
 
3.4.2. Heart Gene Expression during T. cruzi Infection 
 
 Considering that the CD4 and CD8 T cell number were lower in the heart from 
Gal-3P-/-P mice at 14 dpi, and the macrophage cell number was lower at 14 and 28 dpi, it 
was tested the gene expression in the same way that it was done for the spleen. The 
expression of the same genes was quantified by RT-PCR. This would provide us 
information about the nature of subjacent immune response that occurs in the heart. The 
number of immune cells in infiltrating cells is not high in control non infected hearts, 
and no differences have been yet reported for Gal-3P-/-P mice under normal conditions. As 
expected, there were no significant differences in gene expression between non-infected 
wild type and Gal-3 deficient mice. 
  We next analyzed gene expression at 14 and 28 days post-infection, comparing 
again infected tissue versus non-infected tissue. Results are summarized in table 3. 
When galectin gene expression was quantified, it was observed in wild type mice that 
gal-3 mRNA was highly up-regulated during infection, but no significant changes were 
seen regarding other galectins. However, although no changes for mRNA gal-1 were 
detected, Gal-1 is up-regulated in infected hearts, as it was seen by western blotting. In 
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the gal-3 deficient model, gal-7 mRNA was up-regulated, and increase of Gal-1 protein 
expression was also detected. 
  
 TLRs expression was increase in wild type mice as expected, because it is known 
that TLR2,-4 and -9 are implicated in T. cruzi recognition, but nothing has been 
reported about TLRs and immune response in the heart during Chagas disease. TLRs 
expression was much more up-regulated in the Gal-3P-/-P mice, although due to the high 
variability that was found between animals regarding TLRs expression, only the change 
in TLR2 was significantly different.  
  
 Consistently with the current knowledge about immune response in Chagas 
disease, some important immune genes were up-regulated, both in wild type mice and in 
Gal-3P-/-P mice, like IFN-γ, IL-12, TNF-α, iNOS, Arg I or COX-2, genes related to 
quimiotaxis and cell migration, like Ccr2, Ccr5, Ccl2, selectins and integrins. However, 
some of these genes were differentially regulated in the Gal-3P-/-P mice. There was a 
200old increase of IFN-γ expression observed in wild type mice, in contrast to the 22 
fold increase in the knock-out mice. IL-12, TNF-α and iNOS were not so up-regulated 
in the Gal-3 mice like in the wild type. Their mRNA expression levels were around one 
half compared with the wild type model. Even the lower number of infiltrating cells 
does not explain such lower induction folds, when the cell number difference was as 
much as two fold. Taken together, all the data pointed out to a diminished immune 
response in the gal-3-/- mice. Indeed, we found some differences regarding expression 
of genes implicated in migration. Ccr2, Ccr5, Sel-e and Sel-p showed a significant 
diminished overexpression in the Gal-3 -/-mice at 14 days post infection, meanwhile 
Ccl2 and integrin-alpha showed no difference. At 28 days post infection, significant 
differences were observed only for Ccr2.  
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Table 3. Heart. Regulated genes during T. cruzi infection in mice. 
Gene BL6 14dpi BL6 28dpi Gal-3-/- 14dpi Gal-3 -/- 28dpi 
gal-1 - - 3.41 ± 0.38 - 
gal2 - - - - 
gal-3 42.86 ± 23.60  28.25 ± 32.50 x x 
gal4 - - - - 
gal7 - - 3.16 ± 0.75 10.93 ± 5.77 
gal-8 - - - - 
gal-9 2.46 ± 0.6 - 5.12 ± 2.86 2.91 ± 0.02 
TLR1 46.43 ± 53.93   51.65 ± 70.07 79.15 ± 75.68 118 ± 20.01 
TLR2 6.94 ± 5.38 4.57 ± 3.69 13.23 ± 0.98 10.89 ± 1.93 
TLR4 2.56 ± 1.99  - 270.02 ± 
208.19 
289.56 ± 135.17 
TLR6 16.23 ± 14.05 18.74 ± 24.84 53.83 ± 57.27 56.76 ± 24.00 
IFN-γ 205.67 ± 49.07 37.82 ± 3.55 22.93 ± 3.66 5.91 ± 0.47 
Cox-2 8.58 ± 2.21 - 6.49 ± 1.77 2.03 ± 0.72 
Arg I 22.00 ± 22.09 - 21.67 ± 3.44 - 
iNOS 12.97 ± 6.27 - 5.28 ± 0.96 - 
IL12b 54.21 ± 22.81 14.71 ± 2.66 19.07 ± 3.43 7.28 ± 0.80 
TNF 17.96 ± 2.52 4.21 ± 0.37 9.16 ± 0.06 4.06 ± 0.75 
FasL 5.12 ± 0.36 2.55 ± 0.41 6.65 ± 0.76 7.56 ± 1.71 
Stat1 7.89 ± 0.52 10.96 ± 9.40 3.81 ± 0.86 4.05 ± 2.78 
Ccl2 46.39 ± 31.41 - 41.16 ± 4.72 - 
Ccr2 20.54 ± 12.55 15.62 ± 4.44 8.04 ± 1.42 5.20 ± 1.47 
Ccr5 15.11 ± 12.40 6.46 ± 0.29 8.96 ± 2.49 4.92 ± 1.87 
Itgam 10.79 ± 3.27 2.26 ± 1.71 28.12 ± 19.94 5.85 ± 4.45 
Icam-1 8.54 ± 3.54 3.32 ± 1.41 8.58 ± 1.45 4.39 ± 0.28 
Sel-e 16.65 ± 2.24 - 12.56 ± 10.27 - 
Sel-p 24.08 ± 15.47 -  23.87 ± 25.03 - 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Quantification of gene expression in the heart tissue of infected C57BL/6 mice and gal-3 -
/- mice. RNA was isolated from hearts on the indicated days after infection; RT-PCR was performed to 
quantify expression of the genes listed in Material and Methods. Results are expressed as the fold 
increase values (± SD) of pooled RNA from 5 different mice done in duplicate, comparing infected 
tissue at given times with the non-infected control. Values in red typing represent more than five times 
up-regulated genes.  
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4- GALECTIN-3 DEFICIENT DENDRITIC CELLS  
 
 We have shown that galectin-3 is up-regulated in B cells and are constitutively 
expressed in antigen presenting cells that migrate to the heart during infection. The role 
of galectin-3 seems to be important and global during the initiation and establishment of 
the immune response, because galectin-3 knock-out mice showed an impaired cytokine 
serum levels, a deficient immune cells migration and deficient expression of genes 
related to inflammation and immune response. Looking for the mechanism underlying 
this lack of response, we focused our attention in the cells responsible of initiate the 
immune response, the dendritic cells. These cells are known to express and secrete 
galectin-3, and are the most powerful antigen presenting cells, so they are a good 
candidate to find out an explanation that could explain the phenotype that we had 
described in the Gal-3 -/- mice.  
 
4.1. Gal-3 -/- Dendritic Cells Differentiated from Bone Marrow Precursors Show a 
Normal Surface Marker Expression.  
 
 We decided to work with DCs in order to explain the altered response observed in 
the gal-3 deficient mouse. It has been published that galectin-3 is expressed on DCs and 
that this protein is important for dendritic cells functions, like cytokine production 
(Bernardes, Silva et al. 2006), or migration (Brustmann 2006). Gal-3 does not play any 
role in differentiation and maturation (Breuilh, Vanhoutte et al. 2007), but there are 
some reports involving other galectins in DCs maturation (Dai, Nakagawa et al. 2005; 
Fulcher, Hashimi et al. 2006). However, there is no evidence on the relevance of 
galectin-3 in DCs differentiation in vitro from bone marrow cells. To rule out the 
possibility that gal-3 -/- bone marrow precursors could not differentiate to viable DCs, 
we incubated cells with GM-CSF for 9 days, and then we checked first the presence of 
galectin-3 (Figure 28,A-D), and then the expression of CD11c, MHC II and the 
costimulatory molecules CD80 and CD86, in non-stimulated DCs and LPS-matured 
DCs. Wild type DCs are supposed to be CD11c+ cells, have high MHCII surface 
expression, low CD80 and CD86 expression of immature DCs, but after maturation 
with LPS these co-stimulatory molecules are up-regulated. This phenotype is exactly 
what we found when we looked at these markers, both on wild type DCs and gal-3 -/- 
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DCs, and both increased CD80 and CD86 expression after LPS treatment, confirming 
thus the nature and viability of gal-3 -/- DCs. (Figure 28, D-L) 
 
 
 
 
 
 
Figure 28. Galectin-3 -/- dendritic cells 
showed a normal expression of surface 
markers. A) Galectin-3 expression was 
tested by flow cytometry on differentiated 
DCs. Isotype antibody control is shown in 
dark grey solid histogram, immature DCs 
in dark grey solid histogram, and DCs after 
over night LPS incubation in black line. It 
is shown the presence of galectin-3 in DCs 
and the up-regulation after LPS incubation 
B) Gal-3P-/- P DCs were stained with antiGal-
3 antibodies too, and no signal was 
detected. C) Gal-3 expression was 
observed by confocal microscopy in non-
infected wild type DCs. D) Isotype 
controls were used for negative controls. 
E, F) Immature Gal-3P+/+ P or Gal-3P-/- P DCs
were analyzed for the surface expression of 
CD11c by flow cytometry (black line). 
Isotype controls antibody was used as 
negative control (solid grey) G, H) 
Immature Gal-3P+/+ P or Gal-3P-/- P DCs were
analyzed for the surface expression of 
MHCII by flow cytometry (black line). 
Isotype controls antibody was used as 
negative control (solid grey). I-L) Gal-3P+/+ P
or Gal-3P-/- P DCs were analyzed for the 
surface expression of CD80 and CD86 by 
flow cytometry. Immature DCs (thin black 
line) and cells after over night LPS 
treatment (thick black line) were analyzed, 
and isotype control were used as control 
(solid grey). Both co-stimulatory 
molecules were expressed at low levels in 
immature DCs, and both were up-regulated 
after LPS incubation, in wild type and in 
Gal-3P-/- P DCs. 
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T4.2. Parasite Adhesion and Invasion are Increased in gal-3-/- Dendritic CellsT.  
  
 Because galectin-3 plays a role during T. cruzi recognition, parasite adhesion and 
invasion of DCs could be the first events altered due to the lack of the protein. To check 
out this possibility, adhesion assays were done in the same way that it was done for the 
in vitro adhesion experiments. Surprisingly, we did not find any decrease in parasite 
adhesion as could be expected for a DC lacking Gal-3, a protein that it is known to play 
a role during parasite adhesion to host cells as it has been shown before. Even more, 
what it was observed is that parasites bound better to gal-3P-/-P DCs than wild type DCs. 
(Figure 29A). In concordance with an increased adhesion, we observed an increased 
invasion, because the number of trypomastigotes produced after 72 hours post-infection 
was much higher in gal-3P-/-P DCs (Figure 29B). To further evaluate this phenomenon, we 
checked expression of other galectins on DCs surface looking for a possible molecular 
compensation. It was shown that gal-3 P-/-P mice showed higher expression of galectin-8 on 
the cell surface (Figure 29E-F) This could be related to the higher parasite adhesion to 
the gal-3P-/-P DCs because Gal-8 was found to be the most strong adhesion mediator when 
it was added exogenously.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29. T. cruzi binding and 
invasion of DCs were higher in 
gal3P-/- P due to an up-regulation 
of Gal-8 expression. A) CFSE 
labelled parasites were 
incubated at 1:2 and 1:10 
cell:parasite ratio with wild type 
and Gal-3P-/- P DCs and 
fluorescence attached to the cell 
gate was quantified by FACs. B) 
Trypomastigotes present in cell 
culture medium of infected wild 
type and Gal-3P-/- PDCs were 
counted 72 hours after infection. 
C) Gal-3 surface expression was 
analyzed in control and infected 
wild type (C) and Gal-3P-/- P DCs 
(D). Non-infected DCs and (E) 
infected DCs (F) were checked 
for Gal-8 surface expression by 
FACs. Results are the mean of 
three independent experiments 
in duplicate. Error bars means 
SD, **P<0.01,***P<0.001 
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4.3. Galectin-3 -/- Dendritic Cells Showed a Significantly Diminished Production of 
the Pro-inflammatory Cytokines TNF-α and IL-1 in Response to LPS and T. cruzi 
Infection  
 
 DCs are a key mediator between innate and adaptive immunity, in part because 
after pathogen recognition, they produce a set of cytokines that will influence the 
outcome of the later response. Depending on the pathogen, different recognition 
receptors will be involved, and therefore different cytokines will be produced.  
 Thus, if galectin-3 can act as a potential T. cruzi receptor, its recognition by 
galectin-3 could trigger a cytokine response that will be altered in the deficient DC, and 
this could lead to global systemic consequences. To test this hypothesis, wild type and 
gal-3 -/- DCs were treated with LPS or exposed to T. cruzi trypomastigotes overnight, 
and cytokines levels were measured in the supernatants. (Figure 24) Due to the great 
importance of the Th1/Th2 cytokine balance during the infection, we measured the most 
common cytokines associated to both kinds of responses. GM-CSF used for DCs 
differentiation was removed prior to the assay, because it has been described a direct 
toxic effect of this cytokine to T. cruzi (Olivares Fontt, De Baetselier et al. 1998).  
 In the absence of LPS or parasites, we did not detect almost any cytokine in DCs 
culture medium. Only small amounts of IL-10 were detected on the supernatant of wild 
type and gal-3 -/- DCs. Not surprisingly, after LPS or parasite exposition, cytokine 
levels resulted strongly increased in culture supernatants of wild type DCs. LPS 
maturation of wild type DCs, or incubation with trypomastigotes led to the production 
of the following cytokines: IL-1, TNF-α, IL-12, IL-6, IL-10, and IL-17. Some cytokines 
were measured but not detected, like INF-γ and GM-CSF. This cytokine production by 
DCs in response to pathogenic stimuli can be considered normal, but several important 
differences were observed in the case of gal-3P-/-P DCs (Figure 30), and the differences 
were not restricted to LPS or parasite induced response. The up-regulated production of 
TNF-α and IL-1α in response to LPS and T. cruzi was significantly lower in gal-3P-/- P 
DCs than in wild type P PDCs, as much as six times lower. Both cytokines are pro-
inflammatory, are defined like Th1 cytokines and play an outstanding role during the 
immune response initiation.  
 On the other hand, increased levels of IL-10 after T. cruzi infection were observed 
in the gal-3P-/-P DCs compared to wild type DCs.  IL-10 levels were increased in response 
to LPS too, but no difference was seen between gal-3 -/- and wild type DCs. IL-12 and 
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IL-6 were strongly induced in response to LPS or T. cruzi, but there were no significant 
differences between wild type and deficient DCs.    
 
 
 
 
 
 
 
 
4.4. Galectin-3 Deficient Dendritic Cells Present an Altered Surface Expression of 
Toll Like Receptors when they are Infected by T. cruzi. 
 
 To evaluate further the diminished TNF-α and IL-1α produced by gal-3P-/-P DCs 
upon stimulation, we focused our attention in TLRs expression by those cells. It is well 
known, that T. cruzi is recognized by TLR2, TLR4 and TLR9, and this recognition led 
to an efficient cytokine production. After LPS treatment, TLR2 and TLR4 recognized 
the bacterial product and through well established intracellular signals involving 
MyD88, TRAF and NFκB activation, DCs and macrophages initiate an immune 
response again the pathogen, leading to cytokine production, IL-12 and TNF-α in the 
case of T. cruzi. Thus, if gal-3P-/-P DCs are not producing pro-inflammatory cytokines in 
response to T. cruzi and LPS, the question at this point arises clearly: Do TLRs work 
Figure 30. Cytokine production by dendritic cells in response to LPS and T. cruzi. The 
amounts of GM-CSF, IFN-γ, IL-1α, IL-2, IL-4, IL-5, IL-6, IL-10, IL-17, and TNF-α in the culture 
supernatant of gal-3 +/+ DCs (black columns) and gal-3 -/- DCs (white columns) were determined 
by flow cytometry. IL-12p70 was determined by ELISA. Supernatants culture from immature DCs 
without treatment, from DCs incubated over night with LPS (1µg/mL) and after incubation with T. 
cruzi trypomastigotes (10 parasites per cell) over night were measured. GM-CSF and IFN-γ were 
not detected. Data are the mean of three independent experiments (±SD) performed in duplicate, 
and results are given in protein picograms per millilitre.*P<0.05, **P<0.01 
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properly in the gal-3P-/-P DCs? In order to find out whether the cytokine deficient 
production was due either to a defect in TLRs expression or to the lack of galectin-3 
itself, TLRs surface expression was measured. TLR1, TLR2, TLR4, TLR6 and TLR9 
expression were measured.  
 Surface expression of the mentioned TLRs was measured on wild type and gal-3-
/- DCs, in non-infected and in in vitro infected cells (Figure 31). There were not 
detected any differences regarding TLRs surface expression between wild type and gal-
3P-/-P DCs in the absence of parasites. Nevertheless, after T. cruzi infection, all of the 
TLRs tested were up-regulated in the wild type DCs, as it was expected, but some TLRs 
were not expressed on the surface of gal-3P-/-P DCs. TLR2 and TLR6 maintained the same 
surface expression levels than the wild type DCs, but on the other hand, TLR1 was 
almost absent. TLR4 was in an intermedial status, the expression was lower than the 
wild type, but not so low like the TLR1.   
 
  
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
 
 
 
 
 Figure 31. TLRs surface expression was impaired on gal-3 -/- DCs after T. cruzi infection. TLR-1, -2, 
-4, -6 and -9 surface expression were measured by flow cytometry. Wild type DCs (A-E) and gal-3P-/- P DCs 
(F-J) were cultured over night in the presence of ten trypomastigotes per cell (blue histograms) or in the 
absence of parasites (green histograms). Specific TLR expression measured is indicated in each box. 
Appropriated isotypes antibodies were used in each case as negative controls (pink histograms). TLR1 
was almost absent when gal-3 -/- DCs were infected (G) compared to wild type DCs (B). TLR-4 was also 
down-regulated in deficient DCs (I) compared to wild type (D). 
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DISCUSSION 
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 The central paradigm of modern molecular biology is that biological information 
flows from DNA to protein. But Genome and Proteome are not the only factors in life 
functions of an organism, and carbohydrates play an outstanding role in biology. 
Glycosylation is the most common post-transductional modification, highly conserved 
through the evolution. In mammals, 50% of total proteins are glycosylated, 80% of the 
membrane proteins. This reflects its importance as biological information containers, far 
from the simplistic and classical point of view of sugars as energy source or scaffold 
proteins. Hence, the almost unlimited structural diversity of complex glycans, mainly 
due to the possibility to create branched structures, make them the perfect way to 
contain information in biological terms. On the other hand, this complexity, the 
difficulty in easily determine glycan sequences, and the fact that their biosynthesis 
could not be directly predicted from the DNA template makes the study of glycans one 
of the most complicated challenge in biology. These problems have held back the 
development of the glycobiology and the glycomics, when compared to other 
biomolecules. However, situation is changing nowadays due to the development of a 
variety of new technologies for exploring the structures of sugar chains.  
 Natural ligands of galectins are galactosides, sugars that are of outstanding 
relevance in T. cruzi biology, due to the unique enzyme that this protozoon possesses, 
the trans-sialidase, which is able to modify galactosyl exposition in glycans. Thus, it is 
an attractive possibility that T. cruzi could modify the galectin ligands. On one hand in 
the parasite, altering the pathogen recognition and interaction with host cells, and on the 
other hand in the vertebrate host, altering the immune response mounted against the 
parasite. This conceptual framework prompted us to define the role of galectins during 
the infection with T. cruzi. Some studies have been done, linking galectins and T. cruzi, 
but always in a very specific context. The aim of this work is to study the role of 
galectins during T. cruzi infection in a more broad sense. In order to do this, first we did 
in vitro experiments with recombinant galectins, taking several members of the three 
different subgroups, some of them not ever studied in the context of a parasite disease. 
Then, we studied the expression and role of galectins in a mouse model, and once we 
defined it, deficient mice in galectin genes were infected to confirm their biological role 
by means of characterising its phenotype. Finally, attempting to precise the molecular 
and cell events that galectins are modulating, their role were studied in differentiated 
dendritic cells, master initiators of the immune response.     
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1-In vitro interaction of galectins and T. cruzi 
 
 1-1 T. cruzi binds galectins in vitro 
 The protective and immune response against pathogens exposure is initiated by 
host recognition of specific Pathogen Associated Molecular Patterns (PAMPs), which 
are defined structures present in microorganisms, pathogenic or not, but not in host 
cells. The nature of the PAMPs described so far is variable, including linear or ramified 
structures, glycans, proteins, lipids or nucleic acids, and regarding T. cruzi one of those 
PAMPs might be glycoconjugates on T. cruzi surface, as it has been described in the 
case of GPI-anchored members (Campos, Almeida et al. 2001). Specific interactions 
between galectins and their glycoconjugates ligands are considered to be critical 
determinants in pathogen recognition (Rabinovich and Gruppi 2005). Hence, our first 
goal was to define whether galectins from the host were able to recognize specifically 
glycans exposed on the surface of the pathogen T. cruzi, and we found that galectins 
from the host were able to recognize glycans exposed on the surface of the pathogen T. 
cruzi. It is known that the surface glycoconjugates are extremely different in every 
biological stage. Our results show that galectins bind the three biological forms in vitro, 
however trypomastigotes and amastigotes, infective forms present in the host, are 
recognized by galectins with more avidity than the non-infective epimastigotes. There 
are several reasons to explain this, and reflects the changes that take place in the 
membrane composition, accessibility and exposure of the infective forms. Mucins of 
trypomastigotes are longer, contain additional α-galactopyranosyl residues and 
unsaturated, instead of saturated, fatty acids in the sn-2 position of the 
alkylacylglycerolipid component (Almeida, Camargo et al. 2000). These changes are 
supposed to arise through the evolution in order to survive in the new environment, the 
vertebrate host, where T. cruzi will encounter several galectins and other immune 
proteins. Whether the parasite evolved to display galectin ligands in infective forms, or 
the host developed galectins with high affinity towards parasite structures is difficult to 
predict over the common evolutive pressure of both species. In a more specific way, the 
affinity of different members of the galectin family was quite different considering the 
same parasite biological forms, indicating not only different parasite surface 
composition, but different fine specifity for each galectin. Although all galectins bind 
the common glycan core GalβGlcNAc, other sugar units flanking this core could modify 
the affinity for each particular galectin. Amastigotes are the parasite form that binds 
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galectins with highest affinity and Gal-7 and Gal-8 present the highest affinity for 
trypomastigotes. Amastigotes are mainly intracellular, and this location suggests that 
they could modify intracellular function of galectins, in a variable way depending on the 
cell type and on the galectins expressed intracellularly. It has been described an 
alternative infection cycle inside the host, where intracellular amastigotes release from 
lysate cells, and then infect adjacent cells. As the amastigote is an intracellular non 
motile form, the higher affinity for galectins could favour the entry in new live cells, 
promoting adhesion and invasion. The fact that galectins can bind to T. cruzi is in 
agreement with recent reports that show the ability of galectins to bind to different 
pathogens. It has been shown that Gal-1 is able to bind several human viruses 
(Levroney, Aguilar et al. 2005; Ouellet, Mercier et al. 2005). Gal-3 has been shown to 
interact with pathogens like Helicobacter pylori (Fowler, Thomas et al. 2006), 
Mycobacterium tuberculis (Barboni, Coade et al. 2005), Klebsiella pneumoniae (Mey, 
Leffler et al. 1996), Candida sp., (Kohatsu, Hsu et al. 2006) and the helminth 
Schistossoma mansoni (van den Berg, Honing et al. 2004). Gal-3 and Gal-9 have been 
reported to bind Leishmania major, although the biological implications for each 
galectin binding seem to be very different, since only Gal-9 but not Gal-3 promotes 
adhesion of the parasite to macrophage (Pelletier and Sato 2002; Pelletier, Hashidate et 
al. 2003). Regarding T. cruzi, Gal-3 had already been indirectly described to bind T. 
cruzi surface (Moody, Ochieng et al. 2000; Kleshchenko, Moody et al. 2004). Our data 
confirm that Gal-3 bind to T. cruzi surface and show for the first time that other galectin 
members can do it as well. The relevance of this T. cruzi-galectins interaction might 
vary depending on the individual galectin and on the cell type or matrix component that 
the parasite interacts with. Galectins are present in immune cells, and this interaction 
galectin-parasite could modulate their response, as it will be discussed below regarding 
galectin deficient models.  The interaction between galectins and T. cruzi could be 
considered as a mediator mechanism of cell-parasite adhesion as well, during the 
encounter parasite-host cell, and could mediate interactions with extracellular matrix 
components. 
 Although it was demonstrated the interaction between galectins and T. cruzi, it 
was not clear whether it was carbohydrate-dependent. There was not binding for any 
galectin when assays were done in the presence of lactose, a natural inhibitory hapten 
for galectins. This indicates that T. cruzi recognition is mediated by the CRD in a sugar-
dependent way. Moreover, this was supported by the results obtained in assays using 
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galectin-8 mutants. The lack of carbohydrate binding activity in one CRD showed a 
very disminished affinity and the mutant with no sugar binding activity (both active 
CRDs are mutated) showed no binding at all.  
  
 Location of the main galectin ligands on the surface of T. cruzi was seen under 
confocal microscopy. Many of the ligands were located all over the parasite surface 
with some intracellular diffuse staining. For amastigotes only surface ligands were seen 
in the case of amastigotes for all galectins tested, and for galectin-8 with 
trypomastigotes. Further work will be needed to identify the nature of particular parasite 
galectin ligands. Using a classical approach of affinity chromatography with 
immobilized recombinant galectins we could not identify any T. cruzi ligand. These 
preliminary attempts failed most probably to the inherent low affinity interactions, since 
galectins covalently linked to immobilized columns do not present multivalency. Using 
an alternative approach like western blot using soluble streptavidin-labelled galectins, in 
which the multivalency of galectins is preserved, we could observe many more 
unidentified ligands. A band around 75KDa was the main T. cruzi ligand of all the 
galectins tested, but its nature remains unknown. 
 We could identify one potential ligand of Gal-3, Gal-7 and Gal-8, the mucin 
AgC10. Moody et al showed a 45KDa parasite mucin that was detected as a Gal-3 
ligand (Moody, Ochieng et al. 2000), and indeed, it could be AgC10. AgC10 is a highly 
glycosilated mucin, that has been shown to exert several immunomodulatory effects, 
leading to T cell immunosuppresion, inhibiting IL-2 effects (Kierszenbaum, Fresno et 
al. 2002; Alcaide and Fresno 2004). Host molecules that may interact with AgC10 could 
be implicated in the immunosupressor activities attributed to the mucin, and galectins 
are reasonable candidate, since it is known that Gal-3 modulate T cell responses by 
control of TCR clustering at the immune synapse (Demetriou, Granovsky et al. 2001) 
and other galectins might be implicated because different galectins could bind common 
receptors as it has been described (Patnaik, Potvin et al. 2006), although the biological 
functions must not be necessarily the same. However, further investigations need to be 
done in order to confirm this hypothesis.  
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1.2- Galectins promote parasite-cell adhesion in vitro. 
 
 As galectins are multivalent proteins, they can cross-link receptors mediating 
cell-cell adhesion and/or cell-extracellular matrix, processes that make the galectin 
family important markers during tumour progression (Liu and Rabinovich 2005). Thus, 
in vitro experiments were done in order to evaluate the ability of galectins to promote 
parasite adhesion to host cells. Two cell lines were used in the experiment, THP-1 and 
LLcMK2. Both are susceptible of being infected, and express β-galactosides that can 
interact with extracellular galectins. Adhesion experiments were done with infective 
tissue trypomastigotes, as this biological stage is the more frequent way of infecting 
new cells during the disease. Experiments were done at 4ºC to block penetration, 
because at this temperature it is known that parasite invasion are almost inhibited, so we 
can assume that we are measuring only parasite adhesion to host cell surfaces.  
  In clear correlation with the previous binding assays, the galectins that showed 
higher affinity to trypomastigotes, Gal-3, Gal-7 and Gal-8, were the galectins that 
promoted adhesion to monocytes. The galectin induced adhesion was concentration 
dependent, and the CRD was implicated, since the effect was abolished in the presence 
of lactose. When Gal-8 mutants were used instead of the wild type protein, adhesion 
was not promoted, implicating an active CRD as a required element to favour parasite 
adhesion to host cells. However, the Gal-8 mutant that has a non-functional N-terminal 
domain, Gal-8R233, is still able to promote parasite adhesion to host cells, although in a 
lesser extent than the wild type. Gal-8R233 is supposed not to cross-link glycosylated 
receptors, as only one terminal domain of the protein can. It could be argued that the 
mutated CRD interact with some host molecules in a sugar independent way. However, 
that is not occurring in the parasite binding because lactose totally inhibits wild type 
galectin-8 binding to the parasite. Another possible explanation, is that Gal-8, although 
it is a tandem repeat galectin, form homodimers through the N-terminal CRD, as it has 
been published recently (Stowell, Arthur et al. 2008), allowing the Gal-8 dimer to be 
bivalent even when one of the two CRDs displays no sugar binding activity. In that way 
Gal-8 could still bind with relative high affinity to cognate ligands.  
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1-3 Galectin processing by T. cruzi 
  
 The association of Gal-3 with T. cruzi results in the formation of truncated form 
of Gal-3, which contains the intact CRD but lacks the N-terminal collagen-like domain. 
This truncated Gal-3 is unable of oligomerize. The cleavage sites within the N-terminal 
domain were identified in three specific sequences that can be associated in two groups, 
suggesting the action of at least two parasite proteases. The nature of the proteases 
implicated in Gal-3 cleavage was defined as a Zn-metalloprotease and a collagenase. In 
a systematic analysis of all protease families inhibitors, just OPA, a specific Zn-
metalloprotease inhibitor, and HgCl B2 B, inhibited Gal-3 processing, confirming the 
previous idea of two proteases. There is a report of HgCl B2 Bas an inhibitor of a T. cruzi 
collagenase (Santana, Grellier et al. 1997) that could be the protease responsible of one 
of the cleavages observed in Gal-3. The N-terminal domain of Gal-3 might be an 
appropriate substrate for a collagenase, because the domain of Gal-3 shares a high 
degree of homology with collagen. The inhibition of just one protease did not affect the 
activity of the other one, indicating that both proteases work independently.  Cruzipain 
is the more abundant protease described in T. cruzi so far, but it is not implicated in Gal-
3 processing, because a specific inhibitor (E64) was unable to inhibit Gal-3 cleavage. 
Our data suggest that Gal-3 is cleaved mainly by non-secreted surface proteases. It is 
known that Gal-3 forms lattices on cell surfaces that can affect many of the innate 
immune responses triggered by Gal-3. Lateral mobility of receptors such as TCR on T 
cells or polarization of Th1 responses are controlled by Gal-3 lattice formation. Thus, 
destruction of the N-terminal domain of Gal-3 might lead to modulate innate host 
immune responses depending on Gal-3 oligomerization. T. cruzi could affect even more 
to Gal-3 functions, if the intracellular amastigotes are able to process intracellular Gal-3, 
as it is known that the pleiotropic effects of galectins depend on their subcellular 
location. In this context, the first cleavage would affect to the phosphorylation site that 
control the translocation of the protein from nucleus to cytosol (Tsay, Lin et al. 1999), 
and it is unclear how this changes could affect to the regulation of cell apoptosis or cell 
growth. Further experiments must be done in order to explain the consequences of Gal-
3 cleavage in vivo. The control of Gal-3 biological activities is not new, and it has been 
reported before the existence of proteases implicated in Gal-3 processing, either by the 
mammalian matrix metalloproteases 2 and 9 (Ochieng, Fridman et al. 1994; Nangia-
Makker, Raz et al. 2007), and by the pathogen Leishmania major (Pelletier and Sato 
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2002). The first one is an example of how cleavage of Gal-3 could modulate 
endogenous functions of the protein, and the second one exemplifies how a pathogen 
could use a similar system to modulate endogenous galectins to promote its survival and 
replication, in this case L. major, in a way resembling to what we have reported for T. 
cruzi. Gal-3 is also processed by an unidentified metalloprotease like L. major does, but 
the implication of collagenases had not been reported for any other microorganisms so 
far. 
 We report here for the first time that there are other members of the galectin 
family that experiment proteolitic processing after T. cruzi interaction. Both Gal-4 and 
Gal-8 are cleaved by T. cruzi in the linker peptide rendering to monomeric galectin 
forms. This might inhibit the inherent functions depending on the natural Gal-4 and 
Gal-8 bivalency. Cleavage of these two galectins was inhibited by OPA, indicating the 
action of the same or different Zn-metalloprotease. Gal-8 is being nowadays associated 
to the immune system, for instance controlling neutrophil functions, adhesion and 
superoxide production (Nishi, Shoji et al. 2003; Yamamoto, Nishi et al. 2008). Thus, the 
cleavage of Gal-8 by T. cruzi might represent a direct advantage for the outcome of the 
infection. Gal-4 is reported to be restricted to the epithelial tract, situated in-between 
enterocytes in the epithelial lumen, although its expression in other tissues can not be 
ruled out. Another point is that galectins processing could be necessary for the advance 
of the parasite through extracellular space in order to reach the host cells.  
 
1.4 Inhibition of parasite proteases leads to parasite killing by recombinant 
galectins   
 
 During Chagas disease, the parasite T. cruzi must evade complex defensive 
systems that are present in the host. Some of them include molecules that are intended 
to induce direct parasite killing. The complement system is one of the first innate 
mechanisms that target the parasite. However, T. cruzi is able to escape from the 
complement because the calreticulin of T. cruzi binds specifically to recognitionP 
Psubcomponents of the classical and lectin activation pathways of the human 
complement, preventing parasite killing (Ferreira, Valck et al. 2004). Glycoconjugates 
are major targets of different innate defensive systems. Among them it can be found 
collectins, defensins, dectins or anti-glycans antibodies, that are innate microbicides.   
For example, collectins are soluble CBPs able to induce microbial clearance (van de 
  115
Wetering, van Golde et al. 2004) and sera of patiens with chronic Chagas´ disease 
contain elevated levels of anti-α-galactosyl antibodies that are lytic to T. cruzi.(Milani 
and Travassos 1988; Gazzinelli, Pereira et al. 1991). Galectins could induce parasite 
death in a similar way to the anti-galactosyl antibodies, since both groups of proteins 
may bind the same T. cruzi ligands . It has been reported that the smallest unit that was 
reactive with anti-galactosyl antibodies was Galα1-3Galβ1-4GlcNAcol (where 
GlcNAcol is N-acetyl-glucosamininitol), isolated from a mucin-like protein from T. 
cruzi termed F2/3 (Almeida, Ferguson et al. 1994). Galectins might be able to bind to 
this mucin-like protein, and could exert an effect similar over T. cruzi to that produced 
by lytic anti-gal antibodies by means of cross-linking parasite glycans. Moreover, it is 
known that Gal-1 and Gal-3 are quickly released from cells after T. cruzi interaction as 
part of the innate immune response, and it is likely to be the same for other members.  
 Our results show that indeed galectins are able to induce direct parasite killing, 
when the protease processing galectins is inhibited by OPA. The galectins that bind 
with high affinity to the parasite, Gal-3, Gal-4 and Gal-8, induced direct parasite death 
when the galectin processing was inhibited. Thus, functional cross-linking of crucial 
glycoconconjugates of T. cruzi can induce direct parasite death. A vegetal lectin, 
Euonymus Europeaus Agglutinin (EEA), with related binding affinity to the shown by 
galectins and anti-α-gal lytic antibodies can induce killing as well (Almeida, Krautz et 
al. 1993). Therefore, we can not rule out that anti-gal antibodies, galectins and EEA are 
interacting with the same molecules. The F2 fraction recognized by most of the anti-gal 
antibodies corresponds mostly to a 74KDa mucin-like protein (Almeida, Krautz et al. 
1993), and this is close to the molecular weight of the major T. cruzi ligand of the 
galectins tested, as we have seen by western blot using recombinant galectins as a 
probe. This F2 fraction could be the galectin ligand on T. cruzi surface responsible of 
galectin mediated death, and further work must be done to confirm this hypothesis.    
 It is likely that T. cruzi has developed protective mechanisms to avoid the 
protective lytic role of galectins and limit or block their effector functions, in this case 
using specific proteases able to process galectins. After this processing, galectins are not 
able any more to cross-link receptors on T. cruzi surface, preventing parasite death. 
Interestingly, the resulting truncated galectins still have a functional CRD. We can 
speculate that galectin fragments around the parasite might provide some advantages in 
the host, like galactosyl epitopes hiding or interaction with host cells promotion. It has 
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been published that Gal-3 can induce death of Candida albicans (Kohatsu, Hsu et al. 
2006), in agreement with the hypothesis that galectins are direct microbicidal agents. 
The specific mechanism has not been described, but in contrast to the reported affinity 
of Gal-3 to β-galactosides, Gal-3 binds to mannose complex present on Candida sp. 
This is the only reference as galectins as direct microbicidal agents, and our data is the 
first demonstration of a pathogen mechanism able to prevent this action. Thus, 
identification of the proteases implicated in galectin processing might represent a 
promising candidate in the search for molecular targets seeking effective 
chemotherapeutic agents to treat Chagas´ disease        
 The fact that galectins bind to infective parasites can increase parasite adhesion 
to host cells thanks to their multivalency seems to be paradoxical regarding to the 
ability of galectins to kill the parasite on the basis of the same multivalency, because a 
truncated galectin is unable to promote parasite adhesion to the cell. So, does T. cruzi 
use galectins like molecular bridges to the host cells, or does it cleave the bridges that 
galectins form in its own surface to kill the parasite?  The experimental conditions of 
our in vitro experiments allowed us to look at both events independently. Adhesion 
experiments were performed at 4ºC. This reduce the rate of enzymatic activity of the 
proteases, meanwhile processing experiments were done at 37ºC, temperature of the 
host where the parasite should encounter galectins. Most importantly, the cleavage of 
galectins seems to be a process that needs more time than the passive interaction of 
parasite-galectins. It could be postulated that first T. cruzi interacts with full length 
galectins-T. cruzi, and this promotes parasite adhesion to host cells, at the same time 
that many other parasite and host molecules are interacting. Adhesion of parasite to host 
cells is a fast event, and once the parasite is attached to cell membrane, it starts cell 
penetration and galectin processing, preventing the microbicide action.  
  
 However, this simple scenario may be much more complicated in vivo due to 
several factors. Different glycans in different cell types present variable affinity for 
galectins, competition between host glycans and parasite glycans, presence of more than 
one galectin at the same time, depending on the infected cell type, galectin 
concentration, glycan tissue profile, or even the existence of parasite CBPs that could 
compete with host galectins, both over parasite or endogenous host ligands.  
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2- Galectin expression in the murine model of experimental infection 
 
 The data obtained from experiments in vitro suggest that galectins might play an 
important role during the outcome of Chagas´ disease in the infection establishment, 
playing a role in parasite recognition, parasite adhesion to host cells and parasite killing. 
In addition, galectins interact not only with T. cruzi, but with host receptors to modulate 
immune responses, regulating subsequent events like inflammation, cell migration, 
cytokine production, activation of the innate immune response and subsequent linking 
to the adaptive one. Many studies have demonstrated that galectins are related to the 
mentioned events, but they have been done in a particular galectin, in a specific 
environment. Our goal was to perform a systematic study of different galectin 
expression in different immune cell types. The context of Chagas disease and its study 
under the murine experimental infection provide us the opportunity to get insight on the 
role of different galectins under the same pathogenic circumstance.   
 Indeed, the fact that galectins may be of outstanding relevance during Chagas 
disease was confirmed by the data obtained from infected mice. Galectins were 
differentially regulated in spleen, a peripheral lymphoid tissue, and in immune cells 
migrated to a target organ of T. cruzi, the heart. 
 
2.1- Galectin expression profile in immune cells 
 
 In the immune system, galectins are mostly expressed by activated but not 
resting T and B cells, and they are significantly up-regulated in activated macrophages 
and regulatory T cells (Liu and Rabinovich 2005; Rabinovich, Toscano et al. 2007). The 
course of T. cruzi infection is not an exception, and it is known that some galectins are 
up-regulated and secreted in several cell types during the disease, Gal-1 in B cells and 
macrophages (Zuniga, Gruppi et al. 2001; Zuniga, Rabinovich et al. 2001), and Gal-3 in 
DCs and B cells (Vray, Camby et al. 2004). Our results confirm these reported 
observations, and provide for the first time a global scenario of galectin expression in T 
cells, B cells and antigen presenting cells.  
 T cells showed an increase in Gal-1, -3 and -9 surface expression after T. cruzi 
infection. Crosslinkage of T cell surface receptors by galectins can trigger different 
transmembrane signalling through which different processes such as survival and 
activation are modulated (Toscano, Ilarregui et al. 2007). Our results demonstrate the 
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presence of these galectins on T cell surface subsets, but it is not clear if these galectins 
are expressed by the T cells or by other surrounding cell types, interacting 
extracellularly with exposed ligands on the T cell surface. Since galectins are actively 
secreted by many immune cells, they can work in an autocrine or paracrine way. Thus, 
it has been suggested that the induction of apoptosis by Gal-1 in T cells is dependent on 
the Gal-1 secreted by B cells during T. cruzi infection (Zuniga, Rabinovich et al. 2001), 
and it is possible that other galectins present on T cells surface could come from other 
cells like B cells, macrophages or DCs.  
 Regarding B cells, although it has been described an increase in Gal-1 levels in 
B cells infected with T. cruzi, we have not seen such increase. Nevertheless, it is known 
that Gal-1 is mainly secreted by B cells, so we could hypothesized that Gal-1 secreted 
by B cells are bound to receptors in other cell types like T cells. It was found an up-
regulation of Gal-3 expression, as it has been reported before showing that Gal-3 
mediates IL-4-induced survival and differentiation of B cells towards a memory cell 
phenotype (Acosta-Rodriguez, Montes et al. 2004). It can not be ruled out that other 
galectins could be implicated in this process as well. In this regard, we have observed 
down-regulation of Gal-8 and up-regulation of Gal-9 at mRNA levels during the 
experimental infection. The precise role of each galectin over B cell fate still remains 
unclear, but it is likely that competition and/or cooperation between different galectins 
are implicated to control B cell responses.    
 The presence of Gal-1, -3 and -9 was demonstrated on the surface of APCs 
(macrophages and DCs) on spleen of control and infected mice. The amount of these 
galectins on the surface of APCs was up-regulated in response to the infection. In 
concordance, splenic DCs from infected animals increase Gal-3 expression, affecting so 
their migration (Vray, Camby et al. 2004). Compelling evidence has implicated 
galectins in macrophages and DCs immune responses. As we have shown that Gal-1 
and -3 binds to T. cruzi in vitro, we could speculate that these proteins might favor 
parasite phagocytosis or activation of the immune response, suggesting that galectins 
could work as PRRs. Gal-1 has been described to lead macrophage activity towards 
resistance or susceptibility to T. cruzi depending on its concentration (Zuniga, Gruppi et 
al. 2001).. This author shows that Gal-1 concentration address the macrophage activity 
in vitro after T. cruzi challenge. Low Gal-1 concentrations decrease IL-12 and NO 
production, favoring parasite replication. High concentration induces apoptosis, killing 
phagocyted parasites and controlling the spread of the infection. An interesting issue 
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would be to compare Gal-1 produced by immune cells from different mice strains 
associated to resistance or susceptibility to the disease, to confirm this effect in vivo.  
  
 Galectins work as versatile molecules capable of modulating the physiology of 
different immune cells. We have shown that after T. cruzi infection, spleen cells change 
their galectin expression profile. An extra regulation point consists in modulating the 
glycan structure of their ligands. This is done by changes on galactosyltranferases under 
pathological conditions, which in turn will modify glycan structures. In addition, in the 
case of T. cruzi infection, host glycan composition can be modified by the enzyme 
trans-sialidase, unique to T. cruzi, by exposition on galactosydes residues. According to 
this, our results show that spleen cells during infection present the highest affinity for 
galectins at day 14 after infection, correlating with the highest parasite burden, and then 
with the highest amount of circulating tran-sialidase. By means of higher exposure of 
galactosyl ligands, host galectin ligands might be modificated, increasing the affinity for 
galectins, and modifying the cellular responses triggered by galectins. How 
desialylation affects to the carbohydrate binding specifity of galectin-1 has been 
recently demonstrated (Toscano, Bianco et al. 2007). This work shows that Th2 T cells 
are protected from Gal-1 mediated apoptosis through differential α2,6- sialylation of 
cell surface glycoproteins, meanwhile Th1 and Th17 effector cells express low 
sialylation levels, that in turn allows the formation of Gal-1 lattices on the cell surface 
triggering apoptotic signals to the cell. As T. cruzi retires terminal sialic acids from 
exposed glycoconjugates, it could be hypothesized that Gal-1, and most likely other 
galectins, would not form lattices on the cell surface, affecting so clustering membrane 
receptors and signal transduction.  
 
2.2- Galectin expression in heart of infected animals.  
 
 Gal-1 and Gal-3 were up-regulated in heart tissue during the infection time. We 
analyzed the presence of other galectins during the course of infection, but only a 
slightly increase in gal-9 mRNA was detected. Although Gal-8 is normally expressed in 
heart tissue, we failed to detect the protein by western blot, but we did not observed any 
difference in gal-8 mRNA levels during infection, so we can assume that the role of 
Gal-8 is not so relevant as the one seen for Gal-1 and Gal-3, both up-regulated upon 
infection.  
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 Neither Gal-1 nor Gal-3 expression was detected in hearts from non-infected 
animals, but were highly up-regulated during the infection, reaching the maximal 
expression at day 21 post infection, when the highest parasite burden occurs in heart 
tissue.  
 Most of the Gal-1 was expressed by cardiac cells, but it is likely that infiltrating 
immune cells are expressing Gal-1 as well. Gal-1 was clearly up-regulated, in 
accordance with previous results observed in humans (Giordanengo, Gea et al. 2001), 
but we did not observed any gal-1 mRNA increase, so other posttranscriptional 
regulatory systems should be responsible of the protein up-regulation like mRNA 
stabilization or an decrease in protein turn-over. Unlike the anti-inflammatory Gal-1, 
Gal-3 is not expressed by cardiac cells; infiltrated CD68- macrophages are the main 
source of Gal-3 in infected hearts. These cells are expressing arginase I, a marker of 
alternative macrophage activation (Cuervo, Pineda et al. 2008). Supporting this, Gal-3 
has been described as a new alternative activation marker (MacKinnon, Farnworth et al. 
2008). The induction of Gal-3 reached maximal values at 14 days post infection, when 
it was already observed high macrophage heart infiltration.  
  
 So, galectins are highly regulated in lymphocytes and antigen presenting cells, 
and it is likely that they participate in immune response through cell activation and cell 
migration to the heart after T. cruzi invasion. But it is the use of galectin-1 and specially 
galectin-3 deficient mice the most valuable tool that we had to define the role of those 
galectins in the immune system. Thus, supporting on the galectin expression profile 
over time of infection in the wild type model, the results obtained by use of recombinant 
galectins, and the reported data, it can be proposed the following scenario during T. 
cruzi murine infection. Gal-3 could participate in T. cruzi recognition, leading to the 
production of effector molecules able to activate the immune system. The up-regulation 
of Gal-3 would induce pro-imflammatory responses, Th1 responses activating the 
protective axis IFNγ-iNOS-NO that control parasite replication and spread. As a potent 
chemotactic agent, Gal-3 could favor inflammation promoting recruitment of immune 
cells to the sites of infection. Gal-1 could compete with Gal-3 ligands counteracting its 
pro-inflammatory actions, skewing the Th1 rsponse to a Th2 one and inducing apoptosis 
of activated Th1 but not of Th2 effector T cells. In heart, macrophages expressing Gal-3 
would be targeted by Gal-1 controlling the inflammatory responses initiated previously. 
Role of Gal-1 as a suppressive mediator is supported by its ability to induce apoptosis to 
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activated but not resting T cells, and by its expression in organs of immune privilege, 
where the cellular immune response should be quickly eliminated.  
 
 The galectin knock-out models served to confirm the roles of Gal-1 and Gal-3 
during the outcome of the immune response upon infection. It is noteworthy to mention 
the importance of the genetic background of the mice used in this study. Control wild 
type and the deficient models posses a C57BL/6 background. This strain is 
characterized by a high resistance to parasite infections. Those mice develop reduced 
parasitemia compared with other susceptible mice like Balb/c, show almost an absence 
of clinical symptoms and do not show any mortality rate. The causes that make one 
strain resistance and other susceptible remains unclear and it represents a promising 
field of study in order to find host parameters associated to natural resistance to the 
infection. A Th-1 polarized response seems to be linked to the resistant strains, but it is 
still unclear. The results obtained in this study could give many differences in a model 
using a susceptible strain. Actually, an important problem lies in Chagas disease 
research. Host genetic factor together with the intrinsic genetic variability found 
between different T. cruzi polyclonal strains might be the cause of some apparently 
contradictory reported observations in the literature.  
   
3- Study of the Immune Response in Deficient Galectin Mice 
 
 Infection of Gal-1P-/-P mice mice showed no major differences during the course of 
infection compared to wild type in clear contrast to what could be expected, due to the 
large number of immune processes that Gal-1 is affecting, and because of the strong up-
regulation of the protein in the wild type murine model. However, neither the 
parasitemia nor the immunologic parameters evaluated were significantly different 
compared to the wild type mouse. This could be due to the functional compensation of 
other galectin members not evaluated, like the galectin-2, a monomeric galectin 
structurally closely related, but functional redundancy between different galectins has 
not been demonstrated so far. Another possibility is that the main actions of Gal-1 up-
regulation is related to control the mounted immune response, which could lead to 
potencially damage the host, and then the lack of Gal-1 could not generate any 
abnormality in the early stages of the infection.    
  122
 On the other hand, deficient galectin-3 mice presented many immune alterations, 
as it was evidenced by the higher parasitemia found, confirming the importance of Gal-
3 during the host response against T. cruzi. Results regarding Gal-3 deficient mice will 
be discussed below. 
 
 3-1 Study of humoral response in galectin-3 deficient mice 
   
 In the case of T. cruzi infection, polyclonal lymphocyte activation has been 
proposed as the hallmark of immunological dysregulation during the acute phase 
of.Chagas disease (Minoprio, Itohara et al. 1989). Several studies indicate the 
importance of Abs for host survival and parasite clearance (Krettli and Brener 1976; 
Rodriguez de Cuna, Kierszenbaum et al. 1991).In addition, immunoglobulin 
IgG1/IgG2a balance is associated to a Th1 or Th2 response. High levels of IgG1 are 
linked to Th2 responses, and predominance of IgG2a to the protective Th1 response. 
The higher parasitemia observed in Gal-3P-/-P mice was not due to a different IgG1 or 
IgG2a production, where no differences were observed. 
  However, we investigated further the nature of the antibodies produced over the 
time of infection regarding glycoconjugates epitopes. Gal-3 is able to bind to T. cruzi 
glycans, molecules highly antigenic. So, the humoral response raised against glycan 
epititopes could be altered in the Gal-3P-/-P mice. Analysis of the specificity of antibodies 
to different glycans showed interesting differences. Serum from non-infected healthy 
mammals showed a set of natural antibodies able to recognize specific glycans 
structures, and no differences were found in this regard between wild type and Gal-3P-/-P 
mice. However, the number of glycan structures recognized by serum from infected 
mice was highly increased in wild type mice, suggesting the recognition of new 
glycosylated T. cruzi antigens, but most of these glycans were not detected by serum 
from infected Gal-3P-/-P mice, and moreover, the most antigenic glycan structures in the 
case of Gal-3 conserved the core Galβ1-3GlcNAcβ1-3Galβ1-4GlcNAc, what is indeed 
the basic structure of the natural Gal-3 ligands. It is difficult to explain now the origin of 
this phenomenon. One possibility could be that during infection, host Gal-3 binds to T. 
cruzi glycoconjugates, hiding this sugar epitopes. In the absence of Gal-3, Galβ1-
3GlcNAcβ1-3Galβ1-4GlcNAc containing sugars would be exposed, and would generate 
immunogenic responses. However, many other glycan structures resulted invisible for 
  123
the B cell repertoire in the Gal-3P-/-P mice, suggesting that Gal-3 is a necessary factor for 
this glycan recognition. We cannot rule out the possibility that some of these glycan 
structures are exclusively present in the parasite, and it is possible that they could be 
found in the host glycoconjugates, leading to the suppression or appearance of 
autoimmune processes. Further studies should be done to explain the nature of this 
phenomenon, and the possible implications for the resistance against T. cruzi infection. 
The glycan array used is composed by 406 glycans, and this represents a modern 
technique to evaluate the glycan binding profile of any carbohydrate binding protein. It 
will be available soon a pathogen glycan array, consisting in a microarray of 96 specific 
pathogenic bacteria polysaccharides derived from dozens of Gram-negative bacteria, 
thus allowing the use of this glycanarray for therapeutical diagnosis. 
 
3-2 Study of the Cellular Response in Gal-3-/- Mice 
 
 Analysis of the cytokine levels in serum from infected mice clearly shows that 
during T. cruzi infection Gal-3P-/-P mice mount a misbalanced cytokine profile expression 
in response to the parasite. Decreased proinflammatory cytokines levels were present in 
serum from Gal-3P-/-P. IL-2 was almost absent, suggesting that Gal-3 is necessary to 
induce IL-2 by T cells. This is in agreement with reported observations, showing that 
the inhibition of Gal-3 expression by anti-sense oligonucleotides decreases the 
proliferation of activated T lymphocytes inhibiting IL-2 synthesis (Joo, Goedegebuure 
et al. 2001). This could be a cause of the diminished levels of T cell-dependent cytokine 
levels, including Th1 and Th2, IFN-γ, IL-5 and IL-10. However, this cannot be the only 
explanation, because in T. cruzi infection, other cell types appear to be important for 
this cytokines synthesis, and although a deficient T cell activation could occur in the 
Gal-3P-/-P mice, we cannot rule out implications of other cell types, as NK cells and CD4-
CD8- T cells, both producers of IFN-γ (Zhang and Tarleton 1996). Similarly, 
macrophages and B cells are important producers of IL-10, apart from T cells, so any 
could present a deficient in IL-10 production. However, although is virtually impossible 
to attribute the decreased seric cytokine levels to a particular immune cell type, the 
deficient in IL-2, IL-6, IL-5 and IFN-γ suggests T cell abnormalities in the Gal-3P-/-P mice. 
However, the observed decrease in cytokines levels is not restricted to any polarized 
response or cytokine, showing a reduction in the strength of the response instead of its 
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nature. Since Gal-3 plays important roles in the synapse formation between APCs and T 
cells (Demetriou, Granovsky et al. 2001; Seminario and Bunnell 2008), phagocytosis 
and antigen uptake and presentation (Sano, Hsu et al. 2003), Gal-3P-/-P APCs could show a 
limited T cell activation capacity, correlating with the absence of IL-1 in serum, a key 
regulator of the initiation of imflammatory processes produced by APCs during the 
early stages of infection. Supporting this, Gal-3 potentiates IL-1 production in human 
monocytes (Jeng, Frigeri et al. 1994) and our results showed that isolated Gal-3P-/-P DCs 
presented a strongly decreased IL-1 and TNF-α production after incubation with LPS or 
T. cruzi in the absence of other immune cell types. The late IL-1 boost observed in Gal-
3 P-/-P mice at 28days after infection is likely to depend on other mechanisms appart from 
the lack of Gal-3, maybe as a consequence of the fully activation of the immune system 
and network of multiple cytokines.  
 The dramatically altered seric cytokine levels of Gal-3P-/-P upon infection could be 
due to an abnormal immune response, resulting in different total numbers of immune 
cells subtypes. However, at least in spleen we could not see any difference, neither in 
total cell number nor in cell composition. Gal-3 mice showed the normal chagasic 
splenomegaly, lymphocyte activation and proliferation and increase in the number of 
APCs, so we can conclude that Gal-3 is not related to the changes in spleen physiology 
related to the infection. 
 Gene expression profile in spleen confirmed the idea that Gal-3P-/-P mice develop a 
reduced response against T. cruzi, and it corroborated the changes in galectins 
expression at protein levels observed by flow citometry in C57BL/6 mice. In Gal-3P-/- P 
mice this regulation was quite similar, only gal-1 mRNA expression was lower in 
deficient mice at 14 days post infection. This could indicate that no other galectin is 
assuming the role of the missing Gal-3 in the knock-out model.  
 In addition, changes in chemokines receptors and integrins were observed both 
in wild type mice and in Gal-3P-/-P, with no significant differences between strains, 
indicating that these processes are independent of Gal-3 or compensated in some way. 
However, some other genes resulted in an altered expression in the Gal-3P-/-P mice, mainly 
related to inflammation and protective immune responses. This is the case of IFN-γ, 
COX-2 and iNOS. This prompted us to define Gal-3 as a possitive regulator of T. cruzi 
mediated imflammation. The deficient inflammatory response observed in Gal-3P-/-P mice 
is in agreement with several works showing important inflammatory deficiencies related 
to Gal-3 like lower granulocyte migration after artificial induction of peritonitis (Colnot, 
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Ripoche et al. 1998), lower number of infiltrating macrophages (Hsu, Yang et al. 2000), 
deficient Gal-3 mast cells lower amount of active mediators released by mast cells 
(Chen, Sharma et al. 2006)  and reduced phagocytosis (Sano, Hsu et al. 2003). 
 
 Inflammation is of great relevance in Chagasic pathology, because cardiac 
lesions are consistent with a process of inflammation and myocardial remodeling, which 
includes T cell/macrophage-rich myocarditis, hypertrophy, and fibrosis with heart fiber 
damage (Higuchi Mde, Benvenuti et al. 2003). Since inflammation is one of the 
hallmarks of cardiac lesions, one might speculate about its role in the disease outcome. 
Study of infected heart in Gal-3P-/-P mice showed that the parasite burden was similar 
during the acute phase of the infection, indicating that Gal-3 is not responsible of heart 
invasion by T. cruzi. However, the number of infiltrating host cells in heart tissue was 
markedly lower in the absence of Gal-3, consisting in lower number of CD4, CD8 T 
cells and macrophages. In contrast to wild type mice, whose number of infiltrating 
macrophages goes up at 28 days post infection, in Gal-3P-/-P mice it is stabilized, and keep 
at low levels during the infection, showing that Gal-3 is necessary for the recruitment of 
macrophages to the heart.  
 Our results are in concordance with other models of study using Gal-3P-/-P mice. 
When they have been infected with S. pneumoniae, a defect in immune cells migrations 
to the sites of infection has been reported (Nieminen, St-Pierre et al. 2008), colitis was 
reduced after C. albicans colonization (Jawhara, Thuru et al. 2008) and presented less 
inflammation in a murine model of asthma (Zuberi, Hsu et al. 2004). Discrepancies 
have been described by several authors relating the pro-inflammatory role of Gal-3 
during schistosome infection (Bickle and Helmby 2007; Breuilh, Vanhoutte et al. 2007; 
Oliveira, Frazao et al. 2007).     
  Our results regarding gene expression in hearts from T. cruzi infected mice 
confirmed the deficient inflammatory response in mice lacking Gal-3. In Gal-3 deficient 
mice IL-12, TNF-α, IFN-γ and iNOS, outstanding Th1 cytokines were repressed 
compared to the wild type mice. Controversially, parasite burden was not significantly 
different from wild type mice. Reduced expression of the chemokine receptors Ccr2 and 
Ccr5 correlate with the lower number of infiltrating immune cells. However, the 
differences in the total immune cell number could not be enough to justify the 
differences observed in Ccr2 and Ccr5 or cytokines gene expression. It is possible that 
Gal-3P-/-P mice express less chemokine receptors, what would lead to a deficient cell 
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migration, but this issue should be study in isolated immune cells. The relevance of 
Ccr2 and Ccr5 to mount an effective response against T. cruzi in heart has been shown 
by the fact that both knock-out models result to present higher parasite burden in heart 
(Machado, Koyama et al. 2005; Hardison, Kuziel et al. 2006).  
 Data from murine models show that inflammatory cytokines play a central role 
in T. cruzi infection. The innate and adaptive immune responses triggered by the 
parasite and its derived surface molecules, such as GPI anchors, during the acute phase 
lead to exacerbated production of inflammatory cytokines, including IL-12, TNF-α, and 
IFN-γ, and chemokines such as CCL3 (MIP-1a), CXCL10 (IP-10), and CCL5 
(RANTES) (Teixeira, Gazzinelli et al. 2002). Now, Gal-3 might be considered as an 
inductor of this processes, and the lack of Gal-3 results in a decreased cardiac 
inflammation. Further experiments to evaluate cardiac damage will help to explain 
whether the origin of Chagas cardiopathy is produced by host self-targeted responses or 
by the persistence of the parasite, taking advantage of a system with the same parasite 
burden, but a strongly decreased inflammatory process.   
 The origin of this defective inflammation could be related to the ability of Gal-3 
to bind glycans present on the T. cruzi surfaces. Acting as a PRR, Gal-3 could trigger 
activation signals in immune cells in order to mount the immune response. Thus, APCs 
responsible of initiate the immune response would be less efficient due to the lack of 
one of their PRR.  This could explain why TLRs are highly up-regulated in Gal-3P-/-P, as a 
possible compensation process to cover the lack of a functional related protein, in this 
case Gal-3. Unfortunately, the anti-TLRs available antibodies did not work properly for 
protein detection in western blotting, and we do not know whether the increase in 
mRNA of TLRs correlates with higher protein expression.  
 
3.3- Deficient Galectin-3 Dendritic Cells 
 
 DCs possess special features that allow them to act as APCs and are central in 
the initiation and development of immunity and tolerance. Immature DCs capture and 
process Ag via their high endocytic activity and undergo a process of maturation and 
activation after recognition of PAMPs present in microorganisms by PRRs. In addition 
to the well known TLRs, a vast array of extracellular and intracellular non-TLR innate 
receptors exists in DCs (Sabatte, Maggini et al. 2007), each one adapted to recognize 
specific pathogens and therefore lead to an appropriate immune response. Besides, it has 
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been reported that Gal-3 and its ligands are up-regulated in DCs after T. cruzi infection 
with functional consequences on their capacities of adhesion and migration (Vray, 
Camby et al. 2004), and changes in glycosylation patterns after maturation have been 
confirmed (Bax, Garcia-Vallejo et al. 2007), highlighting the importance of glycans and 
CBPs in DCs mediated responses. Thus, the lack of Gal-3 in DCs could lead to 
insufficiencies related to T. cruzi recognition, and related to intracellular signaling into 
the DCs. Thus, DCs are a reasonable candidate to explain the altered immune response 
observed previously in Gal-3 P-/-P mice.   
 Gal-3P-/-P DCs showed a normal differentiation process from bone marrow 
precursors, so it seems that Gal-3 is not necessary for DC differentiation in vitro. It is 
not probably neither that Gal-3 is implicated in DCs maturation, because LPS treatment 
and T. cruzi infection induced properly the expression of the activation markers CD80 
and CD86. We observed that T. cruzi was able to infect the wild type DCs in vitro, 
supporting in intracellular replication, as previously reported (Van Overtvelt, 
Vanderheyde et al. 1999). However, we expected that Gal-3P-/-P DCs were more resistant 
to infection, because it was shown that Gal-3 mediates interaction of T. cruzi with host 
cells in vitro. Surprinsingly, Gal-3P-/-P DCs showed higher parasite adhesion and led to an 
augmented trypomastigotes release to the medium. This contradictory data can be easily 
explained, because of the higher expression of Gal-8. Experiments in vitro showed that 
Gal-8 is a much stronger adhesion promotor than Gal-3, what can explain the enhanced 
adhesion of T. cruzi to Gal-3 knock-out DCs. However, this does not imply that Gal-8 
can compensate the functions of Gal-3. We have seen in vitro that ligands of Gal-8 in T. 
cruzi are different from those of Gal-3, and meanwhile Gal-3 forms lattices, Gal-8 tends 
to cross-link receptors. So, intracellular signals triggered by Gal-3 and Gal-8 may be 
completely different.  In fact, Gal-3P-/-P DCs showed a strong deficiency in the production 
of IL1 and TNF-α in response to LPS and T. cruzi. This could initiate an inadequate 
immune and inflammatory response, as it was observed in the T. cruzi infection of Gal-
3P-/-P mice. Secretion of other pivotal cytokines were not affected by the lack of Gal-3, 
like IL-12 and IL-6, meanwhile the anti-inflammatory IL-10 production was 
significantly increased after T. cruzi infection. It seems that Gal-3P-/-P DCs show a Th-2 
polarized phenotype, and the increase of IL-10 together with the decreased TNF-α 
levels reminds to the function of recently described regulatory DCs. What it is clear is 
that the absence of Gal-3 affects surface receptors expression somehow, because DCs 
result unresponsiveness to LPS and T. cruzi. It is quite surprise that Gal-3P-/-P do not 
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produce TNF-α after LPS-challenge. Our data are contradictory to other reports, 
showing that Gal-3P-/-P DCs secrete normal amounts of TNF-α when they were incubated 
with LPS (Breuilh, Vanhoutte et al. 2007).  Differences could be attributed to different 
LPS serotype or concentration.  
 In an attempt to find out the cause of the lack of TNF-α production, we checked 
TLRs expression on DCs surface, since it is well reported that LPS is recognized by 
TLR2 and 4, and that TLR2 and TLR9 recognize GPI anchors and parasite DNA, 
triggering MyD88 and TRIF-dependent intracellular signals (Tarleton 2007) 
  
 Wild type DCs showed an up-regulation of TLRs after T. cruzi infection as 
expected. In the case of Gal-3P-/-P DCs, TLR2 and TLR9 were up-regulated in a similar 
way to the wild type DCs, but contrary to the wild type model, surface expression of 
TLR1 was almost missing in Gal-3P-/-P. TLR1 has not been implicated in T. cruzi 
recognition, but it is relevance because, in order to trigger intracellular signals, TLR2 
may work as a dimer, either with TLR1 or TLR6. In our model, TLR2 could form 
dimmers with TLR6, but the heterodimer TLR1-TLR2 is not present. This could explain 
the absence of TNF-a and IL1 production, meanwhile IL-12 or IL-6 is produced 
normally by Gal-3-/ DCs and IL-10 resulted increased. This points out that in DCs Gal-
3 is modifying but not suppressing the profile of immune receptors.  
 We still do not know much about the relation between Gal-3 and TLR1-TLR2 
complex. It is possible that the problem is related to internalization and recycling to the 
membrane of receptors. Lattice formation following the binding of galectins to complex 
N-glycans on the cell surface effectively traps glycoprotein receptors on the cell surface, 
preventing their endocytosis, and regulating distribution of cell surface receptors as well 
as the cell responsiveness to receptor agonists. This could be the case of Gal-3 P-/-P DCs 
and TLRs. TLRs are glycosilated proteins, thus potential ligands of Gal-3. It has been 
reported a direct interaction between Gal-9 and TLR3, but no other one has been 
demonstrated so far. This would allow getting insight in the process. Other possibility is 
that Gal-3 collaborates with TLR2 and TLR1 to form a complex, all of them 
recognizing T. cruzi. This would support the role of Gal-3 as a danger molecule. Gal-3 
is released in response to pathogens, and its interaction with T. cruzi and TLRs complex 
would indicate to the innate system the pathogenic nature of the microbe. In the absence 
of Gal-3, there is a lack of the danger signal that keeps the innate system in an anergic 
  129
status. It can be possible that another unknown molecules link Gal-3 to TLRs. It has 
been shown the existence of a Gal-9 ligand termed Tim-3 (T cell immunoglobulin 
mucin-3) that synergizes with TLRs to promote TNF-α on DCs (Anderson, Anderson et 
al. 2007). Whether Tim-3, or other Tim member, work together with Gal-3 to induce 
TNF-α production is an interesting question that may be answered by further 
experiments. Finally, Gal-3P-/-P mice reduced TNF-α production in response to C. albicans 
in a way dependent of TLR2 (Jouault, El Abed-El Behi et al. 2006), in agreement with 
our observations. 
  
 4- Final remarks 
  
 Understanding the sugar code is a major challenge for immunologists and will 
be critical to support the design of rational therapeutical approaches aiming at 
manipulate imflammatory or autoimmune disorders. These therapeutic approaches will 
be aimed at blocking the formation of specific glycans, controlling the expression of 
specific glycan processing enzymes or interfering with glycan-CBP interactions. .The 
glycomic era should emerge close to the development of effective tools to understand 
the glycobiology. 
  The present work shows how galectins can control and address the relation 
between the parasite and the host, acting as decoders of the information contained in T. 
cruzi and host glycans in a bidirectional way, and dictating the fate of the innate and 
subsequent immune response. However, this is only the first step towards the complete 
understood of the relevance of galectins during Chagas disease, and by extrapolation, 
during other infectious, autoimmune or tumorogenic processes.  
 The advance in the field of glycobiology may mark the beginning of a new era 
of therapeutic strategies, and it could be possible the use of sugar-binding proteins or 
their antagonists for the treatment of inflammatory and immunological disorders. 
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1- Human recombinant galectin-1,-3,-4,-7 and -8 are able to bind T. cruzi in a 
carbohydrate recognition domain dependent way. The affinity of galectins for T. 
cruzi surface ligands is much higher for infective forms, amastigotes and 
trypomastigotes, than for the non-infective form. The interaction of galectins 
with T. cruzi promotes parasite adhesion to host cells in vitro.  
 
2- T. cruzi expresses proteases that are able to process galectin-4, -8, and -3; Zn-
metalloproteases cleave galectin-4 and -8 in the linker peptide region, and 
galectin-3 is processed by the action of two different proteases, a Zn-
metalloprotease and a collagenase. 
 
3- The inhibition of the proteases present in T. cruzi responsible of galectin 
processing leads to direct killing of the parasite by recombinant human 
galectins.  
 
4- During experimental infection with T. cruzi in C57BL/6 mice, presence of 
galectin-1,-3 and -9 were increased in T cells, B cells increase galectin-3, and-9 
and decrease galectin-8 expression, and galectin-1,-3, and -9 were constituvely 
expressed in macrophages and dendritic cells. Cardiac cells increase the 
expression of galectin-1, and galectin-3 is strongly expressed by infiltrating 
CD68+ macrophages. 
 
5-  In murine the model genetically deficient for galectin-3, the infection courses 
with higher parasitemia than wild type controls, correlating with impared seric 
IL-2, IL-1, IL-5, IFN-γ and IL-10 levels.  
 
6- The profile of anti-glycan antibodies in response to T. cruzi is totally different in 
galectin-3 deficient mice compared to the wild type model. The main difference 
is related to the generation of antibodies able to recognize the glycan Galβ1-
3GlcNAcβ1-3Galβ1-4GlcNAc in the deficient model, structure that results not 
immunogenic for wild type infected mice. 
 
7- Galectin-3 deficient mice show a deficient inflammatory and inmune response 
during T. cruzi infection, show a diminished expression of IFN-γ, COX-2 and 
iNOS genes in spleen and heart in response to the infection and reduced a ability 
to recruit macrophages and T cells to the heart, with no significant changes in 
the parasite burden in heart compared to wild type animals. 
 
8- The absence of galectin-3 does not affect dendritic cell differentiation and 
activation in vitro, but it is responsible of the reduction of TNF-α and IL-1 in 
response to LPS and T. cruzi, through a mechanism involving TLR2-TLR1 
heterodimer surface formation.  
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1- Galectinas recombinantes humanas 1,3,4,7 y 8 son capaces de unir T. cruzi de 
modo dependiente del dominio de reconocimiento a carbohidrato. La afinidad de 
las galectinas recombinantes es mucho mayor por formas infectivas del parasito, 
amastigotes y trypomastigotes, que por las formas no infectivas. La interacción 
de las galectinas con T. cruzi promueve adhesión a células hospedadoras in 
vitro. 
2- T. cruzi expresa proteasas capaces procesar galectina-2, 4 y 8; Zn-
metalloproteasas cortan las galectinas 4 y 8 en la región del linker peptídico, y la 
galectina-3 es procesada por la acción de dos proteasas diferentes, una Zn-
metaloproteasa y una colagenasa 
3- La inhibición de las proteasa presentes en T. cruzi responsables del 
procesamiento de galectinas conduce a la muerte del parásito por galectinas 
recombinantes 
 
4- Durante la infección experimental por T. cruzi en ratones C57BL/6, se 
incrementó la presencia de galectinas 1,3 y 9 en células T, células B 
incrementaron expresión de galectina-3 y 9 mientras que redujeron la expresión 
de galectina-8, y las galectinas 1,3 y 9 son constitutivamente expresadas en 
macrofagos y células dendriticas. Células cardiacas aumentan la expresión de 
galectina-1 durante la infección, y galectina-3 es expresada por macrofagos 
infiltrados en el corazón de ratones infectados 
 
5- En el modelo murino geneticamente deficiente en galectina-3, la infección cursa 
con una elevada parasitemia que en lo ratones salvajes, correlacionandose con 
una producción desajustada de IL-2, IL-1, IL-5, IFN-γ and IL-10 en suero. 
 
6- El repertorio de anticuerpos anti-glicanos generados en respuesta a T. cruzi es 
totalmente diferente en ratones deficientes en galectina-3 comparado a ratones 
control salvajes. La principal diferencia esta relacionada con la generación de 
anticuerpos capaces de reconocer el glicano Galβ1-3GlcNAcβ1-3Galβ1-
4GlcNAc en el modelo deficiente, estructura que no resulta antigénica en el 
modelo salvaje. 
 
7- Ratones geneticamente deficientes en galectina-3 muestran una respuesta 
inmune e inflamotaria deficiente durante la infección por T. cruzi, una expresión 
disminuida de los genes IFN-γ, COX-2 and iNOS en azo y corazon en respuesta 
a la infección y una capacidad reducida para reclutar macrofagos y células T al 
corazón, sin diferencias significativas en la carga parasitaria  
 
8- La ausencia de galectin-3 no afecta a la diferenciación y activación de celulas 
dendriticas in vitro, pero es responsable de la reducción de TNF-α y IL-1 en 
respuesta a LPS y a T. cruzi, a traves de un mecanismo que implica la formación 
de heterodimeros TLR1-TLR2 
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